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This thesis describes the synthesis of fluorinated cyclopropane analogues to enhance the 
metabolic stability of a previously published lead candidate for prostate cancer treatment. A 
structural unique motif such as the bicyclo[1.1.0]pentane was also incorporated to investigate its 
potential as cyclopropane bioisostere. Preliminary results from liver microsome and luciferase 
assays suggested that fluorinations on the cyclopropane carbon atoms have little impact on the 
metabolic stability. However, fluorination on other labile sites showed enhanced metabolic 
stability while retaining compound potency. An enantioselective route to improve the original 
racemic synthesis of these analogues was also investigated. The key step was a Co(II)-salen 
catalyzed enantioselective cis-cyclopropanation of an olefin with ethyl diazoacetate to provide 
the cyclopropyl amide in 98% ee over three high-yielding steps.  
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1.0  SYNTHESIS OF SMALL MOLECULE ANTAGONISTS AT THE NUCLEAR 
ANDROGEN RECEPTOR FOR PROSTATE CANCER TREATMENT 
1.1 INTRODUCTION 
1.1.1 Prostate cancer 
Prostate cancer is the uncontrolled growth of cells in the prostate gland. It is the third leading 
cause of cancer death in men in the United States.1 Recent statistics from the American Cancer 
Society showed that prostate cancer is the most common cancer in men – about one in seven men 
will be diagnosed with prostate cancer. The risk of developing prostate cancer is found to be 
higher in men aged 65 and older, mainly due to the changes in testosterone level with age 
although recently an increase in new diagnoses has been found in men below 55 years. There are 
often no symptoms associated with prostate cancer in the early stage, and it is only diagnosed 
during routine check-up through prostate-specific antigen (PSA) screening. In some cases, 
patients may experience pain and blood during urination, and the need to urinate more frequently 
when the urethra is being compressed by the tumor mass.  
Long-term studies reported that most cases of early diagnosis are benign and slow-
growing cancer cells that are not life-threatening.2-4 Active monitoring showed that these cancer 
cells do not have significant progression over the years and the patients have high survival rates 
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even without any form of medical treatment. However, advanced stages of prostate cancer could 
be malignant, metastatic, and eventually cause death. Treatments for patients diagnosed with 
advanced prostate cancer include radical prostatectomy, radiation therapy, and androgen 
deprivation therapy (ADT).5 Unfortunately, some patients eventually develop castration-resistant 
prostate cancer (CRPC), an incurable stage of cancer where the cells are resistant to hormone 
therapy.6 Previously known as hormone-refractory prostate cancer, CRPC contributes to the 
majority of deaths from prostate cancer as the mean survival time is only one to two years. 
Almost all CRPC patients also develop metatheses where the tumors rapidly spread to other 
organs, including bones and lymph nodes, causing extreme pain. Thus, it is important to 
understand the mechanism of CRPC and the elements that play a key role in its progression in 
order to develop an efficient treatment for CRPC.  
1.1.2 Androgen receptor (AR) and androgen 
The prostate gland is a compound tubuloalveolar exocrine gland of the male reproductive system 
that is responsible for male sexual differentiation and functions. The growth and maintenance of 
healthy prostate cells are regulated by the androgen receptor (AR), a ligand-dependent nuclear 
transcription factor that belongs to the steroid hormone receptor superfamily.7,8 The AR gene 
encodes a protein of 919 amino acids that consists of four major functional domains: (a) N-
terminal domain (NTD), (b) DNA binding domain (DBD), (c) hinge region, and (d) ligand 
binding domain (LBD) (Figure 1).9  
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Figure 1. Structural domains of AR.9 Copyright © 2016 American Chemical Society 
The NTD consists of 555 amino acid residues, and takes up more than half the size of the 
AR. A combination of experimental and computational analyses suggests that the NTD exists as 
partially folded protein intermediate (neither full random coil nor stable globular 
conformation).10 The intrinsic disorder of the NTD provides the flexibility that allows for 
binding to multiple structurally diverse protein partners. Folding is triggered by the binding event 
and initiates specific transcriptional functions.11 The ligand-independent activation function 1 
(AF1) located within the NTD is important for the transcriptional activation of the AR gene.12  
 
Figure 2. Crystal structure of AR DBD dimer (PDB:1R4I). Copyright © 2014 Nature Publishing Group 
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The DBD is a highly conserved cysteine-rich domain that houses 2 zinc finger domains, 
where the zinc ions are coordinated to four cysteine residues, respectively (Figure 2).13 Three 
amino acid residues (Gly-Ser-Val) situated at the α-helix of the N-terminus, named the P box, 
make contacts with the DNA groove at the promoter region. The AR forms a homodimeric 
structure when bound to the DNA. The second zinc finger contains the D box, which is a 
sequence of five amino acid residues (Ala-Ser-Arg-Asn-Asp) that functions as DBD/DBD 
binding interface during dimerization.14,15 Although the main purpose of the DBD is DNA 
binding, studies have reported that the DBD may also be involved in other AR regulations.16-18 
Between the DBD and LBD is the hinge region that contains part of the nuclear localization 
signal (NLS) responsible for AR nuclear import. The translocation of AR (a 110kDa protein) 
from the cytoplasm into the nucleus is mediated by the binding of NLS to importin-α.19 
 
Figure 3. Crystal structure of AR LBD (PDB:1E3G). Copyright © 2014 Nature Publishing Group 
 5 
The C-terminal LBD is made up of twelve α-helices and four short β-strands arranged in 
a three-layer, antiparallel α-helical sandwich fold, a feature unique to the nuclear receptor family. 
The X-ray crystallography (XRC) structure of the androgen-bound AR-LBD showed that there is 
a ligand binding pocket (LBP) buried in the helices that interacts with the ligand at H3, H5 and 
H11 (Figure 3).13,20 The repositioning of H12 was observed as it acts as a ‘lid’ that closes the 
LBP after binding of AR agonists, possibly to prevent ligand dissociation. This conformational 
change also induces the formation of a hydrophobic interaction surface called activation function 
2 (AF2).21 Similar to AF1, the binding of coregulators to AF2 triggers the transactivation 
function of the AR. In contrast with other nuclear receptors, AF2 also interacts preferentially 
with the NTD to stabilize the AR dimer complex.22 In the absence of androgen, AR is exported 
from the nucleus into the cytoplasm by the nuclear export signal (NES) located in the LBD.23 
 
Figure 4. Structure of testosterone and DHT 
AR activation is initiated through the binding of endogeneous androgens such as 
testosterone and 5α-dihydrotestosterone (DHT) to the LBD (Figure 4). Testosterones are mostly 
synthesized in the testes (>95%) and are bound to sex hormone binding globulin (SHBG) while 
circulating in the extracellular matrix.24 As testosterone enters the prostatic cytoplasm, the 
enzyme 5α-reductase readily converts testosterones to DHT, which is a more potent agonist of 
the AR. In the absence of androgen, the AR is mostly located in the cytoplasm as a complex with 
heat shock proteins (HSP-90, -70, -56) and other chaperones. The binding of DHT to the AR-
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LBP results in the dissociation of heat shock proteins from the AR and induces a series of 
conformational changes that promote nuclear translocation. The AR homodimer interacts with 
the androgen response element (ARE) at the promoter region of the DNA and triggers the 
recruitment of coregulators to the AF1 and AF2 domains. Consequently, the docking of 
coregulators to AF1 and AF2 domains activates the transcription process of the target AR gene 
(Figure 5).13, 25-26  
 
Figure 5. AR signaling in prostate cells.7 Copyright © 2014 Nature Publishing Group 
1.1.3 Androgen deprivation therapy (ADT) 
Androgen and AR action play a vital role in the growth of cancerous prostate cells, and the 
suppression of androgen levels and androgen-AR interactions can impede the progression of 
advanced prostate cancer. Surgical castration was the conventional method of lowering androgen 
production prior to the development of hormone therapy. A groundbreaking discovery by 
Charles Huggins in 1941 in the use of chemical castration or estrogenic injection that led to 
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tumor regression and reduced levels of acid phosphatase (a prostate cancer marker), won him the 
1966 Nobel Prize.27 Since the identification of AR as a therapeutic target, steroidal and non-
steroidal hormones, also called antiandrogens, have been developed to reduce androgen levels 
and inhibit nuclear AR signaling in prostate cancer patients, resulting in the apoptosis of 
androgen-dependent prostate cancer cells.  
 
Figure 6. Steroidal antiandrogens of the AR compared to native androgen DHT. 
Steroidal antiandrogens such as cyproterone acetate, oxendolone, and spironolactone 
were found to be competitive inhibitors of testosterone and DHT as they have high affinity to the 
AR-LBD.7, 28-29 The excellent binding affinity is attributed to a common structural motif, which 
is a [6,6,6,5]-tetracyclic core, much like the native androgens as well as other naturally-occurring 
hormones (Figure 6). Unfortunately, this structural similarity also means that steroidal 
antiandrogens could be potential AR agonists and weak activators of other nuclear receptors, 
hence they were soon removed from prostate cancer treatment due to off-target actions and 
significant side effects.  
In the subsequent years, more effort has been invested in the development of non-
steroidal antiandrogens that possess high selectivity for AR. The antiandrogen flutamide 
(Eulexin) was patented by Schering-Plough Corporation, and approved by the U.S. Food and 
Drug Administration (FDA) in 1989, followed by bicalutamide (Casodex), and nilutamide 
(Nilandron) (Figure 7a).30-33 They were approved for combined androgen blockade (CAB) 
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therapy in addition to luteinizing hormone-releasing hormone (LHRH) agonists, which suppress 
the production of luteinizing hormone (LH) and inhibit testicle testosterone synthesis. Multiple 
randomized trials demonstrated that patients who were administered either of these 
antiandrogens on top of LHRH agonists or orchiectomy showed a significant improvement in 
survival and progression-free survival time.34,35  
 
Figure 7. Development of non-steroidal antiandrogens. (a) First generation antiandrogen marketed for advanced 
prostate cancer. (b) Second generation AR inhibitors.  
Some patients eventually become resistant to ADT and progress into CRPC with 
aggressive tumor growth. There are multiple mechanisms proposed for the initiation and 
propagation of CRPC, including the overexpression of the AR gene, activation of mutant AR by 
alternative ligands, ligand-independent AR activation via other signaling pathways, and a 
completely AR-independent pathway.36-38 For example, studies showed that residual androgens 
from in situ tumoral synthesis and adrenal synthesis could activate the AR in CRPC cells that 
became hypersensitive due to lower threshold of androgens, thus amplifying AR gene 
expression. Literature reports suggested that amino acid substitutions from AR mutations at the 
LBD decreased ligand selectivity and specificity, whereby native hormones such as estrogen, 
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progesterone, and glucocorticoid assume the role of DHT and reactivate AR functions.7 Other 
AR-LBD mutations also caused AR antagonists to induce an agonist role where in a specific 
case, a single amino acid mutation discovered during bicalutamide treatment allowed more room 
in the binding site to accommodate bicalutamide molecule so that it could coordinate in an 
agonist conformation.39 In many of these cases, AR signaling kept a central role in the 
proliferation of CRPC.  
Enzalutamide (Xtandi®) and abiraterone acetate (Zytiga®) are second generation AR 
inhibitors approved for CRPC treatment (Figure 7b).40,41 Abiraterone is a steroidal CYP17A1 
inhibitor, which interferes with the enzyme-catalyzed biosynthesis of androgens. Enzalutamide is 
a novel, more potent antiandrogen that not only competitively inhibits the binding of androgen to 
AR but also efficiently inhibits translocation of the AR into the nucleus.42,43 Nonetheless, some 
cases of enzalutamide resistance have been observed.44,45 Since there is no curative effect, all the 
treatment options for metastatic CRPC hitherto are directed toward a palliative care approach to 
improve the patients’ quality of life and extend survival time. The crucial need for new regimens 
to effectively inhibit AR functions and prolong life beyond a few months continues to prompt the 
search for a more competent drug.  
1.1.4 High-throughput screening (HTS) 
Johnston et al. reported the first HTS that aimed to identify small molecules capable of impeding 
nuclear translocation in AR in CRPC cell lines.46 An assay to screen 219,055 compounds from 
the National Institutes of Health (NIH) library was developed using C4-2 CRPC cells transfected 
with a green fluorescent protein tagged AR (2GFP-AR) expression vector, and the fluorescence 
intensities within the nucleus and cytoplasm were quantified.  
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Figure 8. Identification of novel antiandrogens from HTS campaign. 
Three small molecules were found to inhibit nuclear localization of 2GFP-AR with little 
or no cytotoxicity in C4-2 CRPC cell lines: treatment with HTS-1 and HTS-2 showed a 
significant shift of 2GFP-AR into the cytoplasm while treatment with HTS-3 suggested 
downregulation of AR expression without cytoplasmic localization (Figure 8). Three hits are 
structurally distinct from the currently known antagonists, implying that the mechanism of 
inhibition could involve other components of AR signaling instead of the AR-LBP. This finding 
was very promising as the uncovering of the actual mechanism could open up a new strategy for 
CRPC drug discovery. 
1.1.5 Development of lead compound JJ-450 
After the HTS campaign, a structure-activity relationship (SAR) study on HTS-3 was conducted 
by Johnson et al. to explore more potent analogues for nuclear localization inhibition in CRPC.47 
These analogues were subjected to an in vitro luciferase assay using CRPC C4-2 cell lines 
transfected with a prostate-specific antigen (PSA) promoter-driven Firefly luciferase reporter 
vector and a Renilla luciferase as the internal control reporter (Figure 9). The luciferase activity 
of the transfected C4-2-PSA-rl cell line was first induced by the synthetic androgen R1881. The 
cells were then treated with the test compounds and measured for the changes in luciferase 
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activity. The amount of expressed luciferase activity corresponds to the measured light 
intensities. Since the PSA promoter activity is a biomarker for AR transcriptional activity, the 
inhibition of AR by the test compounds will result in a decrease in luciferase activity. The 
measured androgen-driven luciferase activity was normalized to the Renilla luciferase activity.  
 
Figure 9. Dual luciferase reporter assay protocol. Copyright © American Society for Photobiology 
HTS-3 was divided into five zones for structural modifications and a total of 35 
analogues were synthesized. Several structural moieties were found to be imperative for activity 
(Figure 10). The ortho-substitution on the phenyl group in zone 1 was important as removing the 
ortho-methyl and altering the methyl group to the meta- or para-position led to a complete loss 
of activity. In zone 2, replacing the piperazine with acyclic and bridged amines resulted in 
decreased activity, while the sterically hindered 2,6-dimethylpiperazine was found to have a 2-
fold increase in activity. The carbonyl group in zone 3 was not required as a sulfonamide or 
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amine were tolerated at that position. The attempt to substitute the thioether linkage in zone 4 
with an ether or N-methyl amine rendered the analogues inactive while a cis-cyclopropane 
significantly improved activity. In zone 5, substituted phenyl groups were equipotent with the 
3,5-dimethylisoxazole present in the initial hit. The cis-cyclopropane analogue (JJ-450) was 
found to be 3-fold more active than the HTS hit and chiral resolution gave the more potent 
(1S,2R)-enantiomer and the 10-fold less potent (1R,2S)-enantiomer. The equipotency of (1S,2R)-
JJ-450 to enzalutamide was a compelling outcome from this hit-to-lead study for the further 
development of a novel CRPC drug candidate.  
 
Figure 10. Hit-to-lead structural modifications and luciferase activity 
1.1.6 Metabolic stability of JJ-450 
The metabolic stability assay of JJ-450 in different species of liver microsomes revealed that it 
has a very short half-life of 5.3 minutes in mouse liver microsomes. Preliminary metabolic 
stability studies using LCMS suggested that JJ-450 may undergo various oxidations and 
fragmentations at the cyclopropane and piperazine amide sites in mouse liver microsomes 
(Figure 11). Our approach to overcome this issue was to install fluorine atoms at these labile 
sites in hopes to develop analogues that are more resistant to metabolic attack. 
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Figure 11. Proposed metabolic pathways of JJ-450 based on LCMS analyses of samples in mouse liver microsomes. 
1.1.7 Fluorine improves metabolic stability in small molecule drugs 
The first fluorine-containing synthetic pharmaceutical drug, fludrocortisone, was granted FDA 
approval in 1955 but prior to that the incorporation of fluorine into medicinal drug was 
unthinkable.48 The lack of fluorinated natural products and the non-trivial method for laboratory 
fluorinations ruled out the feasibility of synthesizing fluorinated drugs. Even 15 years after the 
development of fludrocortisone, which was proven to have more desirable biological properties 
than its non-fluorinated derivative, fluorine-containing small molecule drugs only account for 
2% of the pharmaceutical market in 1970.49 However, the advancement of novel and safe 
fluorinating reagents in the 1970s facilitated the use of fluorine building blocks in drug design.50 
Currently, approximately 30% of the marketed pharmaceuticals contain at least one fluorine 
atom, including top-selling drugs such as Prozac (antidepressant), Crestor (reduces cholesterol 
level), and Seretide (bronchodilator).51  
 One of the major contributions of fluorine substitution in small molecule drugs is the 
increase in metabolic stability.52 Various examples in the literature show that substituting the 
more labile C–H bond with a C–F bond helped prevent oxidative metabolism by the liver P450 
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cytochrome enzymes, thus extending its bioavailability without losing activity.53-55 This 
beneficial effect is attributed to various unique properties of this most electronegative element in 
the periodic table:56  
• the stronger bond energy of the C–F bond (485 kJ mol-1 vs 413 kJ mol-1), which makes it 
harder to be cleaved than the C–H bond.  
• the relatively small size of the fluorine atom compared to the hydrogen atom (1.47 Å vs 
1.20 Å) makes it a good replacement with minimum steric disruptions. 
• the highly electronegative fluorine atom (3.98 Pauling scale) can withdraw electron 
density of adjacent or distal bonds, thus reducing the rate of metabolism. 
 
Figure 12. Development of ezetimibe via metabolic stability optimization using fluorine substituents. 
The rational design of ezetimibe, a cholesterol lowering drug, was a proof of how the 
substitution with a fluorine atom improved metabolic stability and enhanced potency (Figure 
12).57 The parent molecule of ezetimibe, SCH 48461, although having modest potency, contains 
five major metabolically labile sites, and generates metabolites that reduce its overall potency. 
An intensive SAR study was conducted to probe the effects of various substitutions at the sites of 
detrimental metabolic oxidations, leading to ezetimibe.  
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1.2 RESULTS AND DISCUSSION 
1.2.1 Synthesis of fluorinated cyclopropane analogues of JJ-450 
1.2.1.1 Fluorination and trifluoromethylation at the benzylic position  
We proposed that the target compounds can be easily prepared from a fluorinated cyclopropane 
carboxylate intermediate, which can be obtained from a metal-catalyzed cyclopropanation of α-
substituted styrene with a diazo ester based on literature precedence.58  
 
Scheme 1. Synthesis of benzylic fluorinated and trifluoromethylated analogues. 
The starting material, 1-fluoro-4-(1-fluorovinyl)benzene, was synthesized according to a 
literature protocol and subjected to a Cu(II)-catalyzed cyclopropanation with ethyl diazoacetate 
to afford the cyclopropyl carboxylate as a 1:1 cis/trans mixture of diastereomers (with regard to 
the fluorine and carbonyl group according to the Cahn-Ingold-Prelog rule), which could be 
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separated via chromatography on SiO2 (Scheme 1).
59 Base hydrolysis of the cis- and trans-
cyclopropyl esters gave the respective cyclopropyl carboxylic acids without isomerization. A n-
propanephosphonic acid anhydride (T3P)-mediated coupling with the piperazine hydrochloride 
salt A provided the final products cis-5a and trans-5b which are fluorinated at the benzylic 
position. The CF3 analogues cis-6a and trans-6a were obtained with the same route. 
It was reported that the cyclopropanation of vinyl fluoride with Cu(acac)2 catalyst gave 
significantly better yields than with Pd- or Rh-catalysts.60 However, this was not the case for the 
CF3 analogue, as the Cu(acac)2 catalyst did not promote the cyclopropanation of the alkene but 
only yielded fumaric and maleic esters, the homocoupling byproducts of ethyl diazoacetate. 
Fortunately, the desired cyclopropyl ester was obtained as a 1:1.2 cis/trans mixture of 
diastereomers in 88% yield when the cyclopropanation was carried out with Rh2(OAc)4. 
Diastereomers were also separable via chromatography on SiO2.  
1.2.1.2 Fluorination and trifluoromethylation at the α-carbonyl position 
We were motivated by the cyclopropanation with diazo ester to introduce the CF3 group at the α-
carbonyl position by using a trifluoromethyl-substituted carbene. We were delighted to discover 
that carbenoid reactions based on the use of 3,3,3-trifluoro-2-diazopropionate 8 were well-
precedented.61,62 Diazo compound 8 was prepared from ethyl 3,3,3-trifluoropyruvate according 
to a literature procedure.63,64 Cyclopropanation of 8 with p-fluorostyrene employing Rh2(OAc)4 
as the catalyst afforded cyclopropyl ester 9 as a 1:1.6 cis/trans mixture of diastereomers, and 
subsequent hydrolysis with base at elevated temperature proceeded smoothly to give the 
carboxylic acid (Scheme 2). Coupling with the piperazine hydrochloride salt A was slow due to 
the steric hindrance of the trifluoromethyl group but still provided cis-11a and trans-11b 
diastereomers, which were separated by chromatography, albeit in moderate yield.   
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Scheme 2. Synthesis of α-carbonyl trifluoromethylated analogues. 
Since metabolic oxidation may also occur at the benzylic positions of the two phenyl 
groups, we also synthesized analogues 15 and 17 (Scheme 3), where the benzylic positions were 
substituted with trifluoromethyl groups. 
 
Scheme 3. Synthesis of analogues 15 and 17. 
A different approach was examined for the synthesis of α-fluoro-substituted analogues as 
the α-fluoro-α-diazoester is not known in the literature and would likely be unstable. Feit et al. 
reported that the reaction of cyclopropyl carbanions, derived from cyclopropyl ester, in the 
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presence of lithium diisopropylamide (LDA), with electrophiles afforded the corresponding 
trisubstituted derivative (Figure 13).65 It is interesting to note that the product was obtained as a 
single diastereomer; the authors proposed that the phenyl group exerts steric hindrance to the 
approaching electrophile, thus favoring the electrophilic attack on the opposite face to give the 
cis-diastereomer as the sole product.  
 
Figure 13. Reaction of cyclopropyl carbanion with electrophiles. 
 Based on the above example, we anticipated that electrophilic fluorination would 
generate the desired α-carbonyl fluorinated product as a single diastereomer. Unfortunately, no 
product was detected from the reaction with N-fluorobenzenesulfonimide (NFSI) as the 
electrophile (Scheme 4). This target was therefore down-prioritized and we plan to revisit this 
reaction again using other electrophilic fluorinating reagents.  
 
Scheme 4. Effort toward an electrophilic fluorination of a cyclopropyl ester. 
1.2.1.3 Synthesis of gem-difluorocyclopropa(e)ne analogues 
The most common strategy to access the difluorocyclopropane moiety is the stereospecific 
addition of difluorocarbene to an electron rich/nucleophilic alkene. Various precursors to attain 
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difluorocarbene have been developed in the past decades and some of these methods also 
extended to the addition to alkyne.66-67 However, many of the procedures suffer from harsh 
conditions (170 – 190 oC) and limited scope, or the reagents are toxic and difficult to handle 
(PhHgCF3). Due to the increasing demand for gem-difluorocyclopropanes, safer and more 
versatile difluorocarbene precursors have been reported in recent years.68    
Table 1. Attempted difluorocarbene additions to cis-alkene and alkyne 
 
Entry Substrate Conditions Remarks 
1 20 BrCF2CO2Na, diglyme, 150 oC, 15 min RSM + isomerized to trans- 
alkene 
2 21 BrCF2CO2Na, diglyme, 150 oC, 15 min RSM 
3 20 MDFA, KI, TMSCl, diglyme, dioxane, 
120 oC, 2 d 
isomerized to trans-alkene + 
trace difluorocyclopropane 
4 
 
MDFA, KI, TMSCl, diglyme, dioxane, 
120 oC, 2 d 
 
 
We explored the options for a [2+1] cycloaddition of difluorocarbene to relatively 
electron-poor cis-alkenes bearing an ester and an electron-withdrawing p-fluorophenyl group. 
Amii and coworkers discovered the thermolysis of bromodifluoroacetate (BrCF2CO2Na), a 
convenient and efficient alternative to sodium chlorodifluoroacetate (ClCF2CO2Na), in a high-
yielding synthesis of difluorocyclopropa(e)ne.69 Unfortunately, the reaction condition was 
incompatible with our substrates and the cis-alkene was found to isomerize to the trans-alkene 
under high temperatures while there was only recovered starting material with the alkyne 
substrate (Table 1, entries 1 and 2). Dolbier and coworkers showed that in situ generated 
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difluorocarbene from methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (MDFA) under high 
temperature and high concentration reacts with ethyl cinnamate.70 However, the cis-alkene again 
isomerized to the trans-alkene at high temperatures, and only trace amounts of trans-
difluorocyclopropane were detected (entry 3). In order to prove that this result was not simply a 
technical failure or due to impure reagents, we treated ethyl 4-fluorocinnamate under the same 
conditions and found that the reaction proceeded in 61% yield (entry 4).  
 
Scheme 5. Attempt to convert the gem-difluoroolefin to the gem-difluorocyclopropane. 
Since MDFA can also be used in a Wittig-type difluoroolefination of aldehydes via a 
difluoromethylene triphenylphosphonium ylide intermediate, we attempted the reaction of 1,1-
difluoroalkene 26 and ethyl diazoacetate with Cu(II) or Rh(II) catalyst but did not obtain the 
desired difluorocyclopropane 23 (Scheme 5).71  
Table 2. Screening for trans-to-cis isomerization conditions 
 
Entry Conditions Remarks 
1 KOtBu, PhMe, reflux decomposition 
2 KOtBu, tBuOH, reflux ester hydrolyzed 
3 1. Lithium diethylamide, 2. EtOH quench RSM 
4 1. Lithium diisopropylamide, 2. EtOH quench RSM 
 
 With the trans-difluorocyclopropane 25 in hand, we aimed to isomerize the trans-
configuration to the cis-diastereomer 23. Even though the trans-diastereomer is kinetically more 
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stable, the literature shows that trans-to-cis isomerization on a similar scaffold can occur to a 
certain extent.65 Various attempts using strong bases such as potassium tert-butoxide and lithium 
diethylamide or lithium diisopropylamide, however, failed to provide the desired cis-
diastereomer (Table 2).  
 Concurrently, we began to consider other readily available precursors for difluorocarbene 
formation. The Rupert-Prakash reagent (TMSCF3) is known as a trifluoromethylation reagent for 
electrophilic substrates and only recently it was found to be a convenient source for 
difluorocarbene [2+1] cycloaddition to alkenes or alkynes when activated by 
tetrabutylammonium triphenyldifluorosilicate (TBAT) or sodium iodide.72 Analogous 
transformations were subsequently reported by Hu and coworkers using TMSCF2Cl and 
TMSCF2Br.
73,74 We decided to employ TMSCF2Br, rather than TMSCF3, in our investigation 
based upon its broader substrate scope and its more environmental-friendly preparation than 
TMSCF2Cl. Gratifyingly, alkyne 27 was converted to the corresponding difluorocyclopropene 28 
in good yield in the presence of catalytic tetrabutylammonium bromide (Scheme 6). Hydrolysis 
of the ester 28 using potassium hydroxide in methanol resulted in decomposition of the 
difluorocyclopropene ester. This outcome was presumably due to the conjugate addition of 
nucleophilic alkoxy anion, generated by hydroxide in an alcoholic solvent, on the α,β-
unsaturated ester. Lithium hydroxide in a THF/water mixture, a condition regularly employed to 
saponify α,β-unsaturated esters, also failed to deliver the desired carboxylic acid.  
 
Scheme 6. Difluorocyclopropenation of alkyne 27.  
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 We then shifted our focus to screen a series of conditions for cis-hydrogenation of the 
cyclopropene. Zheng and Dolbier demonstrated that Hantzsch’s ester can be used as a hydride 
transfer reagent in the presence of a Brønsted acid for the reduction of difluorocyclopropenyl 
ketone to give the corresponding cyclopropane in a cis-selective fashion.75 However, these 
conditions only resulted in complete decomposition of the starting material (Table 3, entry 1). 
Lipshutz and coworkers developed a “hot” Stryker’s reagent that effectively reduces α,β-
unsaturated double bonds, but our substrate 21 was found to be resistant to their optimized 
conditions (entry 2).76  
Table 3. Condition screening for hydrogenation of difluorocyclopropene 
 
Entry Conditions Remarks 
1 Hantzsch’s ester, TBBA, CH2Cl2, rt, 2 d Decomposition 
2 Cu(OAc)2 H2O, BDPPB, PMHS, tBuOH, PhMe, rt, 18 h RSM 
3 10% Pd/C (2.5 mol%), H2 (balloon), EtOAc, rt, 17 h Trace 
4 10% Pd/C (2.5 mol%), H2 (11 bar), EtOAc, rt, 17 h <10% 
5 10% Pd/C (10 mol%), H2 (6 bar), EtOAc, rt, 17 h 73% 
6 10% Pd/C (10 mol%), H2 (5 bar), EtOH, rt, 17 h Decomposition 
 
We then proceeded to examine the feasibility of a Pd/C reduction of 1,1-
difluorocyclopropene 28. Our concern was that Pd(0) metal-insertion into the C2–C3 bond of the 
difluorocyclopropane ring is irreversible and that bond cleavage releases the ring strain exerted 
by the difluoro-substituent.77 To our delight, we found that a 10 mol% loading of Pd/C under 6 
bar of H2 pressure afforded the reduced product 30 in 73% isolated yield, though accompanied 
by ring-cleavage at the C2–C3 bond as a minor side-product (entry 5). Unfortunately, we were 
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again brought to a dead-end when the subsequent hydrolysis of the difluorocyclopropane ester 
caused a cis-trans isomerization.  
Because all attempts to reach the final target compound were unsuccessful, we revised 
our synthetic route and altered the order of bond formation. We decided to perform the T3P-
mediated amide coupling prior to the formation of the difluorocyclopropane to omit the 
problematic ester hydrolysis step (Scheme 7). 
 
Scheme 7. Revised route to difluorocyclopropene 33 and difluorocyclopropane 34 analogues. 
 We were pleased to discover that the [2+1] difluorocyclopropenation of the complex 
alkyne 32 proceeded well to furnish difluorocyclopropene 33. As discussed previously, 
difluorocarbene addition conditions usually suffer from a narrow scope, and thus, we were very 
satisfied with our result as the reaction condition can be extended to the novel alkynyl amide 
scaffold in high yield. Reduction of the double bond with Pd/C under optimized conditions 
yielded the difluorocyclopropane analogue 34, which was subjected to chiral SFC resolution. 
1.2.2 Bicyclo[1.1.1]pentane (BCP) as a bioisostere in medicinal chemistry 
Our group’s ongoing interests in strained molecules prompted us to investigate the effects of 
incorporating a bicyclo[1.1.1]pentane (BCP) moiety in our analogues. It has been shown that 
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BCP is a beneficial bioisoteric replacement of the phenyl group, and significantly improves 
aqueous solubility, in vitro metabolic stability, and membrane permeability of several drug 
candidates.78-80 Recently, it was reported that BCP can be a promising bioisostere of an internal 
alkyne (Figure 14).81 However, its unique structure and reactivity pose a synthetic challenge, 
and there are only few reported syntheses.  
 
Figure 14. Bicyclo[1.1.1]pentane (BCP) as a bioisosteric replacement of a phenyl ring and an internal alkyne. 
In pioneering studies, Wiberg and Michl showed that a bridgehead 1,3-disubstituted BCP 
can be accessed from a radical addition across the central bond of the [1.1.1]propellane 39 under 
photochemical conditions.82,83 Della and deMeijere described the reaction of propellane with 
strong nucleophiles such as t-BuLi, and aryl Grignard reagents to give a 1,3-disubstituted 
BCP.84,85 An alternative route was reported by Applequist et al. who utilized the addition of 
dichlorocarbene across the bicyclo[1.1.0]butane 45 followed by dechlorination to furnish the 
BCP moiety (Figure 15).86  
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Figure 15. Conventional syntheses of bridgehead 1,3-disubstituted BCP scaffolds. 
1.2.2.1 Design and synthesis of BCP analogues 
We were particularly interested in two independent BCP replacements in our analogues; one for 
the cyclopropane ring and the other for the piperazine ring. We envisioned that BCP analogues 
49 and 51 can be synthesized from a common precursor 52, which can be obtained from a free 
radical addition of the aryl iodide to propellane 39 (Figure 16).87 
 
Figure 16. Proposed strategy to access BCP analogues. 
 Starting from the commercially available methallyl dichloride 53, propellane 39 was 
obtained via a two-step procedure involving a phase-transfer dibromocarbene addition to the 
olefin followed by a lithium-halogen exchange and carbenoid promoted ring-closure.88 
Irradiation of a solution of propellane 39 and 3-iodobenzotrifluoride with a medium-pressure Hg 
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lamp at 254 nm yielded the precursor 52 in low yield. Treatment of 52 with t-BuLi and trapping 
of the resulting lithium species with carbon dioxide afforded acid 55. Finally, T3P-mediated 
amide formation delivered the desired analogue 49 where the cyclopropane was successfully 
replaced with a BCP moiety (Scheme 8). 
 
Scheme 8. Synthesis of BCP analogue 49. 
 In order to have a more accurate direct comparison of the effect of replacing the 
cyclopropane with a BCP, we also synthesized the analogue where the CF3 group on the phenyl 
ring is meta to the cyclopropane instead of the regular para position (Scheme 9). Starting from 
the Rh(II)-catalyzed cyclopropanation of 3-(trifluoromethyl)styrene, the desired cis product 58a 
was obtained in three steps as the minor diastereomer which can be purified via normal phase 
chromatography.  
 
Scheme 9. Synthesis of analogue 58a. 
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We were inspired by the work of Concellón et al. to prepare the cyclopropyl ketone 
scaffold from the reaction of cyclopropanecarboxamides, derived from morpholine, with a series 
of organolithium compounds.89 The intermediate cyclopropanecarboxamide 61 was obtained in 
three steps from the coupling of morpholine to carboxylic acid 31, and subsequent cis-
hydrogenation followed by stereospecific CrCl2-promoted cyclopropanation of the α,β-
unsaturated amide 60 in excellent yield (Scheme 10).  
 
Scheme 10. Efficient synthesis of BCP analogue 51. 
We anticipated that the generation of the corresponding lithium homologue from 52 and trapping 
with morpholine amide 61 will provide BCP analogue 51. While we could isolate the desired 
product, it appeared to be a minor compound and other unidentified major side products were 
also present. Various methods can be attempted to improve the yield, such as using Weinreb 
amide in place of morpholine amide, nickel-catalyzed reductive coupling of BCP iodide with 
cyclopropyl acid chloride, or transmetalation of BCP lithium species with ZnCl and subsequent 
acylation with cyclopropyl acid chloride. Since the compound was found to be inactive in our 
screen, no further effort was spent to optimize the conditions.  
 28 
1.2.3 Configuration determination of cyclopropane analogues 
1.2.3.1 Determination of relative configuration 
The determination of the relative configuration of the cyclopropyl ester intermediates was 
achieved by comparing distinct NMR shifts and J-coupling constants with literature compounds, 
and confirmed by X-ray structure analysis of representative compounds.  
 
Figure 17. Distinct coupling constants in the monofluorinated cyclopropane and X-ray structure of 3b. 
 One of the distinct features of the 1H NMR of the monofluorinated cyclopropane 
diastereomers is the large vicinal 3JH-F coupling constant when the hydrogen and fluorine are cis 
to one another. In the cis-diastereomer, there is only one large 3JH-F = 20.1 Hz while in the trans-
diastereomer there are two large 3JH-F, indicating two vicinal hydrogens that are cis to the 
fluorine atom (Figure 17). In addition, the 19F NMR chemical shifts of the fluorine attached to 
cis- and trans-cyclopropane are significantly different, thus enabling an assignment of the 
relative configuration. The 19F chemical shift of the cis-diastereomer is at -184.9 ppm while the 
trans-diastereomer is about 30 ppm downfield shifted to -152.6 ppm, in agreement to literature 
≡ 
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values.58 The assignment was then confirmed by the XRC structure of the trans-
cyclopropanecarboxylic acid 3b.  
 
Figure 18. Relative stereochemistry assignment of trifluoromethyl-substituted cyclopropane. 
In contrast, there was no 3JH-F coupling in the CF3-substituted cyclopropane, but we were 
still able to extract some information from proton chemical shifts and JH-H coupling constants 
(Figure 18). In the cis-diastereomer, the HB proton is the most shielded proton and thus located 
most upfield in the NMR spectrum. Its configuration is cis relative to Hx and it has a 
3JH-H 
coupling constant of 8.9 Hz, while Hx and HA are trans to one another and therefore have a 
smaller 3JH-H coupling constant of 7.2 Hz. A similar rationalization can be applied to assign the 
trans-diastereomer where HA is the most shielded proton and the coupling constant of Hx and HA 
is larger than the coupling constant of Hx and HB. Intriguingly, the HB proton in both 
diastereomers was identified to engage in a long-range “W”-coupling with the CF3 group (4JH-F = 
1.7 Hz in the cis-diastereomer and 4JH-F = 1.8 Hz in the trans-diastereomer) which led to line 
broadening and fine-splitting of the peaks. Consistent with literature examples, the 19F NMR 
chemical shift on the CF3-group in the cis-cyclopropane (-65.5 ppm) was found at approximately 
5 ppm lower field compared to the trans-cyclopropane (-70.7 ppm).64 Analogous observations 
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were made for the compounds containing a CF3-substitution at the α-carbonyl position; thus, the 
relative configurations were assigned in the same manner.  
 
Figure 19. Through-space effect of the phenyl group in the trans-cyclopropyl ester. 
Another noteworthy trend in determining the relative configuration of the cyclopropyl 
esters was that the chemical shift of the ester -OCH2 and -CH3 protons in the trans-cyclopropane 
were shifted upfield by approximately 0.3–0.4 ppm (Figure 19). This phenomenon can be 
explained by the shielding effect of the aromatic ring’s circulating π-electrons exerted through 
space on the ethyl group of the ester.90 The relative configurations of the final analogues were 
further confirmed by XRC structures of 6a, 11a, and 15 (Appendix C). 
1.2.3.2 Determination of absolute configuration 
The racemates were resolved by chiral supercritical fluid chromatography (SFC) in our lab or 
submitted to our collaborator for chiral high-performance liquid chromatography (HPLC) 
separations to deliver the pure enantiomers. The crystals of enantiomers (-)-6b, (-)-11a, and (-)-
34 were submitted to XRC for determination of absolute configuration, and the absolute 
structures of the other enantiomers were assigned tentatively based on the Cotton effect obtained 
from circular dichroism (CD) spectra and compared to (-)-6b, (-)-11a, and (-)-34.  
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CD is the differential absorption of left and right circularly polarized light at any 
wavelength by a molecule containing chiral chromophores, resulting in a Cotton effect with a 
positive or negative sign. Molecules of identical absolute configurations should give the same 
Cotton effect while the Cotton effect signs for enantiomers would be opposite of each other. In 
our case, the substrates contain two chromophores on the cyclopropane: the aromatic ring and 
the amide carbonyl. We assumed that the Cotton effects observed arose from the overall 
interaction of these two chromophores with the circularly polarized light.  
X-ray data showed that analogue (-)-6b, where the aromatic group and the amide are in a 
cis-configuration, has an absolute configuration of 1S,2S and CD spectra showed that it has a 
negative Cotton effect with λmax = 217.2 nm (Table 4, entry 1). Correspondingly, the 
difluorocyclopropane analogue (-)-34 has the same absolute configuration and a negative Cotton 
effect (entry 7). Based on this observation, we tentatively assigned the remaining substrates 
where the aromatic and amide are cis and have a negative Cotton effect with the same absolute 
configuration, while their corresponding enantiomers were assigned the opposite absolute 
configuration (entries 2-6).   
Enantiomer (-)-11a, where the two chromophores are in a trans-orientation, has an 
absolute configuration of 1S,2S based on the X-ray structure analysis. Its CD spectra showed a 
negative Cotton effect with λmax = 228.2 nm (entry 9). Accordingly, we assigned the substrates in 
which the chromophores are trans and showed a negative Cotton effect to the analogous absolute 
configuration as (-)-11a (entries 10-16). 
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Table 4. Tentative absolute configuration assignment of the analogues. 
Entry ID Relative configuration 
Optical 
Rotation 
CD λmax 
(nm) 
Absolute configuration 
1 
6b 
 
 (-) 
(-) 
217.1 
 
2 (+) 
(+) 
217.6 
 
3 
5b 
 
 (-) 
(-) 
220.8 
 
4 (+) 
(+) 
221.9 
 
5 
17 
 
 (+) 
(-) 
224.0 
 
6 (-) 
(+) 
223.1 
 
X-ray 
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Entry ID Relative configuration 
Optical 
Rotation 
CD λmax 
(nm) 
Absolute configuration 
7 
34 
 
 (-) 
(-) 
230.2 
 
8 (+) 
(+) 
230.8 
 
9 
11a 
 
 (-) 
(-) 
228.3 
 
10 (+) 
(+) 
227.7 
 
11 
6a 
 
 (-) 
(-) 
219.6 
 
12 (+) 
(+) 
216.7 
 
 
 
X-ray 
X-ray 
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Entry ID Relative configuration 
Optical 
Rotation 
CD λmax 
(nm) 
Absolute configuration 
13 
5a 
 
 (-) 
(-) 
225.6 
 
14 (+) 
(+) 
225.1 
 
15 
15 
 
 (-) 
(-) 
232.3 
 
16 (+) 
(+) 
231.8 
 
 
1.2.4 Biological data 
The in vitro metabolic stability of the analogues was analyzed via a pooled male mouse liver 
microsomes assay in the presence of the cofactor of P450 cytochrome enzyme, NADPH, by 
measuring the percent compound remaining at 0, 15, 30, 45, and 60 min via a LCMS/MS 
analysis. The negative control samples were prepared, by replacing NADPH with H2O, to 
differentiate non-metabolic related degradation of the test compounds, and a known substrate, 
verapamil, was used as the positive control.  
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Table 5. Half-life of analogues in mouse liver microsomes.a 
Entry ID Structure 
MLMb t1/2 
(min) 
1c (-)-JJ-450 
 
5.3 
2c (+)-JJ-450 
 
7.3 
3 (±)-5a 
 
n/a 
4 (-)-5a (-)-5a 6.8 
5 (+)-5a (+)-5a 28.6 
6 (±)-5b 
 
n/a 
7 (-)-5b (-)-5b 5.1 
8 (+)-5b (+)-5b 12.8 
9 (±)-6a 
 
n/a 
10 (-)-6a (-)-6a 7.3 
11 (+)-6a (+)-6a 15.0 
12 (±)-6b 
 
n/a 
13 (-)-6b (-)-6b 2.4 
14 (+)-6b (+)-6b 7.6 
15 (±)-11a 
 
n/a 
16 (-)-11a (-)-11a 11.2 
17 (+)-11a (+)-11a 2.9 
18 (±)-11b 
 
23.7 
19 (-)-11b (-)-11b n/a 
20 (+)-11b (+)-11b n/a 
a. Data obtained from Pharmaron 
b. MLM = mouse liver microsomes 
c. Synthesized by James Johnson 
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Compared to the lead compound JJ-450 (Table 5, entries 1 & 2), the addition of F- and 
CF3-substitutions around the cyclopropane ring had little effect in enhancing the metabolic 
stability of the analogues (entries 4-5, 7-8, 10-11, 13-14, 16-17, 19-20). In some cases, it was 
found that the addition of a CF3 group decreased the metabolic stability (entries 13 & 17). This 
result suggested that the major metabolic sites might not be at the cyclopropane ring. 
Table 6. Half-life of analogues with more stable side chains in mouse liver microsomes.a 
Entry ID Structure 
MLMb t1/2 
(min) 
1c (-)-KT-73-454 
 
59.4 
2c (+)-KT-73-454 
 
59.4 
3 33 
 
13.5 
4 (-)-34 
 
123.6 
5 (+)-34 
 
175.6 
6 49 
 
109.7 
7 (±)-58a 
 
n/a 
8 (-)-58a (-)-58a 5.0 
9 (+)-58a (+)-58a 27.6 
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Entry ID Structure 
MLMb t1/2 
(min) 
10c (-)-KT-76-617 
 
227.3 
11c (+)-KT-76-617 
 
158.8 
12 (±)-15 
 
n/a 
13 (-)-15 (-)-15 227.9 
14 (+)-15 (+)-15 * d 
15 (±)-17 
 
n/a 
16 (-)-17 (-)-17 457.9 
17 (+)-17 (+)-17 126.4 
a. Data obtained from Pharmaron 
b. MLM = mouse liver microsomes 
c. Synthesized by Keita Takubo 
d. * = intrinsic clearance < 0; t1/2 = ∞ 
Specifically, the data suggested that the most labile sites were the aryl rings located at the 
terminal positions as seen in the increase in t1/2 by 10-fold compared to JJ-450 when the p-fluoro 
and m-chloro on the phenyl groups were replaced by CF3 (Table 6, entries 1 & 2). Accordingly, 
we made some alterations to the core while maintaining these highly fluorinated side chains. 
Interestingly, the difluorocyclopropene analogue 33 was found to be quite stable in mouse liver 
microsomes (entry 3), while the gem-difluorocyclopropane enantiomers acquired two to three 
times longer half-lives compared to the analogues without the gem-difluoro-moiety (entries 4 & 
5). Finally, we were pleased to find that replacing the cyclopropane with a BCP scaffold also 
increased metabolic stability (entry 6 vs 8 & 9). We discovered that a further stability 
enhancement was achieved when all three substituents on the phenyl rings were replaced with 
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CF3 groups (entries 10 & 11). Once the major metabolically labile terminal positions were 
stabilized, the addition of CF3 at the α-carbonyl position of the cyclopropane ring proved to deter 
the further propagation of metabolic attack as seen in the significant increase in half-lives 
(entries 14 and 16). 
Table 7. Luciferase activity of selected analogues.a 
Entry ID Structure 
Luciferase Activity, 
EC50 ± SD (µM)b 
1 (-)-JJ-450c 
 
1.7 ± 0.2 
2 (+)-JJ-450c 
 
15.2 ± 3.3 
3 (±)-5b 
 
3.1 ± 0.5 
4 (-)-5b (-)-5b 3.2 ± 0.9 
5 (+)-5b (+)-5b 16.2 ± 3.8 
6 (±)-11a 
 
5.9 ± 2.3 
7 (-)-11a (-)-11a 15.6 ± 1.7 
8 (+)-11a (+)-11a 3.9 ± 2.6 
9 (±)-11b 
 
11.8 ± 5.7 
10 (±)-17 
 
6.9 ± 4.6 
11 (-)-17 (-)-17 9.8 ± 5.5 
12 (+)-17 (+)-17 10.6 ± 3.7 
13 33 
 
18.9 ± 5.4 
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Entry ID Structure 
Luciferase Activity, 
EC50 ± SD (µM)b 
14 (-)-34 
 
13.6 ± 3.8 
15 (+)-34 
 
4.0 ± 0.3 
16 49 
 
13.3 ± 1.2 
17 (±)-58a 
 
6.5 ± 1.1 
18 (-)-58a (-)-58a 14.4 ± 1.2 
19 (+)-58a (+)-58a 10.5 ± 2.3 
a. Data obtained from Department of Urology, University of Pittsburgh School of Medicine 
b. Assay repeats; n = 2 
c. Synthesized by James Johnson  
The luciferase activity of these analogues was determined and compared to JJ-450 using 
assay conditions developed by our collaborators using the Dual-Glo luciferase assay system 
(Promega).  All cells were treated with compounds at concentrations of 0.2 μM, 0.8 μM, 3.2 μM, 
12.8 μM, and 25 μM in triplicate wells.  In this assay, the most potent analogue was compound 
5b, and the (-)-enantiomer (EC50 = 3.2 µM) was more active than the (+)-enantiomer (Table 7, 
entry 4 vs 5). We were pleased to find that analogue (-)-17, which was one of the most 
metabolically stable compounds, was shown to possess moderate activity (entry 11). 
Interestingly, analogue 11a, where the aryl ring and the amide are trans to each other, was found 
to be more active than the diastereomer 11b (entry 6 vs 9). This result was in contrast with the 
other analogues where the more active species had a cis relationship between the aryl and amide 
moieties. The difluorocyclopropene analogue 33 maintained activity (entry 13) while the 
saturated difluorocyclopropane analogue (+)-34 showed better activity than 33 and (-)-34 (entry 
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15). It was noted that (+)-11a was also found to be more active than the (-)-enantiomer (entry 8 
vs 7). Replacing the cyclopropane with a bicyclopentane moiety showed comparable activity in 
49 (entry 16 vs 17-19). 
1.2.5 Conclusion 
A total of 32 fluorinated analogues were synthesized and tested for their microsomal metabolic 
stability and their ability to inhibit AR signaling in CRPC cell lines. Structurally unique scaffolds 
such as the gem-difluorocyclopropane and BCP were successfully incorporated following an 
intensive method optimization. The further expansion on the BCP analogues seemed promising 
but its tedious and challenging synthetic route would be a major drawback for compound 
derivatizations in drug development.  
The benzylic positions on the phenyl side chains of JJ-450 were found to have a more 
rapid metabolism rate than the cyclopropane ring. The enhancement of metabolic stability from 
the addition of fluorine atoms around the cyclopropane ring was more significant when the 
terminal substituents were highly fluorinated. On the other hand, there was no distinctive trend in 
the structure-activity relationship from the luciferase assay. We found that some of the data 
provided by our collaborators were inconsistent and we were unable to draw a distinct 
correlation between the structures and measured activity. However, all the analogues were also 
submitted for multiple studies such as protein binding studies, dog and human liver microsome 
studies, as well as a cytotoxicity assay. Results from these assays are still pending, and the lead 
compounds for further development will be selected based on optimal properties in all assays. At 
the next stage, animal studies will be used to evaluate antitumor potential in the most resistant 
prostate cancer cell lines.  
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2.0  EFFORTS TOWARD AN ENANTIOSELECTIVE CO(II)-CATALYZED 
CYCLOPROPANATION  
2.1 INTRODUCTION 
2.1.1 Synthetic route toward JJ-450 and its analogues 
Racemic JJ-450 was synthesized over five steps, and the construction of the cyclopropane was 
achieved via hydrogenation of the internal alkyne 63 followed by a stereospecific CrCl2-
promoted cyclopropanation of the cis-alkene 64 (Scheme 11).47  
 
Scheme 11. Synthetic route to racemic JJ-450 and chromatographic resolution. 
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 This process was employed for the scale-up synthesis of JJ-450 as well as analogues with 
a similar cis-1,2-disubstituted cyclopropane scaffold. However, there were a few major 
drawbacks that we hoped to improve. A significant amount of material was lost in the chiral 
separation as the recovery was only approximately 50–60%. Another disadvantage of this route 
was the need for a large excess of cyclopropanating reagents, CrCl2 (6.0 eq) and 
chloroiodomethane (5.0 eq). Inductively coupled plasma optical emission spectrometry (ICP-
OES) analyses showed that final compounds were found to still be contaminated with chromium 
(1.33 ppm Cr), and had to be filtered through basic alumina multiple times to ensure complete 
removal of the excess chromium, which is known to be highly toxic. We aimed to develop an 
efficient enantioselective route to eliminate the need for chiral separation and chromium reagents 
in our syntheses.  
2.1.2 Enantioselective cis-cyclopropanation 
One of the most versatile approaches to construct 1,2-disubstituted cyclopropyl esters or 
cyclopropyl amides is the addition of a carbene derived from the metal-catalyzed decomposition 
of a diazo compound to an olefin.91, 92 There is a plethora of literature devoted to catalysts that 
competently mediate the diastereoselective and enantioselective synthesis of trans-
cyclopropanes.93-95 On the other hand, there is still much development needed to improve the 
diastereoselective synthesis of the thermodynamically less favorable cis-cyclopropanes, and 
reports on asymmetric routes are scarce.96,97 Katsuki’s group made a major contribution in the 
advancement of cis- and enantioselective cyclopropanation using chiral Co, Ru, and Ir catalysts 
with simple olefins and diazoacetates (Scheme 12).  
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 They reported the first highly cis- and enantioselective cyclopropanation using (R,R)-
(NO+)(salen)ruthenium(II) complex 65 (up to 89% ee) under incandescent light.98 It was 
hypothesized that a transient active species was generated by a ligand-dissociation induced by 
irradiation, as the reaction was slow and diastereoselectivity was poor when the reaction was 
carried out in the dark. However, the mechanism of asymmetric induction was unclear. 
 
Scheme 12. Katsuki’s development of an asymmetric cis-cyclopropanation. 
 Nakamura et al. initially developed a chiral Co(II)-salen complex for asymmetric 
cyclopropanation but the stereoselectivity was unsatisfactory.99 Having been successful in 
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developing a trans-selective Co(III)-salen complex, Katsuki and coworkers attempted to prepare 
a novel Co(II)-salen complex that has the same ligand as complex 65 for a cis-selective 
cyclopropanation.100,102 Indeed, the reaction using Co(II)-salen complex 66 furnished the desired 
cis-cyclopropane with an outstanding 98:2 cis/trans dr and 98% ee. The optimized conditions 
were applied to other p-substituted styrenes, and commercially available ethyl diazoacetate also 
delivered the corresponding cis-product in excellent yield and selectivity. It was interesting to 
note that complex 67, which is different in the diamine chirality, delivered the cis-product with 
the opposite enantioselectivity, albeit with a sluggish reaction and much lower yield.  
 Within the Group 9 metals, Ir remained rather unexplored for this type of reaction at that 
time, which prompted Katsuki’s group to venture into the advancement of a new class of Ir(III)-
complexes.103 To their delight, complex 68 was found to give the respective cis-isomer in 
quantitative yield and quintessential diastereo- and enantioselectivity when the reactions were 
carried out at low temperature. Unlike other Ir catalysts, this type of Ir(III)-salen complex is air 
stable and can be easily handled on the benchtop.  
 To date, the results on this topic from Katsuki’s group remain the state of art and limited 
further discoveries have been made in the past decade for asymmetric cyclopropanations. Based 
on its overall performance and opportunity to fine-tune the catalyst, we selected Co(II)-salen 
complex 66 as a starting point for the cyclopropanation of our substrate. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Design and synthesis of Co(II)-salen complexes 
The synthesis of the salen ligand began with the treatment of commercially-available (R)-binol 
with N-phenylbistrifluoromethanesulfonamide to give monotriflate 69 which was subjected to a 
Kumada coupling with phenylmagnesium bromide in the presence of a NiCl2(dppe) catalyst 
(Scheme 13). Intermediate 70 was protected as a MOM ether 71, then underwent a formylation 
reaction with DMF to give aldehyde 72. MOM deprotection with trimethylsilyl bromide gave the 
free alcohol 73, and a condensation reaction with (1R,2R)-(−)-1,2-diaminocyclohexane afforded 
the tetradentate salen ligand. Coordination of cobalt (II) with the salen ligand in ethanol 
delivered the corresponding Co(II)-salen complex 66, which can be easily handled in air and 
stored in the desiccator over several months.104-105   
 
Scheme 13. Synthesis of Co(II)-salen complex 66. 
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We examined the efficiency of this Co(II)-salen complex in the cyclopropanation of p-
CF3 and m-CF3 styrene. We were delighted to find that the cyclopropyl esters 74 and 75 were 
obtained in excellent yields and high cis-selectivity with a 99:1 dr (Scheme 14). Saponification 
of the ester to the corresponding carboxylic acid proceeded smoothly with retention of 
stereochemistry, and subsequent T3P coupling with piperazine C delivered the final cis-
analogues (+)-78 and (+)-79. Chiral SFC analyses revealed that the major enantiomers were 
obtained with enantioselectivities up to 94% ee. The absolute configurations were assigned by 
comparison of the elution order with previously analyzed samples of the same compound. This 
approach successfully simplified and improved the original synthesis as the enantiopure 
analogues can now be readily synthesized over three high-yielding steps under mild conditions 
without the need for additional chiral separation. 
 
Scheme 14. Asymmetric route for the synthesis of analogues with complex 66. 
Motivated by these results, we proceeded to synthesize the Co(II)-salen complex that 
would provide the opposite enantiomer. Katsuki and coworkers noted that the enantioselectivity 
is dictated by the chirality of the diamine. Even though they were able to obtain excellent 
selectivity for the opposite enantiomer by reversing the chirality of the diamine, the reaction was 
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very sluggish. To explore the possibility of increasing the throughput, we decided to synthesize a 
Co(II)-salen complex that has both its diamine and binaphthyl chirality reversed, which is 
essentially the enantiomer of complex 66. In an attempt to further improve the enantioselectivity, 
we also synthesized complexes 81 and 82, where the phenyl group was replaced by the bulkier 
(naphthyl)phenyl substituent (Figure 20). We envisioned that the steric hindrance imposed by 
the bulkier substituent would limit the flexibility of the salen ligand and lock its transition state 
in a single conformation to deliver the product with high selectivity. These complexes have not 
been prepared or tested for their efficiency in enantioselective cyclopropanation. 
 
Figure 20. Novel Co(II)-salen complexes 80-82. 
Table 8. Asymmetric cyclopropanation using Co(II)-salen complexes 
Entry Catalyst Yield of 74 (%) cis:trans 74a % ee of 78 
1 80 84 95:5 93.4b 
2 81 99 99:1 96.8c 
3 82 90 99:1 96.8c 
a. Determined by 1H NMR analysis 
b. Absolute configuration is 1S,2R 
c. Absolute configuration is 1R,2S 
The novel Co(II)-salen complex 80 was synthesized analogously using (S)-binol and 
(1S,2S)-(+)-1,2-diaminocyclohexane as the chiral components. We found that the desired cis-
cyclopropyl ester 74 was obtained in 84% yield with a 95:5 dr, a huge improvement compared to 
Katsuki’s complex 67 in terms of isolated yield. After subsequent saponification and T3P 
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coupling, (-)-78 was attained with an enantioselectivity of 93.4% ee (Table 8, entry 1). We were 
extremely pleased to discover that catalysts 81 and 82 showed excellent cis-selectivity (99:1 dr) 
and enhanced enantioselectivity of 96.8% ee (entries 2 and 3). 
2.2.2 Gram-scale Co(II)-salen catalyzed asymmetric cyclopropanation 
 
Scheme 15. Gram-scale enantioselective synthesis of analogues. 
As a proof-of-concept, we utilized this enantioselective route for the scale up synthesis of 
analogues containing the pentafluorosulfanyl (SF5) moiety. The starting material 4-
(pentafluorosulfanyl)styrene was obtained from the Wittig reaction of commercially available 4-
(pentafluorosulfanyl)benzaldehyde according to a literature protocol. The cyclopropanation of 4-
(pentafluorosulfanyl)styrene using catalyst 80 afforded cyclopropyl ester 83 in 92% yield and 
>95:5 dr. The Co(II)-complex can be recovered by trituration with hexanes and reused. 
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Subsequent saponification and T3P-coupling provided analogues 85 and 86 in excellent yield 
and ee. The desired enantiomer of each analogue was enriched by recrystallization from 
CH2Cl2/hexanes to 98.6% ee and 97.6% ee respectively. All in all, we successfully obtained 1.9 
– 2.0 g of the final enantiomers over three high yielding steps.  
2.2.3 Proposed mechanism for asymmetric induction 
The mechanism for asymmetric induction in the metal-salen system was studied intensively by 
Katsuki’s group. XRC structures of other salen-Mn(III) and salen-Co(II) have been 
determined.106,107 Based on these results and the observed selectivity, they proposed that these 
salen-Co(IV) intermediates derived from their corresponding Co(II) complexes will also adopt a 
homologous conformation as the literature complexes.108  
They assumed that the flexible salen ligand in the Co(IV)-carbenoid species will take a 
folded stepped-conformation, where the naphthalene rings are orthogonal (Figure 21). The five-
membered chelate rings including the Co-ion and the two imino nitrogen atoms are assumed to 
adopt a half-chair conformation, and the nitrogen atoms are at an equatorial position on the 
cyclohexyl ring. In the (1R,2R,R,R)-87 species derived from 66, the ester group is shown to 
protrude forward due to the presence of 2”-phenyl group located at the back, which allows the 
olefin to approach the carbenoid over the downward naphthalene ring side along the Co-Nb bond 
and rotate counterclockwise to attain the observed cis-enantioselectivity (Figure 21, top right). 
Katsuki’s group observed that switching the chirality of the diamine will give the 
opposite enantiomer, which is due to the change in the folding that positions the diamine in the 
equatorial position as shown in (1S,2S,R,R)-88 (Figure 21, bottom left). The olefin now 
approaches the carbenoid center along the less hindered Co-Na axis over the downward 
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naphthalene ring. However, the approaching pathway of the olefin is obstructed by the 2”-phenyl 
group, thus resulted in a sluggish and low yielding reaction.  
The Co(II)-salen complex 80 that we synthesized effectively solved this problem as it 
adopts the conformation as shown in (1S,2S,S,S)-89 (Figure 21, bottom right). The enantioface 
selectivity is still controlled by the chiral diamine but the 2”-phenyl group no long protrudes 
toward the olefin’s approaching path as it is located below the downward naphthalene ring. The 
olefin can now access the carbenoid center smoothly to give the cis-product with excellent 
enantioselectivity. 
 
Figure 21. Proposed model for the conformation of the Co(IV)-carbenoid species. 
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2.2.4 Conclusion 
Despite the relatively tedious synthetic route to the Co(II)-salen complexes 66 and 80 – 82, we 
were able to conveniently access both enantiomers in high yields and % ee. The catalyst was 
shown to be highly efficient in providing the desired enantiomers in large scale without the need 
for additional chiral resolution step. The sophisticated mechanistic control of the diastereo- and 
enantioselectivity rendered the Co(II)-salen complex a very useful catalyst for asymmetric 
cyclopropanation.  
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3.0  EXPERIMENTAL SECTION 
3.1 GENERAL PROCEDURE 
Moisture and air-sensitive reactions were performed under a N2 or Ar atmosphere and glassware 
used for these reactions was flamed dried and cooled under N2 or Ar prior to use. THF and Et2O 
were distilled from sodium/benzophenone ketyl. Toluene and CH2Cl2 were distilled from CaH2. 
CrCl2 was stored and used in a glovebox. Melting points were determined using a Mel-Temp II 
instrument and are not corrected. Infrared spectra were determined using a Smiths Detection 
IdentifyIR FT-IR spectrometer. High resolution mass spectra were obtained on a Micromass UK 
Limited, Q-TOF Ultima API, Thermo Scientific Exactive Orbitrap LC-MS. Automated column 
chromatography was done using an Isco Combiflash Rf. 1H and 13C NMR spectra were obtained 
on Bruker Advance 300 MHz, 400 MHz, or 500 MHz instruments. Chemical shifts (δ) were 
reported in parts per million with the residual solvent peak used as an internal standard, δ 1H/13C 
(Solvent): 7.26/77.16 (CDCl3); 2.50/39.52 (DMSO-d6); and are tabulated as follows: chemical 
shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, br d = broad doublet, t = triplet, 
app t = apparent triplet, q = quartet, m = multiplet), coupling constant(s), and number of protons. 
13C NMR spectra were obtained at 75 MHz, 100 MHz, or 125 MHz using a proton-decoupled 
pulse sequence and are tabulated by observed peak. CDCl3 was filtered through dried basic 
alumina prior to use. Thin-layer chromatography was performed using pre-coated silica gel 60 
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F254 plates (EMD, 250 µm thickness) and visualization was accomplished with a 254 nm UV 
light and by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 95% 
EtOH) or a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH 
solution). Chromatography on SiO2 (Silicycle, Silia-P Flash Silica Gel or SiliaFlash® P60, 40-63 
µm) was used to purify crude reaction mixtures. Final products were of >95% purity as analyzed 
by RP HPLC (Alltech Prevail C-18, 100 × 4.6 mm, 1 mL/min, CH3CN, H2O and 0.1% TFA) 
with UV (210, 220 and 254 nm), ELS (nebulizer 45 oC, evaporator 45 oC, N2 flow 1.25 SLM), 
and MS detection using a Thermo Scientific Exactive Orbitrap LC-MS (ESI positive). All other 
materials were obtained from commercial sources and used as received. 
3.2 EXPERIMENTAL PROCEDURES 
 
 
cis- and trans-Ethyl 2-fluoro-2-(4-fluorophenyl)cyclopropane-1-carboxylate (1a and 1b).58 
In a flame-dried 3-neck round-bottom flask equipped with a stir bar, reflux condenser, septum, 
and stopper, Cu(acac)2 (64.9 mg, 0.248 mmol, 3 mol%) was dissolved in distilled CH2Cl2 (11 
mL). The solution was stirred for several minutes. A few drops of phenylhydrazine were added 
and the stirring continued. 1-Fluoro-4-(1-fluorovinyl)benzene (1.16 g, 8.27 mmol) was added 
and the mixture was heated to reflux. A solution of ethyl diazoacetate (1.48 mL, 12.4 mmol) in 
distilled CH2Cl2 (22 mL) was added via syringe pump over 8 h. The solution was then heated to 
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reflux for an additional 4 h, after which it was cooled and diluted with CH2Cl2 (150 mL). The 
solution was washed with saturated NaHCO3 solution and distilled water (300 mL). The organic 
layer was dried (MgSO4), filtered, and concentrated under reduced pressure. NMR analysis of 
the crude product revealed a conversion of 65%. Purification of the crude product with 
chromatography on SiO2 (1:1 CH2Cl2/hexanes) afforded a mixture of 1:1 cis/trans diastereomers 
as a yellow oil. The diastereomers were separated by chromatography on SiO2 (1:2 
CH2Cl2/hexanes) where the trans-isomer eluted first followed by the cis-isomer. cis-1a (474 mg, 
2.10 mmol, 25%): 1H NMR (500 MHz, CDCl3) δ  7.32 (dd, J = 8.1, 5.2 Hz, 2 H), 7.08 (t, J = 8.4 
Hz, 2 H), 4.29-4.19 (m, 2 H), 2.28 (dt, J = 20.1, 7.4 Hz, 1 H), 2.15 (ddd, J = 9.5, 7.7, 2.7 Hz, 1 
H), 1.59 (ddd, J = 10.5, 9.5, 7.1 Hz, 1 H), 1.30 (t, J = 7.1 Hz, 3 H); 13C NMR (75 MHz; CDCl3) δ  
167.9 (d, JC-F = 2 Hz), 162.9 (dd, J C-F = 248, 2 Hz), 133.4 (dd, J C-F = 22, 3 Hz), 127.3 (dd, J C-F = 
8, 6 Hz), 115.8 (d, J C-F = 22 Hz), 80.7 (d, J C-F = 228 Hz), 61.4, 28.8 (d, J C-F = 12 Hz), 18.8 (d, J 
C-F = 13 Hz), 14.4; 
19F NMR (CDCl3, 470 MHz) δ  -113.2 (s, 1 F), -184.9 (s, 1 F).  
trans-1b (481 mg, 2.13 mmol, 26%): 1H NMR (CDCl3, 500 MHz) δ  7.48-7.44 (m, 2 H), 7.06 (t, 
J = 8.4 Hz, 2 H), 3.98-3.90 (m, 2 H), 2.56 (ddd, J = 17.8, 10.3, 7.6 Hz, 1 H), 1.95 (dt, J = 12.2, 
7.3 Hz, 1 H), 1.82 (ddd, J = 19.2, 10.3, 7.1 Hz, 1 H), 1.04 (t, J = 7.1 Hz, 3 H); 13C NMR (CDCl3, 
125 MHz) δ  169.0 (d, J C-F = 2 Hz), 163.3 (dd, J C-F = 249, 3 Hz), 130.6 (dd, J C-F = 8, 4 Hz), 
129.3 (dd, J C-F = 21, 3 Hz), 115.5 (dd, J C-F = 22, 2 Hz), 82.6 (d, J C-F = 221 Hz), 60.98, 27.9 (d, 
J C-F = 17 Hz), 16.8 (d, J C-F = 11 Hz), 14.14; 
19F NMR (CDCl3, 470 MHz) δ  -111.8 (s, 1 F), -
152.6 (s, 1 F). 
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cis- and trans-Ethyl-2-(4-fluorophenyl)-2-(trifluoromethyl)cyclopropane-1-carboxylate (2a 
and 2b). To a flame-dried round-bottom flask was added Rh2(OAc)4 (128 mg, 0.290 mmol, 5 
mol%) and 1-fluoro-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene (1.20 g, 5.81 mmol) in distilled 
CH2Cl2 (5 mL). A solution of ethyl diazoacetate (1.04 mL, 8.71 mmol) in CH2Cl2 (18 mL) was 
added via syringe pump over 16 h at room temperature. After addition of the diazo compound, 
TLC analysis showed that there was still alkene present. Another 2 mol% of the Rh2(OAc)4 
catalyst was added and 0.5 equiv of diazo compound dissolved in CH2Cl2 (10 mL) was added 
dropwise over 9 h. The mixture was filtered through a plug of SiO2 and washed with CH2Cl2. 
The solution was concentrated under reduced pressure and the crude mixture was purified via 
chromatography on SiO2 (1:2 CH2Cl2/hexanes), where the trans-isomer eluted first followed by 
cis-isomer, as yellow oils. cis-2a (554 mg, 2.01 mmol, 35%):  1H NMR (CDCl3, 500 MHz) δ 
7.47 (dd, J = 8.6, 5.3 Hz, 2 H), 7.08-7.02 (m, 2 H), 4.32-4.18 (m, 2 H), 2.23 (t, J = 8.1 Hz, 1 H), 
2.04 (dd, J = 7.2, 5.9 Hz, 1 H), 1.46 (ddq, J = 8.9, 5.7, 1.7 Hz, 1 H), 1.31 (t, J = 7.1 Hz, 3 H); 13C 
NMR (CDCl3, 125 MHz) δ  168.0, 163.0 (d, J C-F = 248 Hz), 132.8 (d, J C-F = 9 Hz), 131.8 (d, J C-
F = 3 Hz), 125.2 (q, J C-F = 276 Hz), 115.7 (d, J C-F = 22 Hz), 61.7, 35.0 (q, J C-F = 34 Hz), 27.5, 
14.5 (q, J C-F = 2 Hz), 14.2; 
19F NMR (CDCl3, 471 MHz) δ  -65.6 (s, 3 F), -112.4 (s, 1 F). 
trans-2b (662 mg, 2.40 mmol, 41%); 1H NMR (CDCl3, 500 MHz) δ 7.34 (dd, J = 8.6, 5.3 Hz, 2 
H), 7.05-7.00 (m, 2 H), 4.01-3.91 (m, 2 H), 2.48 (dd, J = 8.8, 6.3 Hz, 1 H), 1.83 (tq, J = 5.8, 1.8 
Hz, 1 H), 1.72 (dd, J = 8.8, 5.5 Hz, 1 H), 1.07 (t, J = 7.1 Hz, 3 H); 13C NMR (CDCl3, 100 MHz) 
δ  168.7, 163.0 (d, J C-F = 248 Hz), 133.0 (d, J C-F = 9 Hz), 127.4 (d, J C-F = 3 Hz), 125.0 (q, J C-F = 
274 Hz), 115.6 (d, J C-F = 22 Hz), 61.3, 35.2 (q, J C-F = 34 Hz), 23.8 (q, J C-F = 2 Hz), 14.7 (q, J C-F 
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= 2 Hz), 14.1; 19F NMR (CDCl3, 471 MHz) δ  -70.7 (s, 3 F), -112.4 (s, 1 F). A fraction 
containing a mixture of both diastereomers was also obtained (192 mg, 0.694 mmol, 12%).  
 
 
cis-2-Fluoro-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid (3a).58 To a solution of 1a 
(0.200 g, 0.884 mmol) in methanol (1.8 mL) was added KOH (0.500 g, 8.84 mmol) in methanol 
(4.4 ml) at 0 oC. The reaction mixture was warm to room temperature and stirred for 16 h. The 
mixture was poured into water and extracted with CH2Cl2 (25 mL). The organic layer was 
discarded and the aqueous layer was acidified with 6 M HCl and extracted with CH2Cl2 (2 x 25 
mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure 
to afford 3a (0.171 g, 0.864 mmol, 98%) as a white solid: 1H NMR (CDCl3, 500 MHz) δ  7.36-
7.32 (m, 2 H), 7.12-7.07 (m, 2 H), 2.32 (dt, J = 20.1, 7.5 Hz, 1 H), 2.18 (ddd, J = 9.5, 7.5, 2.2 
Hz, 1 H), 1.70 (ddd, J = 10.7, 9.4, 7.2 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) δ  173.0, 163.0 
(dd, J C-F = 248, 2 Hz), 132.8 (dd, J C-F = 22, 3 Hz), 127.5 (dd, J C-F = 9, 6 Hz), 115.9 (d, J C-F = 
22 Hz), 81.3 (d, J C-F = 229 Hz), 28.3 (d, J C-F = 12 Hz), 19.3 (d, J C-F = 12 Hz). 
 
 
trans-2-Fluoro-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid (3b).58 To a solution of 1b 
(0.200 g, 0.884 mmol) in methanol (1.8 mL) was added KOH (0.500 g, 8.84 mmol) in methanol 
(4.4 ml) at 0 oC. The reaction mixture was warm to room temperature and stirred for 16 h. The 
mixture was poured into water and extracted with CH2Cl2 (25 mL). The organic layer was 
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discarded and the aqueous layer was acidified with 6 M HCl and extracted with CH2Cl2 (2 x 25 
mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure 
to afford 3b (0.175 g, 0.884 mmol, quant.) as a white solid: 1H NMR (CDCl3, 500 MHz) δ  7.45-
7.41 (m, 2 H), 7.05 (t, J = 8.6 Hz, 2 H), 2.52 (ddd, J = 17.4, 10.0, 7.5 Hz, 1 H), 1.94-1.83 (m, 2 
H); 13C NMR (CDCl3, 100 MHz) δ  174.3, 163.4 (dd, J C-F = 249, 3 Hz), 130.6 (dd, J C-F = 9, 4 
Hz), 128.6 (dd, J C-F = 21, 3 Hz), 115.5 (d, J C-F = 22 Hz), 83.1 (d, J C-F = 222 Hz), 27.5 (d, J C-F 
= 17 Hz), 17.5 (d, J C-F = 10 Hz). 
 
 
cis-2-(4-Fluorophenyl)-2-(trifluoromethyl)cyclopropane-1-carboxylic acid (4a). To a 
solution of KOH (0.463 g, 8.25 mmol) in methanol (3.6 ml) was added 2a (0.228 g, 0.825 mmol) 
in methanol (1.5 mL) at 0 oC. The reaction mixture was gradually warm to room temperature and 
stirred for 12 h. The mixture was poured into water and extracted with CH2Cl2 (25 mL). The 
organic layer was discarded and the aqueous layer acidified with 6 M HCl and extracted with 
CH2Cl2 (2 x 25 mL). The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure to give 4a (0.202 g, 0.812 mmol, 98 %) as a white solid: 1H NMR (CDCl3, 500 
MHz) δ 7.47 (dd, J = 8.6, 5.2 Hz, 2 H), 7.09-7.02 (m, 2 H), 2.28 (t, J = 8.0 Hz, 1 H), 2.09 (dd, J 
= 7.3, 5.9 Hz, 1 H), 1.57-1.53 (m, 1 H); 19F NMR (CDCl3, 471 MHz) δ  -65.3 (s, 3 F), -112.1 (s, 
1 F). 
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trans-2-(4-Fluorophenyl)-2-(trifluoromethyl)cyclopropane-1-carboxylic acid (4b). To a 
solution of KOH (0.406 g, 7.24 mmol) in methanol (3.6 ml) was added 2b (0.200 g, 0.724 mmol) 
in methanol (1.5 mL) at 0 oC. The reaction mixture was gradually warm to room temperature and 
stirred for 12 h. The mixture was poured into water and extracted with CH2Cl2 (25 mL). The 
organic layer was discarded and the aqueous layer acidified with 6 M HCl and extracted with 
CH2Cl2 (2 x 25 mL). The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure to give 4b (0.181 g, 0.731 mmol, 98 %) as a white solid: 1H NMR (CDCl3, 500 
MHz) δ 7.32 (dd, J = 8.3, 5.4 Hz, 2 H), 7.02 (t, J = 8.6 Hz, 2 H), 2.49-2.45 (m, 1 H), 1.77 (dq, J 
= 8.3, 2.9 Hz, 2 H); 19F NMR (CDCl3, 471 MHz) δ  -70.9 (s, 3 F), -112.1 (s, 1 F). 
 
 
cis-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1SR,2RS)-2-fluoro-2-(4-
fluorophenyl)cyclopropyl)methanone (5a). To a solution of 3a (0.0500 g, 0.252 mmol) in 
distilled CH2Cl2 (2.5 mL) at 0 
oC was added 1-(5-chloro-2-methylphenyl)piperazine 
hydrochloride (0.0750 g, 0.303 mmol) and triethylamine (0.11 mL, 0.757 mmol). The cooled 
solution was then treated with T3P (50 wt.% solution in EtOAc, 0.27 mL, 0.378 mmol) 
dropwise. The reaction mixture was stirred at 0 oC for 30 min and allowed to warm to room 
temperature and stirred for 16 h. The reaction was diluted with CH2Cl2 (30 mL) and washed with 
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1 M HCl (20 mL), saturated NaHCO3 (20 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude brown oil residue was purified via chromatography on SiO2 (2:3 
EtOAc/hexanes) to afford 5a (79.1 mg, 0.200 mmol, 79 %) as a white solid: Mp 110.2 – 110.8 
oC (hexanes); IR (CDCl3) 2918, 2819, 1646, 1593, 1516, 1430, 1223, 831, 809, 730 cm
-1; 1H 
NMR (CDCl3, 500 MHz) δ  7.26 (m, 2 H), 7.10 (t, J = 7.8 Hz, 3 H), 6.98 (dd, J = 8.1, 1.9 Hz, 1 
H), 6.93 (d, J = 1.8 Hz, 1 H), 4.04-4.01 (m, 1 H), 3.67-3.57 (m, 3 H), 2.92-2.79 (m, 4 H), 2.39 
(dt, J = 20.7, 7.6 Hz, 1 H), 2.25 (s, 3 H), 2.19 (ddd, J = 9.8, 7.9, 4.6 Hz, 1 H), 1.63-1.58 (m, 2 H); 
13C NMR (CDCl3, 150 MHz) δ  164.7, 162.6 (d, J C-F = 248 Hz), 152.0, 133.9 (d, J C-F = 22 Hz), 
132.2 (d, J C-F = 24 Hz), 132.0, 131.1, 125.6-125.5 (m), 123.8 (d, J C-F = 25 Hz), 119.9 (d, J C-F = 
22 Hz), 116.2-115.9 (m), 79.9 (d, J C-F = 222 Hz), 52.1, 51.7, 46.2, 43.0, 30.5 (d, J C-F = 14 Hz), 
17.7 (d, J C-F = 12 Hz), 17.6; 
19F NMR (CDCl3, 470 MHz) δ  -113.88 (s, 1 F), -188.55 (s, 1 F); 
HRMS (ESI) m/z calcd for C21H22ClF2N2O ([M+H]
+) 391.1383, found 391.1386. 
 
 
trans-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1SR,2RS)-2-fluoro-2-(4-
fluorophenyl)cyclopropyl)methanone (5b). To a solution of 3b (0.0500 g, 0.252 mmol) in 
distilled CH2Cl2 (2.5 mL) at 0 
oC was added 1-(5-chloro-2-methylphenyl)piperazine 
hydrochloride (0.0750 g, 0.303 mmol) and triethylamine (0.11 mL, 0.757 mmol). The cooled 
solution was then treated with T3P (50 wt.% solution in EtOAc, 0.27 mL, 0.378 mmol) 
dropwise. The reaction mixture was stirred at 0 oC for 30 min and allowed to warm to room 
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temperature and stirred for 16 h. The reaction was diluted with CH2Cl2 (30 mL) and washed with 
1 M HCl (20 mL), saturated NaHCO3 (20 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude brown oil residue was purified via chromatography on SiO2 (2:3 
EtOAc/hexanes) to afford 5b (76.0 mg, 0.195 mmol, 77 %) as a colorless oil: IR (CDCl3) 2922, 
2855, 1641, 1593, 1517, 1432, 1225, 1193, 812, 735. 1H NMR (CDCl3, 500 MHz) δ  7.34-7.30 
(m, 2 H), 7.10-7.06 (m, 3 H), 6.97 (dd, J = 8.1, 2.1 Hz, 1 H), 6.74 (d, J = 2.1 Hz, 1 H), 3.78-3.75 
(m, 1 H), 3.66 (t, J = 5.0 Hz, 2 H), 3.40 (ddd, J = 12.4, 8.6, 3.3 Hz, 1 H), 2.85-2.81 (m, 1 H), 
2.77-2.73 (m, 1 H), 2.68 (ddd, J = 18.8, 10.9, 7.9 Hz, 1 H), 2.38 (ddd, J = 11.5, 8.3, 3.0 Hz, 1 H), 
2.30 (dt, 1 H, J = 11.4, 5.7 Hz), 2.22 (s, 3 H), 2.11 (dt, J = 12.3, 7.6 Hz, 1 H), 1.84 (ddd, J = 
20.6, 10.8, 7.4 Hz, 1 h); 13C NMR (CDCl3, 100 MHz) δ  165.3, 162.8 (d, J C-F = 248 Hz,), 151.8, 
132.1 (d, J C-F = 21 Hz), 131.1, 130.6 (dd, J C-F = 21, 3 Hz), 127.6 (d, J C-F = 7 Hz), 127.5, 123.9, 
119.8, 115.5 (d, J C-F = 22 Hz), 81.5 (d, J C-F = 222 Hz), 51.9, 51.6, 46.1, 42.5, 29.6 (d, J C-F = 13 
Hz), 17.5, 16.5 (d, J C-F = 10 Hz); 
19F NMR (CDCl3, 470 MHz) δ  -113.19 (s, 1 F), -164.01 (s, 1 
F); HRMS (ESI) m/z calcd for C21H22ClF2N2O ([M+H]
+) 391.1383, found 391.1384. 
 
 
Racemic trans-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1SR,2RS)-2-fluoro-2-(4-
fluorophenyl)cyclopropyl)methanone was separated on a SFC Chiralpak-IC semiprep (250 x 
10 mm) column (30% MeOH, 7 mL/min, 220 nM, P=100) to afford (-)-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)(-2-fluoro-2-(4-fluorophenyl)cyclopropyl)methanone (retention 
time 4.76 min) as a colorless oil (100% purity by ESLD): [a]20D -141.9 (c 0.84, MeOH); 
1H 
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NMR (CDCl3, 500 MHz) δ  7.35-7.31 (m, 2 H), 7.10-7.06 (m, 3 H), 6.97 (dd, J = 8.1, 2.1 Hz, 1 
H), 6.75 (d, J = 2.1 Hz, 1 H), 3.78-3.74 (m, 1 H), 3.69-3.64 (m, 2 H), 3.43-3.38 (m, 1 H), 2.85-
2.81 (m, 1 H), 2.77-2.73 (m, 1 H), 2.68 (ddd, J = 18.8, 10.9, 7.9 Hz, 1 H), 2.41-2.37 (m, 1 H), 
2.31 (td, J = 11.0, 5.4 Hz, 1 H), 2.22 (s, 3 H), 2.11 (dt, J = 12.3, 7.6 Hz, 1 H), 1.84 (ddd, J = 
20.5, 10.8, 7.4 Hz,1 H); HRMS (ESI) m/z calcd for C21H22ClF2N2O ([M+H]
+) 391.1383, found 
391.1379. The enantiomeric excess was >99% ee (SFC Chiralpak-IC (250 x 10 mm); 30% 
MeOH, 220 nm, 7 mL/min; retention time: 4.77 min). 
(+)-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(-2-fluoro-2-(4-
fluorophenyl)cyclopropyl)methanone (retention time 5.60 min) was obtained as a colorless oil 
(100% purity by ESLD): [a]20D +145.1 (c 0.86, MeOH); 
1H NMR (CDCl3, 500 MHz) δ  7.34-
7.31 (m, 2 H), 7.10-7.06 (m, 3 H), 6.97 (dd, J = 8.1, 2.1 Hz, 1 H), 6.75 (d, J = 2.0 Hz, 1 H), 3.79-
3.74 (m, 1 H), 3.69-3.65 (m, 2 H), 3.43-3.38 (m, 1 H), 2.85-2.81 (m, 1 H), 2.77-2.73 (m, 1 H), 
2.68 (ddd, J = 18.9, 10.9, 8.0 Hz, 1 H), 2.39 (ddd, J = 11.2, 8.8, 2.6 Hz, 1 H), 2.31 (dt, J = 11.3, 
5.8 Hz, 1 H), 2.22 (s, 3 H), 2.11 (dt, J = 12.3, 7.6 Hz, 1 H), 1.84 (ddd, J = 20.5, 10.8, 7.4 Hz, 1 
H); HRMS (ESI) m/z calcd for C21H22ClF2N2O ([M+H]
+) 391.1383, found 391.1374. The 
enantiomeric excess was >99% ee (SFC Chiralpak-IC (250 x 10 mm); 30% MeOH, 220 nm, 7 
mL/min; retention time: 5.60 min).  
 
Figure 22. SFC chromatogram of racemic 5b. 
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Figure 23. SFC resolution of (-)-5b. 
 
 
Figure 24. SFC resolution of (+)-5b. 
 
 
cis-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1SR,2RS)-2-(4-fluorophenyl)-2-
(trifluoromethyl)cyclopropyl)methanone (6a). A solution 4a (0.100 g, 0.403 mmol) and 1-(5-
chloro-2-methylphenyl)piperazine hydrochloride (0.120 g, 0.484 mmol) in distilled CH2Cl2 (4 
mL) was cooled to 0 oC and then added with triethylamine (0.168 mL, 1.21 mmol). The cooled 
solution was then treated with T3P (50wt.% solution in EtOAc), 0.43 mL, 0.604 mmol) 
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dropwise. The reaction mixture was stirred at 0 oC for 30 min and allowed to warm to room 
temperature and stirred for 18 h. After completion of the reaction by TLC analysis, the reaction 
was diluted with CH2Cl2 (30 mL) and washed with 1 M HCl (30 mL), saturated NaHCO3 
solution (20 mL), dried (MgSO4), filtered and concentrated in vacuo. The brown crude oil 
residue was purified via chromatography on SiO2 (100 hexanes - 40% EtOAc/hexanes gradient) 
to afford 6a (108 mg, 0.245 mmol, 61%) as a colorless oil which foamed up upon drying: IR 
(CDCl3) 2917, 2825, 1651, 1593, 1513, 1435, 1227, 1159, 1137, 835, 727 cm
-1; 1H NMR 
(CDCl3, 500 MHz) δ  7.47 (dd, J = 8.7, 5.2 Hz, 2 H), 7.14-7.06 (m, 3 H), 7.00 (dd, J = 8.1, 2.1 
Hz, 1 H), 6.97 (d, J = 2.1 Hz, 1 H), 3.99-3.87 (m, 3 H), 3.81-3.76 (m, 1 H), 3.01 (t, J = 5.0 Hz, 2 
H), 2.94-2.86 (m, 2 H), 2.31 (s, 3 H), 2.22-2.17 (m, 2 H), 1.60-1.56 (m, 1 H); 13C NMR (CDCl3, 
125 MHz) δ  164.9, 162.9 (d, J C-F = 249 Hz), 152.0, 132.3, 132.0, 131.8 (d, J C-F = 8 Hz), 131.1, 
125.6 (q, J C-F = 276 Hz), 123.9, 119.9, 116.0 (d, J C-F = 22 Hz), 51.7, 51.6, 46.3, 42.9, 35.1 (q, J 
C-F = 34 Hz), 28.1, 17.60, 14.55; 
19F NMR (CDCl3, 470 MHz) δ  -64.7 (s, 3 F), -112.2 (s, 1 F); 
HRMS (ESI) m/z calcd for C22H22ClF4N2O ([M+H]
+) 441.1351, found 441.1350. 
 
 
trans-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1RS,2RS)-2-(4-fluorophenyl)-2-
(trifluoromethyl)cyclopropyl)methanone (6b). A solution of 4b (0.100 g, 0.403 mmol) and 1-
(5-chloro-2-methylphenyl)piperazine hydrochloride (0.120 g, 0.484 mmol) in distilled CH2Cl2 (4 
mL) was cooled to 0 oC and then added with triethylamine (0.168 mL, 1.21 mmol). The cooled 
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solution was then treated with T3P (50wt.% solution in EtOAc), 0.43 mL, 0.604 mmol) 
dropwise. The reaction mixture was stirred at 0 oC for 30 min and allowed to warm to room 
temperature and stirred for 18 h. After completion of the reaction by TLC analysis, the reaction 
was diluted with CH2Cl2 (30 mL) and washed with 1 M HCl (30 mL), saturated NaHCO3 
solution (20 mL), dried (MgSO4), filtered and concentrated in vacuo. The brown crude oil 
residue was purified via chromatography on SiO2 (100 hexanes - 40% EtOAc/hexanes gradient) 
to afford 6b (162 mg, 0.367 mmol, 91%) as a colorless oil which foamed up upon drying: IR 
(CDCl3) 2894, 2820, 1652, 1593, 1514, 1436, 1296, 1226, 1160, 1143, 830, 735; 
1H NMR 
(CDCl3, 500 MHz) δ 7.31 (dd, J = 8.6, 5.3 Hz, 2 H), 7.13 (d, J = 8.1 Hz, 1 H), 7.06-7.00 (m, 3 
H), 6.96 (d, J = 2.0 Hz, 1 H), 3.99-3.86 (m, 2 H), 3.70-3.56 (m, 2 H), 3.07-2.99 (m, 2 H), 2.86-
2.75 (m, 2 H), 2.59 (dd, J = 8.8, 6.2 Hz, 1 H), 2.30 (s, 3 H), 2.12-2.09 (m, 1 H), 1.70 (dd, J = 8.8, 
5.3 Hz, 1 H); 13C NMR (CDCl3, 100 MHz) δ 165.3, 162.9 (d, JC-F = 248 Hz), 151.8, 132.8 (d, J C-
F = 8 Hz), 132.3, 132.1, 131.1, 127.1 (d, J C-F = 3 Hz), 125.4 (q, J C-F = 274 Hz), 124.0, 119.8, 
115.8 (d, J C-F = 22 Hz), 52.1, 51.7, 46.2, 42.8, 34.9 (q, J C-F = 33 Hz), 22.8, 17.6, 13.9. 
19F NMR 
(CDCl3, 470 MHz) δ -69.6 (s, 3 F), -112.4 (s, 1 F); HRMS (ESI) m/z calcd for C22H22ClF4N2O 
([M+H]+) 441.1351, found 441.1351. 
 
 
Racemic trans-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1SR,2SR)-2-(4-fluorophenyl)-2-
(trifluoromethyl)cyclopropyl)methanone was separated on a SFC Chiralpak-IC semiprep (250 
x 10 mm) column (13% MeOH, 7 mL/min, 220 nM, P=100) to afford (-)-(4-(5-chloro-2-
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methylphenyl)piperazin-1-yl)(2-(4-fluorophenyl)-2-
(trifluoromethyl)cyclopropyl)methanone (retention time 6.01 min) as a colorless oil which 
foamed up upon drying (100% purity by ESLD): [a]20D -179.6 (c 0.69, MeOH); 
1H NMR 
(CDCl3, 400 MHz) δ  7.31 (dd, J = 8.6, 5.3 Hz, 2 H), 7.13 (d, J = 7.6 Hz, 1 H), 7.07-7.00 (m, 3 
H), 6.96 (d, J = 2.1 Hz, 1 H), 3.99-3.85 (m, 2 H), 3.71-3.54 (m, 2 H), 3.08-2.98 (m, 2 H), 2.86-
2.74 (m, 2 H), 2.59 (dd, J = 8.8, 6.1 Hz, 1 H), 2.30 (s, 3 H), 2.13-2.08 (m, 1 H), 1.70 (dd, J = 8.8, 
5.3 Hz, 1 H); HRMS (ESI) m/z calcd for C22H22ClF4N2O ([M+H]
+) 441.1344, found 441.1351. 
The enantiomeric excess was >99% ee (SFC Chiralpak-IC (250 x 10 mm); 10% MeOH, 220 nm, 
7 mL/min; retention time: 6.01 min). 
(+)-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(2-(4-fluorophenyl)-2-
(trifluoromethyl)cyclopropyl)methanone (retention time 7.16 min) was obtained as a colorless 
oil which foamed up upon drying (100% purity by ESLD): [a]20D -177.9 (c 0.67, MeOH); 
1H 
NMR (CDCl3, 400 MHz) δ  7.31 (dd, J = 8.6, 5.3 Hz, 2 H), 7.13 (d, J = 8.1 Hz, 1 H), 7.07-7.00 
(m, 3 H), 6.96 (d, J = 2.1 Hz, 1 H), 3.99-3.85 (m, 2 H), 3.71-3.54 (m, 2 H), 3.07-3.00 (m, 2 H), 
2.87-2.74 (m, 2 H), 2.59 (dd, J = 8.9, 6.1 Hz, 1 H), 2.30 (s, 3 H), 2.12-2.08 (m, 1 H), 1.70 (dd, J 
= 8.8, 5.3 Hz, 1 H); HRMS (ESI) m/z calcd for C22H22ClF4N2O ([M+H]
+) 441.1340, found 
441.1351. The enantiomeric excess was >99% ee (SFC Chiralpak-IC (250 x 10 mm); 13% 
MeOH, 220 nm, 7 mL/min; retention time: 7.12 min). 
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Figure 25. SFC chromatogram of racemic 6b. 
 
 
Figure 26. SFC resolution of (-)-6b. 
 
 
Figure 27. SFC resolution of (+)-6b. 
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Ethyl 2-diazo-3,3,3-trifluoropropanoate (8).62,63 To a stirred solution of p-toluenesulfonyl 
hydrazide (11.5 g, 60.5 mmol) in distilled CH2Cl2 (65 mL) was added ethyl trifluoropyruvate 
(7.79 mL, 57.6 mmol). The reaction was stirred at room temperature for 18 h. Phosphorus 
oxychloride (7.05 mL, 74.9 mmol) was added dropwise followed by pyridine (6.11 mL, 74.9 
mmol) (Note: when pyridine was added dropwise the reaction mixture warmed up to a self-
sustaining gentle reflux). The reaction mixture was stirred at room temperature for another 18 h. 
The mixture was washed with water and the organic layer was separated. The aqueous layer was 
extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered and concentrated in vacuo to give ethyl 3,3,3-trifluoro-2-(2-
tosylhydrazineylidene)propanoate 7 as a yellow liquid which solidified to a white solid upon 
standing. The crude product was used in the next step without further purification. To a solution 
of 7 (18.3 g, 54.1 mmol) in anhydrous CH2Cl2 (433 mL) was added triethylamine (15.2 mL, 
0.108 mol) dropwise. The reaction mixture was stirred at room temperature for 2 days. The 
solution was carefully concentrated in vacuo and the crude product was purified via distillation. 
The distillate was washed with 1 M HCl (20 mL x 2) to remove the excess triethylamine. The 
organic layers collected were dried (MgSO4), filtered and carefully concentrated in vacuo to 
afford 8 (4.89 g, 26.9 mmol, 50 % over 2 steps) as a yellow oil: Bp lit: 60 - 62 oC (100 mmHg)4; 
1H NMR (CDCl3, 500 MHz) δ  4.32 (q, J = 7.1 Hz, 2 H), 1.32 (t, J = 7.1 Hz, 3 H); 13C NMR 
(CDCl3, 125 MHz) δ  161.0, 122.8 (q, J C-F = 269 Hz), 62.3, 14.4 (C=N signal not observed). 
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cis- and trans-Ethyl 2-(4-fluorophenyl)-1-(trifluoromethyl)cyclopropane-1-carboxylate (9). 
To a flame-dried flask containing 4-fluorostyrene (3.3 mL, 27.5 mmol) and Rh2(OAc)4 (0.121 g, 
0.275 mmol, 5 mol%) in distilled CH2Cl2 (25 mL) was added 8 (1.00 g, 5.49 mmol) in distilled 
CH2Cl2 (20 mL) via a syringe pump over 16 h at room temperature. After consumption of the 
diazo compound by TLC, the mixture was passed through a pad of SiO2 to remove the rhodium 
catalyst and washed with CH2Cl2. The solvent was removed in vacuo. The crude product was 
purified by chromatography on SiO2 (1:2 CH2Cl2/hexanes) to give 9 (cis/trans ratio 1:1.6) as an 
yellow oil (Note: The mixture also contained side product from the dimerization of the diazo 
compound). cis-9 (597 mg, 2.16 mmol, 34 % calcd yield): 1H NMR (CDCl3, 500 MHz) δ  7.26 
(m, 2 H), 7.00 (t, J = 8.7 Hz, 2 H), 4.33-4.25 (m, 2 H), 3.04 (t, J = 8.9 Hz, 1 H), 1.95 (ddq, J = 
9.5, 5.4, 1.8 Hz, 1 H), 1.88 (dd, J = 8.2, 5.3 Hz, 1 H), 1.34 (t, J = 7.1 Hz, 3 H); 19F NMR (CDCl3, 
470 MHz) δ  -61.1 (s, 3 F), -114.5 (s, 1 F); 
trans-9 (955 mg, 3.46 mmol, 54 % calcd yield): 1H NMR (CDCl3, 500 MHz) δ 7.22 (dd, J = 8.2, 
5.4 Hz, 2 H), 6.98 (t, J = 8.7 Hz, 2 H), 3.96-3.87 (m, 2 H), 2.90 (t, J = 9.0 Hz, 1 H), 2.14-2.11 
(m, 1 H), 1.78 (dd, J = 9.7, 5.7 Hz, 1 H), 0.94 (t, J = 7.1 Hz, 3 H); 19F NMR (CDCl3, 470 MHz) δ  
-66.8 (s, 3 F), -114.5 (s, 1 F). 
 
 
cis- and trans-2-(4-Fluorophenyl)-1-(trifluoromethyl)cyclopropane-1-carboxylic acid (10). 
To a solution of KOH (1.02 g, 18.1 mmol) in methanol (9 ml) was added 9  (0.500 g, 1.81 mmol) 
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dissolved in methanol (3.8 mL). The reaction mixture was heated to 55 oC and stirred at this 
temperature for 24 h. The mixture was cooled to room temperature and poured into water and 
extracted with CH2Cl2 (25 mL). The organic layer was discarded and the aqueous layer acidified 
with 6 M HCl and extracted with CH2Cl2 (2 x 25 mL). The combined organic layers were dried 
(Na2SO4) and concentrated under reduced pressure to give 10 as a pale yellow solid (cis/trans 
ratio 1:1.16) which was used in the next step without purification. cis-10 (168 mg, 0.677 mmol, 
37 % calcd yield): 1H NMR (CDCl3, 500 MHz) δ 7.29-7.26 (m, 2 H), 7.02 (t, J = 8.6 Hz, 2 H), 
3.16 (t, J = 9.0 Hz, 1 H), 2.04-1.97 (m, 2 H); 19F NMR (CDCl3, 471 MHz) δ  -61.5 (s, 3 F), -
114.0 (s, 1 F); 
trans-10 (262 mg, 1.06 mmol, 58 % calcd yield): 1H NMR (CDCl3, 500 MHz) δ  7.18 (dd, J = 
8.4, 5.4 Hz, 2 H), 6.97 (t, J = 8.6 Hz, 2 H), 2.99 (t, J = 9.0 Hz, 1 H), 2.09 (t, J = 6.5 Hz, 1 H), 
1.84 (dd, J = 9.7, 5.8 Hz, 1 H); 19F NMR (CDCl3, 470 MHz) δ  -66.9 (s, 3 F), -114.1 (s, 1 F). 
 
 
cis- and trans-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(2-(4-fluorophenyl)-1-
(trifluoromethyl)cyclopropyl)methanone (11a and 11b). To a suspension of 10 (0.250 g, 1.01 
mmol) in distilled CH2Cl2 (10 mL) cooled to 0 °C was added oxalyl chloride (0.18 mL, 2.01 
mmol) followed by a catalytic amount of DMF and the reaction was gradually warmed to room 
temperature and stirred for another 2 h. The reaction was concentrated in vacuo (water bath 
25°C) to afford the yellow crude acid chloride. The crude residue formed above was dissolved in 
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distilled CH2Cl2 (10 mL) cooled to 0°C and added with 1-(5-chloro-2-methylphenyl)piperazine 
hydrochloride (0.349 g, 1.41 mmol) and Et3N (0.50 mL, 3.60 mmol) and the reaction was 
allowed to warm to room temperature and stirred for 20 h. LCMS and NMR analysis showed 
presence of starting material carboxylic acid (possibly due to hydrolysis of the acyl chloride). 
The reaction mixture was cooled to 0 oC and T3P (50wt.% in EtOAc, 0.85 mL, 1.21 mmol) was 
added to couple the remaining of the carboxylic acid to the piperazine. The mixture was stirred at 
room temperature for 3 days until no starting material was seen in LCMS. The reaction was 
diluted with CH2Cl2 (30 mL) and washed with saturated NaHCO3 (20 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The crude oil residue was dissolved purified via 
chromatography on SiO2 (1:2 Et2O/hexanes) to afford the 11a and 11b respectively as yellow oil. 
cis-11a (107 mg, 0.244 mmol, 24%): IR (CDCl3) 2926, 1647, 1515, 1438, 1226, 1153, 1125, 
842, 738 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.32 (dd, J = 8.5, 5.4 Hz, 2 H), 7.12 (d, J = 8.1 Hz, 
1 H), 7.05-7.00 (m, 3 H), 6.96 (d, J = 2.1 Hz, 1 H), 3.88 (br s, 4 H), 2.94 (br s, 4 H), 2.79 (t, J = 
8.7 Hz, 1 H), 2.30 (s, 3 H), 1.98 (dd, J = 7.9, 6.2 Hz, 1 H), 1.73-1.69 (m, 1 H);  13C NMR 
(CDCl3, 150 MHz) δ  164.6, 162.3 (d, J = 246 Hz), 151.8, 132.3, 132.1, 131.1, 130.7 (d, JC-F = 8 
Hz), 129.3 (d, J C-F = 3 Hz), 124.7 (q, J C-F = 276 Hz), 124.0, 120.0, 115.5 (d, J C-F = 21 Hz), 51.8, 
47.1, 43.4, 34.8 (q, J C-F = 32 Hz), 27.6, 17.6, 14.8
 ; 19F NMR (CDCl3, 470 MHz) δ  -60.7 (s, 3 
F), -114.8 (s, 1 F); HRMS (ESI) m/z calcd for C22H22ClF4N2O ([M+H]
+) 441.1351, found 
441.1352. 
trans-11b (151 mg, 0.342 mmol, 34 %): IR (CDCl3) 2925, 2860, 1643, 1516, 1437, 1226, 1149, 
1132, 845, 812, 733 cm-1; 1H NMR (CDCl3, 500 MHz) δ  7.12-7.04 (m, 5 H), 6.95 (dd, J = 8.1, 
2.1 Hz, 1 H), 6.65 (d, J = 1.7 Hz, 1 H), 3.77 (s, 1 H), 3.49-3.47 (m, 2 H), 3.03 (s, 1 H), 2.80 (dd, 
J = 9.8, 7.5 Hz, 1 H), 2.74-2.71 (m, 1 H), 2.53-2.42 (m, 2 H), 2.16 (s, 3 H), 1.87 (t, J = 7.0 Hz, 1 
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H), 1.79 (dd, J = 9.8, 6.6 Hz, 1 H), 1.51 (s, 1 H); 13C NMR (CDCl3, 100 MHz) δ  162.6 (d, J C-F = 
248 Hz), 161.7, 151.7, 132.1, 132.0, 131.1, 130.9 (d, J C-F = 3 Hz), 128.8 (d, J C-F = 8 Hz), 124.6 
(q, J C-F = 272 Hz), 123.9, 119.8, 116.0 (d, J C-F = 22 Hz), 51.3, 50.9, 46.8, 43.2, 36.8 (q, J C-F = 
33 Hz), 27.3, 17.4, 15.5; 19F NMR (CDCl3, 470 MHz) δ  -66.3 (s, 3 F), -114.0 (s, 1 F); HRMS 
(ESI) m/z calcd for C22H22ClF4N2O ([M+H]
+) 441.1351, found 441.1349. 
 
 
 
Racemic cis-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1SR,2SR)-2-(4-fluorophenyl)-1-
(trifluoromethyl)cyclopropyl)methanone was separated on a SFC Chiralpak-IC semiprep (250 
x 10 mm) column (10% MeOH, 6 mL/min, 220 nM, P=100) to afford (-)-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)(-2-(4-fluorophenyl)-1-
(trifluoromethyl)cyclopropyl)methanone (retention time 14.46 min) as a colorless oil which 
foamed up upon drying (100% purity by ESLD): [a]20D -57.3 (c 0.44, MeOH); 
1H NMR (CDCl3, 
500 MHz) δ 7.32 (dd, J = 8.5, 5.4 Hz, 2 H), 7.13 (d, J = 8.1 Hz, 1 H), 7.05-7.00 (m, 3 H), 6.96 
(d, J = 2.1 Hz, 1 H), 3.89-3.88 (m, 4 H), 2.94 (s, 4 H), 2.79 (t, J = 8.7 Hz, 1 H), 2.30 (s, 3 H), 
1.98 (dd, J = 7.9, 6.2 Hz, 1 H), 1.71 (ddq, J = 9.5, 6.0, 1.8 Hz, 1 H). HRMS (ESI) m/z calcd for 
C22H22ClF4N2O ([M+H]
+) 441.1348, found 441.1351. The enantiomeric excess was >99% ee 
(SFC Chiralpak-IC (250 x 10 mm); 10% MeOH, 220 nm, 6 mL/min; retention time: 14.55 min). 
(+)-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)(-2-(4-fluorophenyl)-1-
(trifluoromethyl)cyclopropyl)methanone (retention time 16.17 min) was obtained as a 
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colorless oil which foamed up upon drying (100% purity by ESLD): [a]20D +58.4 (c 0.42, 
MeOH); 1H NMR (CDCl3, 500 MHz) δ 7.32 (dd, J = 8.5, 5.3 Hz, 2 H), 7.13 (d, J = 8.1 Hz, 1 H), 
7.05-7.00 (m, 3 H), 6.96 (d, J = 2.1 Hz, 1 H), 3.89-3.88 (m, 4 H), 2.94 (s, 4 H), 2.79 (t, J = 8.7 
Hz, 1 H), 2.30 (s, 3 H), 1.98 (dd, J = 7.9, 6.2 Hz, 1 H), 1.71 (ddq, J = 9.6, 6.0, 1.9 Hz, 1 H); 
HRMS (ESI) m/z calcd for C22H22ClF4N2O ([M+H]
+) 441.1348, found 441.1351. The 
enantiomeric excess was >99% ee (SFC Chiralpak-IC (250 x 10 mm); 10% MeOH, 220 nm, 6 
mL/min; retention time: 16.31 min). 
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Figure 28. SFC resolution of 11a. 
 
 
Figure 29. SFC resolution of (-)-11a. 
 
 
Figure 30. SFC resolution of (+)-11a. 
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cis- and trans-Ethyl-1-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-
carboxylate (13a and 13b). To a flame-dried round-bottom flask was added Rh2(OAc)4 (64.2 
mg, 0.145 mmol) and 4-(trifluoromethyl)styrene in distilled CH2Cl2 (3 mL). A solution of 8 
(0.793 g, 4.36 mmol) in distilled CH2Cl2 (10 mL) was added via a syringe pump over 18 h. The 
mixture was stirred for another 2 h and then filtered through a plug of SiO2 and washed with 
CH2Cl2. The solution was concentrated under reduced pressure and the crude residue was 
purified via chromatography on SiO2 (1:2 CH2Cl2/hexanes) to afford 13a and 13b respectively as 
pale yellow oil. cis-13a (224 mg, 0.686 mmol, 24%): 1H NMR (CDCl3, 500 MHz) δ  7.58 (d, J = 
8.2 Hz, 2 H), 7.42 (d, J = 8.1 Hz, 2 H), 4.35-4.27 (m, 2 H), 3.11 (t, J = 8.9 Hz, 1 H), 1.99 (ddq, J 
= 9.5, 5.5, 1.8 Hz, 1 H), 1.94 (dd, J = 8.3, 5.4 Hz, 1 H), 1.35 (t, J = 7.1 Hz, 3 H); 19F NMR 
(CDCl3, 470 MHz) δ  -61.1 (s, 3 F), -62.6 (s, 3 F). 
trans-13b (435 mg, 1.33 mmol, 46%): 1H NMR (CDCl3, 500 MHz) δ  7.56 (d, J = 8.1 Hz, 2 H), 
7.37 (d, J = 8.6 Hz, 2 H), 3.91 (q, J = 7.1 Hz, 2 H), 2.97 (t, J = 8.9 Hz, 1 H), 2.18 (ddq, J = 8.0, 
6.0, 2.0 Hz, 1 H), 1.84 (dd, J = 9.7, 5.8 Hz, 1 H), 0.91 (t, J = 7.1 Hz, 3 H); 19F NMR (CDCl3, 470 
MHz) δ  -62.6 (s, 3 F), -67.0 (s, 3 F). A fraction containing a mixture of both diastereomers was 
also obtained (157 mg, 0.481 mmol, 17%). 
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cis-1-(Trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (14). 
A solution of 13a (0.220 g, 0.674 mmol) in methanol (1.4 mL) was added to KOH (0.378 g, 6.74 
mmol) in methanol (3.4 ml). The reaction mixture was heated to 55 oC and stirred for 3 d. The 
mixture was cooled to room temperature and poured into water and extracted with CH2Cl2 (15 
mL). The organic layer was discarded and the aqueous layer acidified with 6 M HCl and 
extracted with CH2Cl2 (2 x 15 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure to give 14 (0.190 g, 0.636 mmol, 94%) as a white solid: 1H 
NMR (CDCl3, 500 MHz) δ  7.60 (d, J = 8.2 Hz, 2 H), 7.44 (d, J = 8.2 Hz, 2 H), 3.24 (t, J = 9.1 
Hz, 1 H), 2.10-2.04 (m, 2 H); 13C NMR (CDCl3, 125 MHz) δ  173.7, 137.1, 130.4 (q, J C-F = 33 
Hz), 130.0, 125.6 (q, J C-F = 4 Hz), 124.1 (q, J C-F = 272 Hz), 123.6 (q, J C-F = 275 Hz), 32.9 (q, J 
C-F = 34 Hz), 32.6, 17.0; 
19F NMR (CDCl3, 470 MHz) δ  -61.6 (s, 3 F), -62.7 (s, 3 F).  
 
 
cis-(4-(2,5-Bis(trifluoromethyl)phenyl)piperazin-1-yl)(1-(trifluoromethyl)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (15). A solution of 14 (50.0 mg, 0.168 
mmol) and 1-(2,5-trifluoromethylphenyl)piperazine hydrochloride (73 mg, 0.218 mmol) in 
distilled CH2Cl2 (0.85 mL) was cooled to 0 
oC and then added with triethylamine (0.12 mL, 
0.838 mmol). The cooled solution was treated with T3P (50wt.% solution in EtOAc, 0.14 mL, 
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0.201 mmol) dropwise. The reaction mixture was stirred at 0 oC for 30 min and allowed to warm 
to room temperature and stirred for 3 d. After completion of the reaction by TLC and LCMS 
analysis, the reaction mixture was diluted with CH2Cl2 (10 mL) and washed with 1 M HCl (10 
mL), saturated NaHCO3 (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified via chromatography on SiO2 (1:3 EtOAc/hexanes) to afford 15 as a white 
solid (77.6 mg, 0.134 mmol, 80%): Mp 128.4 – 131.7 oC; IR (CDCl3) 2925, 2833, 1648, 1425, 
1326, 1313, 1122, 1085, 846, 736; 1H NMR (CDCl3, 500 MHz) δ 7.81 (d, J = 8.1 Hz, 1 H), 7.60 
(d, J = 8.2 Hz, 2 H), 7.56 (d, J = 8.3 Hz, 2 H), 7.48 (d, J = 8.1 Hz, 2 H), 3.91-3.87 (m, 4 H), 3.02 
(t, J = 4.6 Hz, 4 H), 2.88 (t, J = 8.6 Hz, 1 H), 2.07 (t, J = 7.1 Hz, 1 H), 1.75 (t, J = 7.8 Hz, 1 H); 
13C NMR (CDCl3, 125 MHz) δ  164.2, 152.2, 137.8, 135.3 (q, J C-F = 33 Hz), 130.9 (q, J C-F = 29 
Hz), 130.1 (t, J C-F = 33 Hz), 129.5, 128.5 (q, J C-F = 5 Hz), 125.5 (q, J C-F = 4 Hz), 124.5 (q, J C-F 
= 281 Hz), 124.2 (q, J C-F = 272 Hz), 123.4 (q, J C-F = 274 Hz), 123.2 (q, J C-F = 273 Hz), 122.6 
(q, J C-F = 4 Hz), 121.2 (q, J C-F = 4 Hz), 53.3, 53.2, 46.9, 43.1, 35.1 (q, J C-F = 33 Hz), 27.9, 14.8 
(d, J C-F = 2 Hz); 
19F NMR (CDCl3, 470 MHz) δ  -60.9 (d, 6 F), -62.6 (s, 3 F), -63.2 (s, 3 F); 
HRMS (ESI) m/z calcd for C24H19F12N2O ([M+H]
+) 579.1300, found 579.1298. 
 
 
trans-1-(Trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid 
(16). A solution of 13b (0.200 g, 0.613 mmol) in methanol (1.3 mL) was added to KOH (0.344 
g, 6.13 mmol) in methanol (3 mL). The reaction mixture was heated to 55 oC and stirred for 3 d. 
The mixture was cooled to room temperature and poured into water and extracted with CH2Cl2 
(15 mL). The organic layer was discarded and the aqueous layer acidified with 6 M HCl and 
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extracted with CH2Cl2 (2 x 15 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure to give 16 (187 mg, 0.627 mmol, quant.) as a white solid: 
1H NMR (CDCl3, 500 MHz) δ  7.54 (d, J = 8.2 Hz, 2 H), 7.33 (d, J = 8.2 Hz, 2 H), 3.04 (t, J = 
9.1 Hz, 1 H), 2.16-2.13 (m, 1 H), 1.89 (dd, J = 9.7, 5.9 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) δ  
170.7, 137.1 (d, J C-F = 1 Hz), 130.3 (q, J C-F = 33 Hz), 129.6, 125.4 (q, J C-F = 4 Hz), 124.1 (q, J C-
F = 272 Hz), 123.9 (q, J C-F = 274 Hz), 34.3 (q, J C-F = 34 Hz), 30.1 (d, J C-F = 1 Hz), 16.2; 
19F 
NMR (CDCl3, 470 MHz) δ  -62.7 (s, 3 F), -67.1 (s, 3 F). 
 
 
trans-(4-(2,5-Bis(trifluoromethyl)phenyl)piperazin-1-yl)(1-(trifluoromethyl)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (17). A solution of 16 (0.100 g, 0.335 mmol) 
and 1-(2,5-trifluoromethylphenyl)piperazine hydrochloride (0.146 g, 0.436 mmol) in distilled 
CH2Cl2 (1.7 mL) was cooled to 0 
oC and then added with triethylamine (0.24 mL, 1.68 mmol). 
The cooled solution was treated with T3P (50wt.% solution in EtOAc, 0.28 mL, 0.402 mmol) 
dropwise. The reaction mixture was stirred at 0 oC for 30 min and allowed to warm to room 
temperature and stirred for 4 d. After completion of the reaction by TLC and LCMS analysis, the 
reaction mixture was diluted with CH2Cl2 (15 mL) and washed with 1 M HCl (15 mL), saturated 
NaHCO3 (15 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude residue was 
purified via chromatography on SiO2 (1:3 EtOAc/hexanes) to afford 17 as colorless oil (51.5 mg, 
0.0890 mmol, 27%): IR (CDCl3) 2925, 2833, 1643, 1510, 1424, 1310, 1115, 1070, 908, 851, 732 
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cm-1; 1H NMR (CDCl3, 500 MHz) δ  7.71 (d, J = 8.2 Hz, 1 H), 7.63 (d, J = 8.2 Hz, 2 H), 7.48 (d, 
J = 8.2 Hz, 1 H), 7.27 (d, J = 8.0 Hz, 2 H), 7.14 (s, 1 H), 4.06-4.01 (m, 1 H), 3.44-3.29 (m, 2 H), 
3.19-3.15 (m, 1 H), 2.86 (dd, J = 9.7, 7.5 Hz, 1 H), 2.82-2.80 (m, 1 H), 2.56-2.43 (m, 2 H), 1.98 
(t, J = 7.0 Hz, 1 H), 1.86 (dd, J = 9.7, 6.7 Hz, 1 H), 1.20 (s, 1 H); 13C NMR (CDCl3, 125 MHz) δ  
161.4, 152.0, 139.6, 135.3 (q, J C-F = 33 Hz), 130.7 (q, J C-F = 29 Hz), 130.4 (q, J C-F = 33 Hz), 
128.4 (q, J C-F = 5 Hz), 127.7, 125.8 (q, J C-F = 4 Hz), 124.5 (q, J C-F = 271 Hz), 123.9 (q, J C-F = 
272 Hz), 123.2 (q, J C-F = 274 Hz), 123.1 (q, J C-F = 273 Hz), 122.4 (q, J C-F = 4 Hz), 120.6 (q, J C-
F = 3 Hz), 52.7, 52.4, 46.7, 43.1, 37.4 (q, J C-F = 33 Hz), 27.5, 15.7; 
19F NMR (CDCl3, 470 MHz) 
δ  -61.1 (s, 3 F), -62.8 (s, 3 F), -63.5 (s, 3 F), -66.2 (s, 3 F); HRMS (ESI) m/z calcd for 
C24H19F12N2O ([M+H]
+) 579.1300, found 579.1299. 
 
 
(3,3-Difluoro-2-(4-(trifluoromethyl)phenyl)cycloprop-1-en-1-yl)(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)methanone (33). Under an inert atmosphere, 1-(4-(2-
methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-yn-1-one 
(0.400 g, 0.908 mmol), TMSCF2Br (0.28 mL, 1.82 mmol), nBu4NBr (14.6 mg, 0.0454 mmol), 
and toluene (3.6 mL) were added into an oven-dried pressure tube at room temperature. After 
being heated at 110 oC for 20 h, The reaction mixture was cooled to room temperature and 
poured into saturated NaHCO3 solution (15 mL) and extracted with EtOAc (2 x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced pressure. 
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The crude product was subjected to chromatography on SiO2 (1:9 EtOAc/hexanes). The fractions 
collected contained ~10% of impurities. The product was resubjected to chromatography on SiO2 
(1:2 CH2Cl2/hexanes) to afford 33 (0.325 g, 0.663 mmol, 73%) as a pale yellow oil that foamed 
up upon drying under vacuum: IR (CDCl3) 2925, 2825, 1776, 1643, 1442, 1303, 1120, 1061, 
1031, 909, 850, 730 cm-1; 1H NMR (CDCl3, 500 MHz) δ  8.13 (d, J = 8.0 Hz, 2 H), 7.79 (d, J = 
8.1 Hz, 2 H), 7.31 (q, J = 8.7 Hz, 2 H), 7.22 (s, 1 H), 3.94 (t, J = 4.7 Hz, 2 H), 3.88 (t, J = 5.0 Hz, 
2 H), 3.04 (dt, J = 25.5, 5.0 Hz, 4 H), 2.41 (s, 3 H); 13C NMR (CDCl3, 125 MHz) δ  155.1, 150.9, 
137.0, 135.5 (t, JC-F = 10 Hz), 134.4 (q, JC-F = 33 Hz), 132.6, 131.8, 129.4 (q, JC-F = 32 Hz), 
126.3 (q, JC-F = 3.6 Hz), 126.0, 124.3 (q, JC-F = 272 Hz), 123.6 (q, JC-F = 273 Hz), 120.9 (q, JC-F 
= 3.9 Hz), 119.7 (t, JC-F = 13 Hz), 116.3 (q, JC-F = 3.6 Hz), 98.8 (t, JC-F = 278 Hz), 52.2, 51.5, 
46.9, 42.6, 18.1; 19F NMR (CDCl3, 470 MHz) δ  -62.3 (s, 3 F), -63.2 (s, 3 F), -102.3 (s, 2 F) ; 
HRMS (ESI) m/z calcd for C23H19ON2F8 ([M+H]
+) 491.1364, found 491.1363. 
 
 
cis-((1SR,3RS)-2,2-Difluoro-3-(4-(trifluoromethyl)phenyl)cyclopropyl)(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)methanone (34). A solution of 33 (260 mg, 0.530 
mmol) in EtOAc (4.6 mL) was added Pd/C (10% Pd on carbon, 56.4 mg, 10.0 mol%). The 
reaction vessel was placed in the parr hydrogenator (7 bar) and stirred for 24 h at room 
temperature. The mixture was filtered through celite and concentrated in vacuo. The crude oil 
was then passed through a plug of SiO2 to remove baseline impurities. The crude residue (270 
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mg) contained a mixture of the desired cis-product and ring-opening side products which was 
inseparable by normal phase column chromatography. 
 
 
The crude racemic 34 was purified and separated on a SFC Chiralpak-IC semiprep (250 x 10 
mm) column (15% iPrOH, 6 mL/min, 220 nM, P=100) to afford the (-)-enantiomer (45.1 mg, 
0.0916 mmol, 17%) and (+)-enantiomer (41.3 mg, 0.0839 mmol, 16%) respectively as a white 
solid: Mp 123.5 – 127.8 oC; IR (CDCl3) 2917, 2820, 1648, 1416, 1323, 1308, 1115, 1070, 986, 
856, 731 cm-1. 
(-)-2,2-Difluoro-3-(4-(trifluoromethyl)phenyl)cyclopropyl)(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)methanone (retention time 7.52 min) was obtained as 
a white solid  (99.5% purity by ESLD): [a]20D -32.1 (c 1.03, iPrOH); 
1H NMR (CDCl3, 500 
MHz) δ  7.60 (d, J = 8.3 Hz, 2 H), 7.44 (d, J = 8.1 Hz, 2 H), 7.28-7.24 (m, 4 H), 7.02 (s, 1 H), 
3.80-3.77 (m, 1 H), 3.66-3.53 (m, 3 H), 3.13 (td, J = 12.6, 2.0 Hz, 1 H), 2.90 (td, J = 12.5, 2.4 
Hz, 1 H), 2.83 (dtd, J = 11.5, 5.8, 3.4 Hz, 2 H), 2.61 (ddd, J = 11.2, 8.0, 3.0 Hz, 1 H), 2.39-2.33 
(m, 1 H), 2.31 (s, 3 H); 19F NMR (CDCl3, 470 MHz) δ  -62.4 (s, 3 F), -62.8 (s, 3 F), -118.9 (d, JF-
F = 161 Hz, 1 F), -147.2 (d, J F-F = 161 Hz, 1 F); HRMS (ESI) m/z calcd for C23H21ON2F8 
([M+H]+) 493.1521, found 493.1522. The enantiomeric excess was >99% ee (SFC Chiralpak-IC 
(250 x 10 mm); 15% iPrOH, 220 nm, 6 mL/min; retention time: 7.54 min). 
(+)-2,2-Difluoro-3-(4-(trifluoromethyl)phenyl)cyclopropyl)(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)methanone (retention time 9.64 min) was obtained as 
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a white solid (99.5% purity by ESLD): [a]20D +33.5 (c 0.60, iPrOH); 
1H NMR (CDCl3, 500 
MHz) δ  7.60 (d, J = 8.2 Hz, 2 H), 7.44 (d, J = 8.1 Hz, 2 H), 7.28-7.24 (m, 5 H), 7.02 (s, 1 H), 
3.81-3.76 (m, 1 H), 3.66-3.52 (m, 3 H), 3.13 (td, J = 12.6, 2.2 Hz, 1 H), 2.90 (td, J = 12.5, 2.6 
Hz, 1 H), 2.83 (dtd, J = 11.5, 5.8, 3.3 Hz, 2 H), 2.61 (ddd, J = 11.4, 7.9, 3.0 Hz, 1 H), 2.39-2.33 
(m, 1 H), 2.31 (s, 3 H); 13C NMR (CDCl3, 125 MHz) δ  160.9, 150.9, 136.9, 135.0, 131.7, 130.1 
(q, JC-F = 32.8 Hz), 129.5 (d, JC-F = 2.7 Hz), 129.3 (q, JC-F = 34.0 Hz), 125.4 (q, JC-F = 3.6 Hz), 
124.2 (q, JC-F = 272.0 Hz), 124.1 (q, JC-F = 272.1 Hz), 120.7 (q, JC-F = 3.7 Hz), 116.0 (q, JC-F = 
3.6 Hz), 111.0 (t, JC-F = 289.7 Hz), 51.7, 51.5, 46.2, 42.1, 31.4 (dd, JC-F = 12.9, 9.8 Hz), 30.3 (dd, 
JC-F = 10.4, 8.9 Hz), 18.0; 
19F NMR (CDCl3, 470 MHz) δ  -62.4 (s, 3 F), -62.8 (s, 3 F), -118.9 (d, 
JF-F = 161 Hz, 1 F), -147.2 (d, J F-F = 161 Hz, 1 F).  HRMS (ESI) m/z calcd for C23H21ON2F8 
([M+H]+) 493.1521, found 493.1522. The enantiomeric excess was >99% ee (SFC Chiralpak-IC 
(250 x 10 mm); 15% iPrOH, 220 nm, 6 mL/min; retention time: 9.66 min).  
 
Figure 31. SFC chromatogram of crude racemic 34. 
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Figure 32. SFC resolution of (-)-34. 
 
 
Figure 33. SFC resolution of (+)-34. 
 
 
1,1-Dibromo-2,2-bis(chloromethyl)cyclopropane (54).88 A solution of NaOH (50 w/w % in 
H2O, 102 mL, 10 eq) cooled to 0 oC was added to a 1 L 3-neck round-bottomed flask equipped 
with mechanical stirrer, internal thermometer, N2 inlet, a vigorously stirred solution of 3-chloro-
2-chloromethyl-1-propene (25.0 g, 0.198 mol) and phase-transfer catalyst aliquat 336 (1.00 mL, 
2.19 mmol, 0.011 eq) in bromoform (44.6 mL, 0.495 mol). The reaction mixture was warmed to 
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an internal temperature of 40 oC using a sand bath. After completion of the reaction (84 h), the 
reaction mixture was then poured into a separating funnel and diluted with water (500 mL). The 
organic layer was separated and the aqueous layer extracted with dichloromethane (3 x 200 mL). 
The combined organic layers were dried (MgSO4), filtered, and concentrated under reduced 
pressure to afford the crude tetrahalide as a dark brown oil. The oil was distilled under vacuum at 
55 oC to remove residual starting material alkene and bromoform and then at 105 oC to afford the 
tetrahalide. The tetrahalide obtained was recrystallized with pentane at -20oC to give the pure 54 
(20.5 g, 69.1 mmol, 35 %) as white needles: 1H NMR (CDCl3, 500 MHz) δ 4.01-3.94 (m, 4 H), 
1.83 (s, 2 H); 13C NMR (CDCl3, 125 MHz) δ  47.8, 35.4, 34.1, 32.2. 
 
 
Tricyclo[1.1.1.01,3]pentane (39).88,109 To a solution of 54 (15.0 g, 50.5 mmol) in distilled Et2O 
(35 mL) under nitrogen at -40 °C (dry ice/acetonitrile) was added phenyllithium solution (1.9 M 
in dibutyl ether, 53.2 mL, 101 mmol) dropwise. The reaction mixture was stirred at -40 °C for 
another 5 min and then warmed to 0 °C and stirred at 0 °C for 2 h. The product was distilled via 
vacuum distillation (30 oC, 60 mmHg) with the catch flask cooled to –78 °C in dry ice/acetone 
bath to afford 39 as a clear, colorless solution in diethyl ether (0.86 M, 2.86 g, 85 %): 1H NMR 
(CDCl3, 500 MHz) δ 1.94 (s, 6 H). 
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1-Iodo-3-(3-(trifluoromethyl)phenyl)bicyclo[1.1.1]pentane (52). To a solution of 39 (2.85 g, 
50 mL, 0.86 M in diethyl ether solution) in pentane (340 mL) and diethyl ether (50 mL) was 
added 3-iodobenzotrifluoride (14.9 mL, 0.103 mol) in a quartz vessel. The reaction mixture was 
irradiated at 254 nm (vycor filter) with a 450-W mercury immersion lamp for 9 h and 
concentrated in vacuo to give an orange oil. The crude mixture was purified via chromatography 
on SiO2 (hexanes) to afford 52 (1.53 g, 4.53 mmol, 11 %) as a pale yellow oil: IR (CDCl3) 2995, 
2917, 2879, 1347, 1301, 1277, 1195, 1125, 1069, 848, 805, 700, 691 cm-1; 1H NMR (CDCl3, 500 
MHz) δ  7.50 (d, J = 7.7 Hz, 1 H), 7.43 (t, J = 7.7 Hz, 1 H), 7.35 (s, 1 H), 7.31 (d, J = 7.6 Hz, 1 
H), 2.62 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ  139.4, 131.0 (q, JC-F = 32.2 Hz), 129.6, 129.1, 
124.1 (q, JC-F = 273 Hz), 124.0 (q, JC-F = 3.7 Hz), 123.0 (q, JC-F = 3.7 Hz), 61.9, 50.1, 6.0; 
19F 
NMR (CDCl3, 470 MHz) δ  -62.7 (s, 3 F). 
 
 
3-(3-(Trifluoromethyl)phenyl)bicyclo[1.1.1]pentane-1-carboxylic acid (55). A solution of 52 
(0.250 g, 0.739 mmol) in distilled diethyl ether (3 mL) was treated with tert-butyllithium 
solution (1.7 M in pentane, 1.1 mL, 1.85 mmol) dropwise at -78 oC over 10 min. The mixture 
was stirred for another 15 min at -78 oC and CO2 gas was bubbled through the mixture and the 
solution was gradually warmed to room temperature. The mixture was extracted with water (3 x 
5 mL) and the combined aqueous layers were acidified with 6 M HCl, saturated with sodium 
chloride solution, and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were 
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dried (MgSO4), filtered, and concentrated under reduced pressure to afford 55 (0.173 g, 0.676 
mmol, 79 % corrected yield) as an off-white solid: 1H NMR (CDCl3, 500 MHz) δ  11.38 (br s, 1 
H), 7.51 (d, J = 7.5 Hz, 1 H), 7.46-7.39 (m, 3 H), 2.40 (s, 6 H); 19F NMR (CDCl3, 470 MHz) δ  -
62.6 (s, 3 F). (Note: The final product isolated also contains 23 mg (12 %) of pivalic acid based 
on NMR calculation.)  
 
 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)(3-(3-
(trifluoromethyl)phenyl)bicyclo[1.1.1]pentan-1-yl)methanone (49). To a solution of 55 (100 
mg, 0.336 mmol, 86% purity) in distilled CH2Cl2 (4 mL) at 0 °C was added 1-(2-methyl-5-
(trifluoromethyl)phenyl)piperazine monohydrochloride (132 mg, 0.470 mmol) and triethylamine 
(0.21 mL, 1.51 mmol). T3P (0.36 mL, 0.503 mmol) was added dropwise and the reaction 
mixture was stirred at 0 °C for 30 min and allowed to warm to room temperature. The reaction 
mixture was stirred for 18 h at room temperature, diluted with CH2Cl2 (10 mL) and washed with 
1 M HCl (10 mL). The aqueous phase was extracted with CH2Cl2 (3 x 5 mL) and the combined 
organic layers were dried (MgSO4), filtered, and concentrated in vacuo. The crude material was 
purified by chromatography on SiO2 (0-35 % EtOAc in hexanes gradient) to afford 49 (155 mg, 
0.321 mmol, 96 %) as a colorless oil which foamed up upon drying under vacuum: IR (CDCl3) 
2977, 2915, 2878, 2821, 1629, 1307, 1117, 1071, 731, 701 cm-1; 1H NMR (CDCl3, 500 MHz) δ  
7.51 (d, J = 7.4 Hz, 1 H), 7.46-7.41 (m, 3 H), 7.30 (m, 2 H), 7.21 (s, 1 H), 3.86-3.80 (m, 4 H), 
2.94 (dt, J = 22.9, 4.8 Hz, 4 H), 2.47 (s, 6 H), 2.38 (s, 3 H); 13C NMR (CDCl3, 125 MHz) δ  
 86 
168.1, 151.3, 140.7, 137.0, 131.7, 130.9 (q, JC-F = 32.1 Hz), 129.6, 129.2 (q, JC-F = 32.2 Hz), 
128.9, 124.3 (q, JC-F = 272 Hz), 124.2 (q, JC-F = 272 Hz), 123.9 (q, JC-F = 3.7 Hz), 123.0 (q, JC-F 
= 3.7 Hz), 120.6 (q, JC-F = 3.9 Hz), 116.2 (q, JC-F = 3.8 Hz), 54.8, 52.0, 51.8, 46.1, 42.7, 42.6, 
39.3, 18.1; 19F NMR (CDCl3, 470 MHz) δ  -62.3 (s, 1 F), -62.6 (s, 1 F). HRMS (ESI) m/z calcd 
for C25H25ON2F6 ([M+H]
+) 483.1866, found 483.1863.   
 
 
1-Morpholino-3-(4-(trifluoromethyl)phenyl)prop-2-yn-1-one (59). To a solution of 3-(4-
(trifluoromethyl)phenyl)propiolic acid (0.310 g, 1.45 mmol) in distilled CH2Cl2 (14 mL) at 0 °C 
was added morpholine (0.17 mL, 1.88 mmol) and triethylamine (0.60 mL, 4.34 mmol). T3P 
(1.44 mL, 2.03 mmol) was added dropwise and the reaction was stirred at 0 °C for 30 min, 
allowed to warm to room temperature, and stirred for another 18 h. The reaction mixture was 
diluted with CH2Cl2 (30 mL) and washed with 1 M HCl (30 mL). The aqueous phase was 
extracted with CH2Cl2 (3 x 20 mL) and the combined organic layers were dried (MgSO4), 
filtered, and concentrated in vacuo. The crude material was purified by chromatography on SiO2 
(1:3 EtOAc/hexanes) to afford 59 (0.397 g, 1.40 mmol, 97 %) as a white solid: 1H NMR (CDCl3, 
500 MHz) δ  7.67-7.62 (m, 4 H), 3.84-3.75 (m, 4 H), 3.71 (s, 4 H); 13C NMR (CDCl3, 125 MHz) 
δ  152.8, 132.7, 132.0 (q, JC-F = 32.7 Hz), 125.7, 124.2, 123.7 (q, JC-F = 272.5 Hz), 89.3, 82.6, 
67.0, 66.6, 47.5, 42.2. 19F NMR (CDCl3, 470 MHz) δ  -63.1 (s, 3 F). HRMS (ESI) m/z calcd for 
C14H13O2NF3 ([M+H]
+) 284.0893, found 284.0890. 
 
 87 
 
(Z)-1-Morpholino-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (60). A solution of 59 
(0.780 g, 2.75 mmol) in EtOAc (13.6 mL) at room temperature was treated with quinoline (1.63 
mL, 13.8 mmol) and 5% Pd/BaSO4 (87.9 mg, 0.0413 mmol, 1.5 mol% based on Pd) and the 
reaction was stirred under an atmosphere of H2 (3 x backfill cycles) and checked by TLC 
analysis every 20 min (50 % EtOAc in hexanes) until all starting material had been mostly 
consumed (~2 h) to avoid over reduction. The reaction was filtered through celite (eluting with 
EtOAc), and the filtrate was washed with 1 M HCl (3 x 25 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified via chromatography on SiO2 (0-70 % 
ethyl acetate in hexanes gradient) to afford 60 (0.739 g, 2.59 mmol, 94 %) as a colorless oil: 1H 
NMR (CDCl3, 500 MHz) δ  7.60 (d, J = 8.2 Hz, 2 H), 7.49 (d, J = 8.2 Hz, 2 H), 6.73 (d, J = 12.6 
Hz, 1 H), 6.16 (d, J = 12.6 Hz, 1 H), 3.67-3.61 (m, 4 H), 3.32 (s, 4 H); 19F NMR (CDCl3, 470 
MHz) δ  -62.7 (s, 3 F). HRMS (ESI) m/z calcd for C14H15O2NF3 ([M+H]+) 286.1049, found 
286.1048. 
 
 
cis-Morpholino((1RS,2SR)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone (61). To a 
flame-dried microwave vial containing anhydrous CrCl2 (1.08 g, 8.76 mmol) was added a 
solution of 60 (0.500 g, 1.75 mmol) in anhydrous THF (17.5 mL) and CH2ICl (0.77 mL, 10.5 
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mmol) at room temperature and under inert atmosphere. The reaction mixture was sealed and 
stirred for 20 h at 75 °C. The reaction was cooled to room temperature, quenched with 1 M HCl, 
and extracted with diethyl ether (3 x 30 mL). The combined organic layers were washed with 
saturated NH4Cl solution (50 mL), water (50 mL), dried (MgSO4), and concentrated in vacuo. 
The crude residue was purified via chromatography on SiO2 (2:1 EtOAc/hexanes) and the 
isolated product was filtered through basic alumina to afford 61 (0.556 g, 1.86 mmol, 88 %) as a 
pale yellow solid: 1H NMR (CDCl3, 500 MHz) δ  7.51 (d, J = 8.3 Hz, 2 H), 7.25 (d, J = 8.9 Hz, 3 
H), 3.65-3.56 (m, 3 H), 3.50 (t, J = 4.8 Hz, 2 H), 3.21 (ddd, J = 12.7, 8.8, 3.4 Hz, 1 H), 3.09 
(ddd, J = 11.1, 8.4, 2.6 Hz, 1 H), 2.95 (dt, J = 11.3, 5.6 Hz, 1 H), 2.49 (q, J = 8.0 Hz, 1 H), 2.20 
(td, J = 8.8, 6.0 Hz, 1 H), 1.90 (q, J = 6.1 Hz, 1 H), 1.40 (td, J = 8.4, 5.6 Hz, 1 H); 13C NMR 
(CDCl3, 125 MHz) δ  166.9, 141.8, 128.9 (q, JC-F = 30.8 Hz), 128.0, 125.2 (q, JC-F = 3.7 Hz), 
124.3 (q, JC-F = 271.7 Hz), 66.9, 66.9, 45.7, 42.3, 24.3, 24.1, 11.1; 
19F NMR (CDCl3, 470 MHz) 
δ  -62.4 (s, 3 F). HRMS (ESI) m/z calcd for C15H17O2NF3 ([M+H]+) 300.1206, found 300.1206. 
 
 
cis-(3-(3-(Trifluoromethyl)phenyl)bicyclo[1.1.1]pentan-1-yl)((1RS,2SR)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (51). A solution of 52 (0.207 g, 0.612 mmol) 
in distilled diethyl ether (2.5 mL) was added tert-butyllithium solution (1.7 M in pentane, 0.30 
mL, 0.51 mmol) at -78 oC dropwise. The mixture was stirred at -78 oC for 30 min. A solution of 
61 (0.168 g, 0.561 mmol) in distilled THF (1.5 mL) was added dropwise and the reaction 
mixture was stirred for 1 h at -78 oC and then left to reach room temperature. The reaction 
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mixture was quenched with saturated NH4Cl solution (5 mL) and extracted with diethyl ether (3 
x 10 mL). The combined organic layers were washed with water, dried (Na2SO4), concentrated 
under reduced pressure and purified via chromatography on SiO2 (1:4 EtOac in hexanes) to 
afford 51 (37.4 mg, 0.0872 mmol, 17 %) as an off-white solid: Mp 82.4 – 84.5 oC; IR (CDCl3) 
2977, 2916, 2878, 1688, 1322, 1309, 1114, 1068, 864, 701 cm-1;  1H NMR (CDCl3, 500 MHz) δ  
7.50 (t, J = 8.0 Hz, 3 H), 7.42 (t, J = 7.7 Hz, 2 H), 7.36 (d, J = 7.3 Hz, 1 H), 7.30 (d, J = 8.4 Hz, 2 
H), 2.78 (q, J = 8.4 Hz, 1 H), 2.71 (ddd, J = 9.3, 7.5, 5.9 Hz, 1 H), 2.25-2.20 (m, 6 H), 1.97-1.94 
(m, 1 H), 1.43 (ddd, J = 8.4, 7.5, 5.0 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) δ 202.5, 140.7, 
140.0, 130.7 (q, JC-F = 32.1 Hz), 129.5, 129.3, 128.8, 124.9 (q, JC-F = 3.7 Hz), 124.2 (q, JC-F = 
271.7 Hz), 124.1 (q, JC-F = 272.3 Hz), 123.8 (q, J = 3.8 Hz), 122.9 (q, JC-F = 3.8 Hz), 52.7, 43.9, 
41.0, 28.8, 26.8, 11.8. 19F NMR (CDCl3, 470 MHz) δ -62.4 (s, 3 F), -62.6 (s, 3 F). HRMS (ESI) 
m/z calcd for C23H19OF6 ([M+H]
+) 425.1335, found 425.1334. 
 
 
cis- and trans-Ethyl 2-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxylate (56). 
Rhodium acetate (0.126 g, 0.285 mmol) and 3-(trifluoromethyl)styrene (1.00 g, 0.86 mL, 5.69 
mmol) were added into a flame-dried round-bottomed flask. Distilled CH2Cl2 (6 mL) was added 
and the mixture was stirred. Ethyl diazoacetate (1.00 mL, 8.54 mmol) in distilled CH2Cl2(17 mL) 
was added via a syringe pump over 16 h. The mixture was stirred for another 2 h and then 
filtered through a SiO2 plug and washed with CH2Cl2. The solution was concentrated under 
reduced pressure and purified via chromatography on SiO2 (40% CH2Cl2 in hexanes) to afford 
the 1:16 cis/trans mixture 56 (1.39 g, 95 %) as a colorless oil. cis-56: 1H NMR (CDCl3, 500 
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MHz) δ 7.53 (s, 1 H), 7.47-7.37 (m, 3 H), 3.93-3.83 (m, 2 H), 2.63-2.57 (m, 2 H), 2.13 (ddd, J = 
9.2, 7.9, 5.7 Hz, 1 H), 1.73 (dt, J = 7.4, 5.4 Hz, 1 H), 1.39 (ddd, J = 8.6, 7.9, 5.2 Hz, 1 H), 0.98 (t, 
J = 7.1 Hz, 3 H); 19F NMR (CDCl3, 470 MHz) δ  -62.6 (s, 3 F). 
trans-56: 1H NMR (CDCl3, 500 MHz) δ 7.47-7.36 (m, 2 H), 7.34 (s, 1 H), 7.29-7.28 (m, 1 H), 
4.18 (qd, J = 7.1, 0.6 Hz, 2 H), 2.62-2.57 (m, 1 H), 1.93 (ddd, J = 8.5, 5.4, 4.2 Hz, 1 H), 1.65 
(ddd, J = 9.2, 5.3, 4.8 Hz, 1 H), 1.34 (ddd, J = 8.5, 6.4, 4.7 Hz, 1 H), 1.29 (d, J = 14.3 Hz, 3 H); 
19F NMR (CDCl3, 470 MHz) δ  -62.7 (s, 3 F). 
 
 
cis- and trans-2-(3-(Trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (57). A solution 
of 56 (1.35 g, 5.23 mmol) in methanol (4 mL) was added to NaOH (1.46 g, 36.6 mmol) in 
methanol (9 ml). The reaction mixture was heated at 55 oC for 5 h. The mixture was cooled to 
room temperature and poured into water and extracted with CH2Cl2 (50 mL). The organic layer 
was discarded and the aqueous layer acidified with 6 M HCl and extracted with CH2Cl2 (3 x 50 
mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure 
to give the mixture of cis/trans acid 57 (1.31 g, 5.69 mmol, quant) as a pale-yellow oil which 
was used without further purification. cis-57: 1H NMR (CDCl3, 500 MHz) δ 7.52 (s, 1 H), 7.48-
7.36 (m, 3H), 2.68 (q, J = 8.5 Hz, 1 H), 2.14 (ddd, J = 9.2, 7.8, 5.6 Hz, 1 H), 1.74 (dt, J = 7.7, 5.4 
Hz, 1 H), 1.47 (ddd, J = 8.7, 7.9, 5.2 Hz, 1 H); 19F NMR (CDCl3, 470 MHz) δ  -62.6 (s, 3 F). 
trans-57: 1H NMR (CDCl3, 500 MHz) δ 7.48-7.36 (m, 2 H), 7.35 (s, 1 H), 7.28 (m, 1 H), 2.63 
(ddd, J = 9.3, 6.6, 4.1 Hz, 1 H), 1.91 (ddd, J = 8.5, 5.3, 4.1 Hz, 1 H), 1.69 (dt, J = 9.3, 5.0 Hz, 1 
H), 1.42 (ddd, J = 8.5, 6.6, 4.8 Hz, 1 H).; 19F NMR (CDCl3, 470 MHz) δ -62.7 (s, 3 F). 
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cis- and trans-(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)(2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone (58a and 58b). To a solution of 57 (0.300 g, 
1.30 mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine monohydrochloride (0.476 g, 
1.69 mmol) in distilled CH2Cl2 (13 mL) was added Et3N (0.55 mL, 3.91 mmol) at 0 
oC. T3P (1.4 
mL, 1.96 mmol) was added dropwise and the reaction was stirred at 0 °C for 30 min and allowed 
to warm to room temperature and stirred for 18 h. The reaction was diluted with CH2Cl2 (20 mL) 
and washed with 1 M HCl (30 mL). The aqueous phase was extracted with CH2Cl2 (2 x 30 mL) 
and combined organic phase was dried (MgSO4), filtered, and concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (30% EtOAc in hexanes) to afford the trans-
isomer as colorless oil followed by the cis-isomer as white solid. cis-58a (0.208 g, 0.456 mmol, 
35 %): IR (CDCl3) 2917, 2822, 1638, 1417, 1326, 1307, 1161, 1115, 1074, 806, 729, 700 cm
-1; 
1H NMR (CDCl3, 500 MHz) δ 7.48-7.46 (m, 2 H), 7.40 (t, J = 7.6 Hz, 1 H), 7.34-7.32 (m, 1 H), 
7.25-7.21 (m, 2 H), 6.92 (s, 1 H), 3.96-3.94 (br m, 1 H), 3.80-3.78 (br m, 1 H), 3.60-3.55 (br m,, 
1 H), 3.25-3.21 (br m, 1 H), 2.79-2.73 (br m, 2 H), 2.53 (q, J = 8.0 Hz, 1 H), 2.29 (s, 3 H), 2.26 
(m, 1 H), 2.19 (br m, 1 H), 2.08-2.04 (m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.42 (td, J = 8.4, 5.6 
Hz, 1 H).;  13C NMR (CDCl3, 125 MHz) δ 166.9, 151.3, 138.9, 137.0, 131.5, 130.8 (q, J C-F = 
32.2 Hz), 130.7, 129.2 (q, J C-F = 31.9 Hz), 128.8, 125.2 (q, J C-F = 3.6 Hz), 124.3 (q, J C-F = 272.0 
Hz), 124.2 (q, J C-F = 272.2 Hz), 123.4 (q, J C-F = 3.8 Hz), 120.5 (q, J C-F = 3.9 Hz), 116.2 (q, J C-F 
= 3.6 Hz), 51.9, 51.8, 45.7, 42.4, 24.3, 24.1, 17.9, 11.0; 19F NMR (CDCl3, 470 MHz) δ  -62.4 (s, 
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3 F), -62.6 (s, 3 F); HRMS (ESI) m/z calcd for C23H23F6N2O ([M+H]
+) 457.1709, found 
457.1708. 
trans-58b (0.312 g, 0.684 mmol, 53 %): IR (CDCl3) 2917, 2823, 1635, 1418, 1328, 1308, 1162, 
1115, 1074, 944, 798, 730, 700 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.47-7.46 (br m, 1 H), 7.41 
(t, J = 7.6 Hz, 1 H), 7.35-7.33 (br m, 2 H), 7.30-7.25 (m, 2 H), 7.20 (s, 1 H), 3.87-3.77 (m, 4 H), 
2.97-2.91 (m, 4 H), 2.62 (ddd, J = 9.0, 6.1, 4.2 Hz, 1 H), 2.37 (s, 3 H), 2.05 (ddd, J = 8.4, 5.3, 4.3 
Hz, 1 H), 1.74 (ddd, J = 9.0, 5.2, 4.6 Hz, 1 H), 1.36 (ddd, J = 8.4, 6.2, 4.5 Hz, 1 H). ; 13C NMR 
(CDCl3, 125 MHz) δ 170.2, 151.3, 142.1, 137.0, 131.7, 131.1 (q, J = 32.1 Hz), 129.9, 129.3 (q, J 
C-F = 32.2 Hz), 129.1, 124.3 (q, J C-F = 272.1 Hz), 124.2 (q, J C-F = 272.3 Hz), 123.3 (q, J C-F = 3.9 
Hz), 122.7 (q, J C-F = 3.8 Hz), 120.5 (q, J C-F = 3.8 Hz), 116.2 (q, J C-F = 3.7 Hz), 52.1, 51.7, 46.2, 
42.8, 25.2, 23.4, 18.1, 16.5; 19F NMR (CDCl3, 470 MHz) δ  -62.3 (s, 3 F), -62.6 (s, 3 F); HRMS 
(ESI) m/z calcd for C23H23F6N2O ([M+H]
+) 457.1709, found 457.1706. 
 
 
Racemic 58a was separated on a SFC Chiralpak-IC semiprep (250 x 10 mm) column (15% 
MeOH, 6.5 mL/min, 220 nM, P=100) to afford (-)-58a (retention time 5.73 min) as a colorless 
oil which foamed up upon drying (100% purity by ESLD): [a]20D -123.8 (c 0.53, MeOH); 
1H 
NMR (CDCl3, 500 MHz) δ  7.48-7.47 (m, 2 H), 7.41 (t, J = 7.6 Hz, 1 H), 7.34-7.32 (m, 1 H), 
7.24-7.22 (m, 2 H), 6.92 (s, 1 H), 3.96-3.93 (br m, 1 H), 3.80-3.78 (br m, 1 H), 3.60-3.55 (br m, 1 
H), 3.26-3.21 (br m, 1 H), 2.80-2.73 (br m, 2 H), 2.53 (td, J = 9.0, 7.0 Hz, 1 H), 2.29 (s, 3 H), 
2.28-2.24 (m, 1 H), 2.22-2.18 (br m, 1 H), 2.09-2.04 (br m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.42 
(td, J = 8.4, 5.6 Hz, 1 H). HRMS (ESI) m/z calcd for C23H23F6N2O ([M+H]
+) 457.1709, found 
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457.1709. The enantiomeric excess was >99% ee (SFC Chiralpak-IC (250 x 10 mm); 15% 
MeOH, 220 nm, 6.5 mL/min; retention time: 6.05 min). 
(+)-58 (retention time 6.41 min) was obtained as a colorless oil which foamed up upon drying 
(100% purity by ESLD): [a]20D +119.4 (c 0.55, MeOH); 
1H NMR (CDCl3, 500 MHz) δ 7.48-7.47 
(m, 2 H), 7.41 (t, J = 7.6 Hz, 1 H), 7.34-7.32 (m,  1 H), 7.24-7.22 (m, 1 H), 6.92 (s, 1 H), 3.96-
3.92 (br m, 1 H), 3.80-3.77 (br m, 1 H), 3.60-3.55 (br m, 1 H), 3.26-3.21 (br m, 1 H), 2.80-2.73 
(br m, 2 H), 2.53 (td, J = 8.9, 7.0 Hz, 1 H), 2.29 (s, 3 H), 2.28-2.24 (m, 1 H), 2.22-2.16 (br m, 1 
H), 2.09-2.04 (br m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.42 (td, J = 8.4, 5.6 Hz, 1 H).; HRMS (ESI) 
m/z calcd for C23H23F6N2O ([M+H]
+) 457.1709, found 457.1704. The enantiomeric excess was 
>99% ee (SFC Chiralpak-IC (250 x 10 mm); 15% MeOH, 220 nm, 6.5 mL/min; retention time: 
6.81 min). 
 
 
Co(II)-salen complex (66).101,107 To a solution of (1R,2R)-l,2-cyclohexanediamine (30.0 mg, 
0.260 mmol) in EtOH (8 mL) was added (R)-3-formyl-2-hydroxy-2'-phenyl-1,1'-binaphthyl103,104 
(195 mg, 0.520 mmol) and stirred at room temperature for 18 h. The resulting light-yellow 
precipitate was filtered and dried under vacuum. This precipitate was added to a solution of 
Co(OAc)2 (46.0 mg, 0.260 mmol) in degassed ethanol (8 mL) under nitrogen. The mixture was 
heated to reflux for 9 h, and cooled to room temperature. The resulting brown precipitate was 
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filtered, washed with degassed ethanol under a nitrogen atmosphere, and dried under vacuum to 
give the corresponding Co(II)-salen complex 66 (153 mg, 0.173 mmol, 67 %) as a dark-brown 
solid: IR (CH2Cl2) 3050, 2934, 2859, 1592, 1545, 1424, 1329, 1295, 1145, 1124, 952, 865, 817, 
759, 697 cm-1; HRMS (ESI) m/z calcd for C60H44CoN2O2 [M
+] 883.2729, found 883.2728. 
(Note: Co(OAc)2 was prepared by heating Co(OAc)2.4H2O at 80 
oC under vacuum for 3 h. The 
color of the solid turned from pink to purple).  
 
 
Co(II)-salen complex (80). To a solution of (1S,2S)-(+)-l,2-Cyclohexanediamine (0.180 g, 1.56 
mmol) in EtOH (48 mL) was added (S)-3-formyl-2-hydroxy-2'-phenyl-1,1'-binaphthyl (1.17 g, 
3.12 mmol) and stirred at room temperature for 18 h. The resulting light-yellow precipitate was 
filtered and dried under vacuum. This precipitate was added to a solution of Co(OAc)2 (0.276 g, 
1.56 mmol) in degassed ethanol (48 mL) under nitrogen. The mixture was heated to reflux for 12 
h, and cooled to room temperature. The resulting brown precipitate was filtered, washed with 
degassed ethanol under a nitrogen atmosphere, and dried under vacuum to give the 
corresponding Co(II)-salen complex 80 (1.07 g, 1.21 mmol, 78%) as a dark-brown solid: IR 
(CH2Cl2) 3051, 2935, 2860, 1591, 1546, 1425, 1330, 1297, 1146, 952, 759, 743cm
-1; HRMS 
(ESI) m/z calcd for C60H44CoN2O2 [M
+] 883.2729, found 883.2733. (Note: Co(OAc)2 was 
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prepared by heating Co(OAc)2.4H2O at 80 
oC under vacuum for 3 h. The color of the solid 
turned from pink to purple). 
 
 
Co(II)-salen complex (81). In a microwave vial, a solution of (1R,2R)-l,2-cyclohexanediamine 
(30.0 mg, 0.260 mmol) in EtOH (8 mL) was added (R)-3-formyl-2-hydroxy-2'-(4-
(naphthyl)phenyl)-1,1'-binaphthyl (260 mg, 0.520 mmol). The vial was sealed and the mixture 
was heated at 110 oC for 12 h. The resulting light-yellow precipitate was filtered and dried under 
vacuum. This precipitate was added to a solution of Co(OAc)2 (46.0 mg, 0.260 mmol) in 
degassed ethanol (8 mL) under nitrogen. The mixture was heated at 110 oC for 18 h in a sealed 
microwave vial. After cooling to room temperature, the resulting brown precipitate was filtered, 
washed with degassed ethanol under a nitrogen atmosphere, and dried under vacuum to give the 
corresponding Co(II)-salen complex 81 (222 mg, 0.195 mmol, 72%) as a dark-brown solid: IR 
(CH2Cl2) 3052, 2933, 2859, 1630, 1563, 1535, 1442, 1384, 1337, 1263, 942, 811, 734 cm
-1; 
HRMS (ESI) m/z calcd for C80H56CoN2O2 [M
+] 1135.3668, found 1135.3667. (Note: Co(OAc)2 
was prepared by heating Co(OAc)2.4H2O at 80 
oC under vacuum for 3 h. The color of the solid 
turned from pink to purple). 
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Co(II)-salen complex (82). In a microwave vial, a solution of (1R,2R)-l,2-cyclohexanediamine 
(30.0 mg, 0.260 mmol) in EtOH (8 mL) was added (R)-3-formyl-2-hydroxy-2'-(3-
(naphthyl)phenyl)-1,1'-binaphthyl (260 mg, 0.520 mmol). The vial was sealed and the mixture 
was heated at 110 oC for 12 h. The resulting light-yellow precipitate was filtered and dried under 
vacuum. This precipitate was added to a solution of Co(OAc)2 (46.0 mg, 0.260 mmol) in 
degassed ethanol (8 mL) under nitrogen. The mixture was heated at 100 oC for 12 h in a sealed 
microwave vial. After cooling to room temperature, the resulting brown precipitate was filtered, 
washed with degassed ethanol under a nitrogen atmosphere, and dried under vacuum to give the 
corresponding Co(II)-salen complex 82 (254 mg, 0.223 mmol, 86%) as a dark-brown solid: IR 
(CH2Cl2) 3051, 2933, 2859, 1628, 1595, 1332, 1319, 1263, 1145, 947, 819, 795, 736 cm
-1; 
HRMS (ESI) m/z calcd for C80H56CoN2O2 [M
+] 1135.3668, found 1135.3667. (Note: Co(OAc)2 
was prepared by heating Co(OAc)2.4H2O at 80 
oC under vacuum for 3 h. The color of the solid 
turned from pink to purple). 
 
 
Ethyl (1R,2S)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-carboxylate (74). To a THF 
solution (4.2 mL) of Co(II)-Salen catalyst 66 (37.1 mg, 0.0419 mmol) was added a THF solution 
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of N-methylimidazole (0.17 mL, 0.5 M, 0.0839 mmol) and the mixture was stirred for 2 min. 4-
(Trifluoromethyl)styrene (0.722 g, 0.62 mL, 4.19 mmol) was added to this solution and the 
mixture was stirred for another 3 min before being treated with ethyl diazoacetate (0.1 mL, 0.839 
mmol). The reaction mixture was stirred for 24 h at room temperature and then concentrated in 
vacuo. The crude residue was purified by chromatography on SiO2 (1:9, EtOAc/hexanes) to give 
the desired cis-product 74 (0.199 g, 0.771 mmol, 92 %) as a colorless oil: 1H NMR (CDCl3, 500 
MHz) δ 7.52 (d, J = 8.1 Hz, 2 H), 7.38 (d, J = 8.6 Hz, 2 H), 3.94-3.85 (m, 2 H), 2.59 (q, J = 8.4 
Hz, 1 H), 2.14 (ddd, J = 9.3, 7.9, 5.7 Hz, 1 H), 1.74 (dt, J = 7.5, 5.4 Hz, 1 H), 1.39 (ddd, J = 8.6, 
7.9, 5.2 Hz, 1 H), 0.99 (t, J = 7.1 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ 170.7, 141.0, 129.8, 
129.1 (q, J C-F = 32.3 Hz), 125.0 (q, J C-F = 3.7 Hz), 124.4 (q, J C-F = 271.7 Hz), 60.5, 25.2, 22.2, 
14.1, 11.5; 19F NMR (CDCl3, 470 MHz) δ  -62.4 (s, 3 F). The cis:trans diastereomic ratio is 
>99:1 based on NMR integration. 
 
 
Ethyl (1R,2S)-2-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxylate (75). To a THF 
solution (4.2 mL) of Co(II)-Salen catalyst 66 (47.2 mg, 0.0534 mmol) was added a THF solution 
of N-methylimidazole (0.21 mL, 0.5 M, 0.107 mmol) and the mixture was stirred for 2 min. 3-
(trifluoromethyl)styrene (0.81 mL, 5.34 mmol) was added to this solution and the mixture was 
stirred for another 3 min before being treated with ethyl diazoacetate (0.13 mL, 0.808 mmol). 
The reaction mixture was stirred for 24 h at room temperature and then concentrated in vacuo. 
The crude residue was purified by chromatography on SiO2 (1:9, EtOAc/hexanes) to give 75 
(0.265 g, 1.03 mmol, 96 %) as a colorless oil: 1H NMR (CDCl3, 400 MHz) δ  7.52 (s, 1 H), 7.47-
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7.36 (m, 3 H), 3.94-3.82 (m, 2 H), 2.60 (q, J = 8.4 Hz, 1 H), 2.13 (ddd, J = 9.2, 7.9, 5.7 Hz, 1 H), 
1.73 (dt, J = 7.4, 5.4 Hz, 1 H), 1.39 (ddd, J = 8.6, 8.0, 5.2 Hz, 1 H), 0.97 (d, J = 14.3 Hz, 3 H); 
13C NMR (CDCl3, 125 MHz) δ  170.7, 137.9, 132.8, 130.5 (q, J C-F = 32.0 Hz), 128.5, 126.4 (q, J 
C-F = 3.8 Hz), 124.3 (q, J C-F = 272.3 Hz), 123.6 (q, J C-F = 3.9 Hz), 60.5, 25.1, 22.0, 14.1, 11.4; 
19F NMR (CDCl3, 375 MHz) δ -62.6 (s, 3 F). The cis:trans diastereomic ratio is >99:1 based on 
NMR integration. 
 
 
(1R,2S)-2-(4-(Trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (76). A solution of 74 
(0.165 g, 0.639 mmol) in methanol (0.6 mL) was added to NaOH (0.179 g, 4.47 mmol) in 
methanol (1.4 ml). The reaction mixture was heated at 55 oC for 5 h. The mixture was cooled to 
room temperature and poured into water and extracted with CH2Cl2 (10 mL). The organic layer 
was discarded and the aqueous layer acidified with 6 M HCl and extracted with CH2Cl2 (3 x 10 
mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure 
to give the acid 76 (0.150 g, 0.652 mmol, quant) as a pale-yellow oil which was used without 
further purification: 1H NMR (CDCl3, 500 MHz) δ 7.50 (d, J = 8.1 Hz, 2 H), 7.33 (d, J = 8.3 Hz, 
2 H), 2.64 (q, J = 8.5 Hz, 1 H), 2.11 (ddd, J = 9.0, 8.0, 5.7 Hz, 1 H), 1.70 (dt, J = 7.7, 5.4 Hz, 1 
H), 1.43 (ddd, J = 8.6, 7.9, 5.2 Hz, 1 H); 19F NMR (CDCl3, 470 MHz) δ -62.5 (s, 3 F). 
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(1R,2S)-2-(3-(Trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (77). A solution of 75 
(0.25 g, 0.968 mmol) in methanol (1 mL) was added to NaOH (0.232 g, 5.81 mmol) in methanol 
(1.5 ml). The reaction mixture was heated at 55 oC for 5 h. The mixture was cooled to room 
temperature and poured into water and extracted with CH2Cl2 (10 mL). The organic layer was 
discarded and the aqueous layer acidified with 6M HCl and extracted with CH2Cl2 (3 x 10 mL). 
The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to 
give the acid 77 (0.230 g, 0.999 mmol, quant) as a colorless oil which solidified upon standing. 
The product was used without further purification: 1H NMR (CDCl3, 500 MHz) δ  7.48 (s, 1 H), 
7.47-7.45 (m,1 H), 7.40-7.33 (m, 2 H), 2.64 (q, J = 8.5 Hz, 1 H), 2.08 (ddd, J = 9.1, 7.8, 5.6 Hz, 
1 H), 1.68 (dt, J = 7.7, 5.4 Hz, 1 H), 1.43 (ddd, J = 8.6, 7.9, 5.2 Hz, 1 H); 19F NMR (CDCl3, 470 
MHz) δ -62.7 (s, 3 F). 
 
  
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1R,2S)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (78). To a solution of 76 (0.14 g, 0.608 
mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine monohydrochloride (0.222 g, 
0.791 mmol) in distilled CH2Cl2 (6 mL) was added Et3N (0.26 mL, 1.83 mmol) at 0 
oC. T3P 
(0.65 mL, 0.912 mmol) was added dropwise and the reaction was stirred at 0 °C for 30 min and 
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allowed to warm to room temperature for 16 h. The reaction was diluted with CH2Cl2 (15 mL) 
and washed with 1 M HCl (15 mL). The aqueous phase was extracted with CH2Cl2 (2 x 15 mL) 
and combined organic phase was dried (MgSO4), filtered, and concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (1:1 EtOAc/hexanes) to afford 78 (0.242 g, 
0.530 mmol, 87 %) as a viscous oil that foamed up upon drying under vacuum: [a]20D +124.1 (c 
0.75, MeOH); 1H NMR (CDCl3, 500 MHz) δ  7.53 (d, J = 8.1 Hz, 2 H), 7.29 (d, J = 8.2 Hz, 2 H), 
7.25-7.21 (m, 2 H), 6.93 (s, 1 H), 3.85-3.83 (m, 1 H), 3.71-3.60 (m, 2 H), 3.36-3.32 (m, 1 H), 
2.82-2.74 (m, 2 H), 2.52 (q, J = 8.0 Hz, 1 H), 2.30-2.25 (m, 5 H), 2.16-2.12 (m, 1 H), 1.92 (q, J = 
6.2 Hz, 1 H), 1.43 (td, J = 8.4, 5.6 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) δ  166.9, 151.2, 142.0, 
136.9, 131.6, 129.3 (q, J = 32 Hz), 129.1 (q, J = 34 Hz), 128.1, 125.2 (q, J = 4 Hz), 124.3 (q, J = 
272 Hz), 124.3 (q, J = 272 Hz), 120.6 (q, J = 4 Hz), 116.0 (q, J = 4 Hz), 52.0, 51.8, 45.7, 42.4, 
24.7, 24.2, 18.0, 11.3; 19F NMR (CDCl3, 470 MHz) δ  -62.5 (s, 3 F), -62.5 (s, 3 F); HRMS (ESI) 
m/z calcd for C23H23F6N2O ([M+H]
+) 457.1709, found 457.1708. The enantiomeric excess was 
93.6% ee (SFC Chiralpak-IC (250 x 10 mm); 30% MeOH, 220 nm, 7.0 mL/min; retention time: 
3.66 min). 
 
Figure 34. SFC chromatogram of racemic sample 78. 
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(b) 
 
(c) 
 
  
Figure 35. Enantiomeric excess of (1R,2S)-78. (a) Co(II)-salen complex 66, (b) Co(II)-salen complex 81, (c) Co(II)-
salen complex 82. 
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(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1R,2S)-2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone (79). To a solution of 77 (0.100 g, 0.434 
mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine monohydrochloride (0.171 g, 
0.608 mmol) in distilled CH2Cl2 (4.3 mL) was added Et3N (0.18 mL, 1.30 mmol) at 0 
oC. T3P 
(0.46 mL, 0.652 mmol) was added dropwise and the reaction was stirred at 0 °C for 30 min and 
allowed to warm to room temperature for 16 h. The reaction was diluted with CH2Cl2 (15 mL) 
and washed with 1 M HCl (15 mL). The aqueous phase was extracted with CH2Cl2 (2 x 15 mL) 
and combined organic phase was dried (MgSO4), filtered, and concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (1:1 EtOAc/hexanes) to afford the desired 
compound (+)-79 (0.179 g, 0.391 mmol, 90 %) as a viscous oil: [a]20D +120.8 (c 0.71, MeOH); 
1H NMR (CDCl3, 300 MHz) δ 7.48-7.46 (m, 2 H), 7.40 (t, J = 7.9 Hz, 1 H), 7.34-7.32 (m, 1 H), 
7.24-7.20 (m, 2 H), 6.92 (s, 1 H), 3.97-3.92 (br m, 1 H), 3.81-3.76 (br m, 1 H), 3.62-3.54 (br m, 1 
H), 3.28-3.19 (br m, 1 H), 2.81-2.72 (br m, 2 H), 2.53 (td, J = 8.9, 7.0 Hz, 1 H), 2.31-2.16 (m, 5 
H), 2.11-2.03 (br m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.42 (td, J = 8.4, 5.6 Hz, 1 H); HRMS (ESI) 
m/z calcd for C23H23F6N2O ([M+H]
+) 457.1709, found 457.1702. The enantiomeric excess was 
94.4% ee (SFC Chiralpak-IC (250 x 10 mm); 15% MeOH, 220 nm, 6.5 mL/min; retention time: 
6.75 min). 
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Figure 36. SFC chromatogram of racemic sample of 79. 
 
 
Figure 37. Enantiomeric excess of (1R,2S)-79. 
  
 
Ethyl (1S,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-carboxylate (74). To a THF 
solution (4.2 mL) of Co(II)-Salen catalyst 80 (37.1 mg, 0.0419 mmol) was added a THF solution 
of N-methylimidazole (0.17 mL, 0.5 M, 0.0839 mmol) and the mixture was stirred for 2 min. 4-
(trifluoromethyl)styrene (0.722 g, 0.62 mL, 4.19 mmol) was added to this solution and the 
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mixture was stirred for another 3 min before being treated with ethyl diazoacetate (0.1 mL, 0.839 
mmol). The reaction mixture was stirred for 24 h at room temperature and then concentrated in 
vacuo. The crude residue was purified by chromatography on SiO2 (1:9, EtOAc/hexanes) to give 
the desired cis-product (1S,2R)-74 (0.181 g, 0.701 mmol, 84 %) as a colorless oil: 1H NMR 
(CDCl3, 500 MHz) δ 7.52 (d, J = 7.6 Hz, 2 H), 7.38 (d, J = 7.8 Hz, 2 H), 3.93-3.84 (m, 2 H), 2.59 
(q, J = 8.5 Hz, 1 H), 2.14 (q, J = 7.6 Hz, 1 H), 1.74 (q, J = 5.9 Hz, 1 H), 1.40 (q, J = 7.1 Hz, 1 H), 
0.99 (t, J = 6.9 Hz, 3 H); 19F NMR (CDCl3, 470 MHz) δ  -62.4 (s, 3 F). The cis:trans 
diastereomic ratio is ca. 95:5 based on NMR integration. 
 
 
(1S,2R)-2-(4-(Trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (76). A solution of 
(1S,2R)-74 (0.180 g, 0.697 mmol) in methanol (0.5 mL) was added to NaOH (0.139 g, 3.49 
mmol) in methanol (1.2 ml). The reaction mixture was heated at 55 oC for 5 h. The mixture was 
cooled to room temperature and poured into water and extracted with CH2Cl2 (10 mL). The 
organic layer was discarded and the aqueous layer acidified with 6 M HCl and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried (Na2SO4), and concentrated under 
reduced pressure to give the acid (1S,2R)-76 (0.176 g, 0.765 mmol, quant) as a pale-yellow oil 
which was used without further purification: 1H NMR (CDCl3, 500 MHz) δ  7.50 (d, J = 7.8 Hz, 
2 H), 7.34 (d, J = 7.7 Hz, 2 H), 2.64 (q, J = 8.6 Hz, 1 H), 2.11 (q, J = 7.6 Hz, 1 H), 1.70 (q, J = 
6.1 Hz, 1 H), 1.44 (q, J = 7.3 Hz, 1 H). 
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(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1S,2R)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (78). To a solution of (1S,2R)-76 (0.170 g, 
0.739 mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine monohydrochloride (0.290 
g, 1.034 mmol) in distilled CH2Cl2 (7.4 mL) was added Et3N (0.31 mL, 2.22 mmol) at 0 
oC. T3P 
(0.78 mL, 1.11 mmol) was added dropwise and the reaction was stirred at 0 °C for 30 min and 
allowed to warm to room temperature for 16 h. The reaction was diluted with CH2Cl2 (15 mL) 
and washed with 1 M HCl (15 mL). The aqueous phase was extracted with CH2Cl2 (2 x 15 mL) 
and combined organic phase was dried (MgSO4), filtered, and concentrated in vacuo. The crude 
material was purified by chromatography on SiO2 (1:1 EtOAc/hexanes) to afford the desired 
compound (1S,2R)-78 (0.249 g, 0.546 mmol, 74%) as a pale yellow oil: [a]20D -123.5 (c 0.78, 
MeOH); 1H NMR (CDCl3, 500 MHz) δ 7.48-7.46 (m, 2 H), 7.40 (t, J = 7.9 Hz, 1 H), 7.34-7.32 
(m, 1 H), 7.24-7.20 (m, 2 H), 6.92 (s, 1 H), 3.97-3.92 (br m, 1 H), 3.81-3.76 (br m, 1 H), 3.62-
3.54 (br m, 1 H), 3.28-3.19 (br m, 1 H), 2.81-2.72 (br m, 2 H), 2.53 (td, J = 8.9, 7.0 Hz, 1 H), 
2.31-2.16 (m, 5 H), 2.11-2.03 (br m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.42 (td, J = 8.4, 5.6 Hz, 1 
H); 19F NMR (CDCl3, 470 MHz) δ -62.5 (s, 3 F), -62.5 (s, 3 F); HRMS (ESI) m/z calcd for 
C23H23F6N2O ([M+H]
+) 457.1709, found 457.1711. The enantiomeric excess was 93.4% ee (SFC 
Chiralpak-IC (250 x 10 mm); 15% MeOH, 220 nm, 6.5 mL/min; retention time: 6.15 min). 
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Figure 38. Enantiomeric excess of (1S,2R)-78. 
 
 
Ethyl (1S,2R)-2-(4-(pentafluorosulfanyl)phenyl)cyclopropane-1-carboxylate (83). To a THF 
solution (5.7 mL) of Co(II)-Salen catalyst 80 (167 mg, 0.189 mmol) was added a THF solution 
of N-methylimidazole (0.75 mL, 0.5 M, 0.377 mmol) and the mixture was stirred for 2 min. 4-
(pentafluorosulfanyl)styrene (1.30 g, 5.66 mmol) was added to this solution and the mixture was 
stirred for another 3 min before being treated with ethyl diazoacetate (0.45 mL, 3.77 mmol, 87 
wt% in CH2Cl2). The reaction mixture was stirred for 24 h at room temperature and then 
concentrated in vacuo. The residue was precipitated with hexanes and filtered to recover the 
catalyst. The hexanes filtrate was concentrated and purified by chromatography on SiO2 (1:9, 
EtOAc/hexanes) to give the desired cis-product (1S,2R)-74 (1.10 g, 3.47 mmol, 92%) as a 
colorless oil: 1H NMR (CDCl3, 500 MHz) δ 7.64 (d, J = 8.8 Hz, 2 H), 7.35 (d, J = 8.2 Hz, 2 H), 
3.96-3.86 (m, 2 H), 2.56 (q, J = 8.4 Hz, 1 H), 2.15 (ddd, J = 9.2, 8.0, 5.7 Hz, 1 H), 1.73 (dt, J = 
7.5, 5.5 Hz, 1 H), 1.41 (td, J = 8.3, 5.2 Hz, 1 H), 1.00 (t, J = 7.1 Hz, 3 H); 19F NMR (CDCl3, 470 
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MHz) δ 84.9 (quintet, J = 150 Hz, 1 F), 63.1 (d, J = 150 Hz, 4 F). The cis:trans diastereomic 
ratio is >95:5 based on NMR integration. 
 
 
(1S,2R)-2-(4-(Pentafluorosulfanyl)phenyl)cyclopropane-1-carboxylic acid (76). A solution of 
(1S,2R)-83 (0.180 g, 0.697 mmol) in methanol (0.5 mL) was added to NaOH (0.139 g, 3.49 
mmol) in methanol (1.2 ml). The reaction mixture was heated at 55 oC for 5 h. The mixture was 
cooled to room temperature and poured into water and extracted with CH2Cl2 (10 mL). The 
organic layer was discarded and the aqueous layer acidified with 6 M HCl and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried (Na2SO4), and concentrated under 
reduced pressure to give the acid (1S,2R)-84 (0.176 g, 0.765 mmol, quant) as a pale-yellow oil 
which solidified upon standing: 1H NMR (CDCl3, 500 MHz) δ 7.62 (d, J = 8.8 Hz, 2 H), 7.31 (d, 
J = 8.5 Hz, 2 H), 2.62 (q, J = 8.5 Hz, 1 H), 2.12 (td, J = 8.5, 5.7 Hz, 1 H), 1.69 (dt, J = 7.7, 5.5 
Hz, 1 H), 1.45 (td, J = 8.2, 5.3 Hz, 1 H); 19F NMR (CDCl3, 470 MHz) δ 84.9 (quintet, J = 150 
Hz, 1 F), 63.0 (d, J = 150 Hz, 4 F). 
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(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1S,2R)-2-(4-
(pentafluorosulfanyl)phenyl)cyclopropyl)methanone (85). To a solution of (1S,2R)-84 (0.550 
g, 1.77 mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine monohydrochloride (0.734 
g, 2.48 mmol) in distilled CH2Cl2 (18 mL) was added Et3N (0.75 mL, 5.32 mmol) at 0 
oC. T3P 
(1.88 mL, 2.66 mmol, 50 wt% in ethyl acetate) was added dropwise and the reaction was stirred 
at 0 °C for 30 min and allowed to warm to room temperature for 16 h. The reaction was diluted 
with CH2Cl2 (30 mL) and washed with 1 M HCl (30 mL). The aqueous phase was extracted with 
CH2Cl2 (2 x 30 mL) and combined organic phase was dried (MgSO4), filtered, and concentrated 
in vacuo. The crude material was purified by chromatography on SiO2 (1:1 EtOAc/hexanes) to 
afford the desired compound (1S,2R)-85 (0.838 g, 1.63 mmol, 92%) as a white solid: Mp 127.3 – 
128.9 oC; IR (CHCl3) 3005, 2912, 2821, 1636, 1439, 1417, 1338, 1308, 1121, 826, 748 cm
-1; 1H 
NMR (CDCl3, 500 MHz) δ 1H NMR (CDCl3, 500 MHz) δ 1H NMR (CDCl3, 500 MHz) δ 7.65 
(d, J = 8.8 Hz, 2 H), 7.26 – 7.22 (m, 4 H), 6.97 (s, 1 H), 3.86 – 3.81 (br m, 1 H), 3.71-3.61 (br m, 
2 H), 3.38 – 3.34 (br m, 1 H), 2.85 – 2.76 (br m, 2 H), 2.50 (q, J = 8.0 Hz, 1 H), 2.33-2.27 (m, 5 
H), 2.18 – 2.15 (br m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.44 (td, J = 8.4, 5.6 Hz, 1 H); 13C NMR 
(CDCl3, 125 MHz) δ 166.7, 152.5 (t, J = 17 Hz), 151.2, 142.0, 136.9, 131.6, 129.4 (q, J = 33 
Hz), 127.9, 125.8 (t, J = 5 Hz), 124.3 (q, J = 272 Hz), 120.6 (q, J = 4 Hz), 116.0 (q, J = 4 Hz), 
52.1, 51.7, 45.7, 42.4, 24.7, 23.9, 18.0, 11.5; 19F NMR (CDCl3, 470 MHz) δ 84.6 (quintet, J = 
150 Hz, 1F), 63.1 (d, J = 150 Hz, 4 F), -62.5 (s, 3 F); HRMS (ESI) m/z calcd for C22H23F8N2OS 
([M+H]+) 515.1398, found 515.1398. The enantiomeric excess was enriched to 98.6% ee after 
recrystallization from CH2Cl2/hexanes (HPLC Chiralpak AD-H (4.6 x 250 mm, 5 µm); 
IPA:hexanes (7:93), 254 nm, 1.0 mL/min; inj. vol.: 20 µL; retention time: 12.07 min). 
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Peak 
Retention time 
(min) 
Area % Area 
1 12.06 14638727 50.5 
2 13.88 14355130 49.5 
Figure 39. HPLC chromatogram of racemic sample 85. 
 
 
Peak 
Retention time 
(min) 
Area % Area 
1 12.07 16997416 99.3 
2 13.98 126266 0.7 
Figure 40. Enantiomeric excess of (1R,2S)-85. 
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(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)((1S,2R)-2-(4-
(pentafluorosulfanyl)phenyl)cyclopropyl)methanone (86). To a solution of (1S,2R)-84 (1.32 
g, 4.26 mmol) and 1-(5-chloro-2-(trifluoromethyl)phenyl)piperazine monohydrochloride (1.67 g, 
5.54 mmol) in distilled CH2Cl2 (43 mL) was added Et3N (1.80 mL, 12.8 mmol) at 0 
oC. T3P 
(4.50 mL, 6.39 mmol, 50 wt% in ethyl accetate) was added dropwise and the reaction was stirred 
at 0 °C for 30 min and allowed to warm to room temperature for 16 h. The reaction was diluted 
with CH2Cl2 (50 mL) and washed with 1 M HCl (50 mL). The aqueous phase was extracted with 
CH2Cl2 (2 x 50 mL) and combined organic phase was dried (MgSO4), filtered, and concentrated 
in vacuo. The crude material was purified by chromatography on SiO2 (1:1 EtOAc/hexanes) to 
afford the desired compound (1S,2R)-86 (1.98 g, 3.70 mmol, 87%) as a white solid: Mp 125.8 – 
127.7 oC; 1H NMR (CDCl3, 500 MHz) δ 7.68 (d, J = 8.8 Hz, 2 H), 7.52 (d, J = 8.5 Hz, 1 H), 
7.27-7.25 (m, 2 H), 7.20 (d, J = 8.5 Hz, 1 H), 6.93 (s, 1 H), 3.99 – 3.96 (br m, 1 H), 3.74 – 3.71 
(br m, 1 H), 3.56 – 3.52 (br m, 1 H), 3.23 – 3.19 (br m, 1 H), 2.79 – 2.74 (br m, 2 H), 2.49 (q, J = 
8.0 Hz, 1 H), 2.29 – 2.22 (m, 2 H), 1.98 – 1.94 (br m, 1 H), 1.91 (q, J = 6.2 Hz, 1 H), 1.45 (td, J 
= 8.4, 5.7 Hz, 1 H); 13C NMR (CDCl3, 125 MHz) δ 166.6, 152.8, 152.5 (t, J = 18 Hz), 142.2, 
139.2, 128.6 (q, J = 5 Hz), 127.9, 125.9 (q, J = 29 Hz), 125.9 (t, J = 5 Hz), 125.8, 124.5, 123.7 
(q, J = 273 Hz), 54.0, 53.0, 45.7, 42.3, 25.0, 23.9, 11.6; 19F NMR (CDCl3, 470 MHz) δ 84.8 
(quintet, J = 150 Hz, 1 F), 63.3 (d, J = 150 Hz, 4 F), -60.4 (s, 3 F); HRMS (ESI) m/z calcd for 
C21H20ClF8N2OS ([M+H]
+) 535.0852, found 535.0852. The enantiomeric excess was enriched to 
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97.6% ee after recrystallization from CH2Cl2/hexanes (HPLC Chiralpak AD-H (4.6 x 250 mm, 5 
µm); IPA:hexanes (1:9), 254 nm, 1.0 mL/min; inj. vol.: 20 µL; retention time: 12.07 min). 
 
Peak Retention time (min) Area % Area 
1 8.04 5589901 49.3 
2 10.48 5756253 50.7 
Figure 41. HPLC chromatogram of racemic sample 86. 
 
 
Peak Retention time (min) Area % Area 
1 7.91 20342400 98.8 
2 10.59 252606 1.2 
Figure 42. Enantiomeric excess of (1R,2S)-86. 
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APPENDIX B 
CIRCULAR DICHROISM SPECTRA
 169 
  
Figure 43. CD spectra for (-)-5a. 
 
 
Figure 44. CD spectra for (+)-5a. 
c = 2.97 x 10-5 M (MeOH) 
λmax = 225.4 nm 
θ = -144129 deg*cm2/dmol 
 
c = 2.97 x 10-5 M (MeOH) 
λmax = 225.4 nm 
θ = +142885 deg*cm2/dmol 
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Figure 45. CD spectra for (-)-5b. 
 
 
Figure 46. CD spectra for (+)-5b. 
 
c = 7.26 x 10-6 M (MeOH) 
λmax = 221.1 nm 
θ = -60136 deg*cm2/dmol 
 
c = 6.96 x 10-6 M (MeOH) 
λmax = 222.0 nm 
θ = +84327 deg*cm2/dmol 
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Figure 47. CD spectra for (-)-6a. 
 
 
Figure 48. CD spectra for (+)-6a. 
c = 1.29 x 10-5 M (MeOH) 
λmax = 218.1 nm 
θ = -52992 deg*cm2/dmol 
 
c = 1.42 x 10-5 M (MeOH) 
λmax = 219.1 nm 
θ = +52344 deg*cm2/dmol 
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Figure 49. CD spectra for (-)-6b. 
 
 
Figure 50. CD spectra for (+)-6b. 
c = 1.37 x 10-5 M (MeOH) 
λmax = 217.3 nm 
θ = -96137 deg*cm2/dmol 
 
c = 1.31 x 10-5 M (MeOH) 
λmax = 217.4 nm 
θ = +111387 deg*cm2/dmol 
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Figure 51. CD spectra for (-)-11a. 
 
 
Figure 52. CD spectra for (+)-11a. 
c = 1.37 x 10-5 M (MeOH) 
λmax = 229.0 nm 
θ = -14456 deg*cm2/dmol 
 
c = 1.36 x 10-5 M (MeOH) 
λmax = 228.0 nm 
θ = +16193 deg*cm2/dmol 
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Figure 53. CD spectra for (-)-15. 
 
 
Figure 54. CD spectra for (+)-15. 
c = 2.28 x 10-5 M (MeOH) 
λmax = 231.8 nm 
θ = -16512 deg*cm2/dmol 
 
c = 1.94 x 10-5 M (MeOH) 
λmax = 231.3 nm 
θ = +18537 deg*cm2/dmol 
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Figure 55. CD spectra for (-)-17. 
 
 
Figure 56. CD spectra for (+)-17. 
c = 2.02 x 10-5 M (MeOH) 
λmax = 224.2 nm 
θ = +40397 deg*cm2/dmol 
 
c = 2.15 x 10-5 M (MeOH) 
λmax = 222.9 nm 
θ = -34495 deg*cm2/dmol 
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Figure 57. CD spectra for (-)-34. 
 
 
Figure 58. CD spectra for (+)-34. 
 
c = 1.18 x 10-5 M (MeOH) 
λmax = 231.2 nm 
θ = -69315 deg*cm2/dmol 
 
c = 1.29 x 10-5 M (MeOH) 
λmax = 230.7 nm 
θ = +58061 deg*cm2/dmol 
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APPENDIX C 
X-RAY CRYSTALLOGRAPHY DATA 
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X-ray structural information for trans-cyclopropyl carboxylic acid 3b: 
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Table 9. Crystal Data for 3b. 
Chemical formula C10H8F2O2 
Formula weight 198.16 g/mol 
Temperature 230(2) K 
Wavelength 1.54184 Å 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 12.4315(14) Å α = 90° 
 
b = 5.6124(7) Å β = 109.803(7)° 
 
c = 13.6208(13) Å γ = 90° 
Volume 894.13(18) Å3 
 
Z 4 
Density (calculated) 1.472 g/cm3 
Absorption coefficient 1.122 mm-1 
F(000) 408 
 
 
Table 10. Data collection and structure refinement for 3b. 
Diffractometer Bruker X8 Prospector Ultra with Apex II CCD 
Radiation source IMuS, Cu Kα 
Theta range for data collection 3.78 to 83.53° 
Index ranges -16<=h<=16, -6<=k<=6, -14<=l<=13 
Reflections collected 3550 
Independent reflections 1500 [R(int) = 0.0775] 
Coverage of independent reflections 75.1% 
Absorption correction Multi-Scan 
Structure solution technique direct methods 
Structure solution program XT, VERSION 2014/5 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014/7 (Sheldrick, 2014) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 1500 / 0 / 131 
Goodness-of-fit on F2 4.676 
Δ/σmax 0.475 
Final R indices 807 data; I>2σ(I) R1 = 0.4436, wR2 = 0.7232 
 
all data R1 = 0.4807, wR2 = 0.7683 
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Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 1.899 and -1.197 eÅ-3 
R.M.S. deviation from mean 0.302 eÅ-3 
 
 
Table 11. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 3b. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 
x/a y/b z/c U(eq) 
C1 0.212(3) 0.532(4) 0.3626(14) 0.123(13) 
F1 0.0116(18) 0.257(3) 0.4719(12) 0.131(6) 
O1 0.3930(17) 0.031(3) 0.3826(13) 0.116(7) 
C2 0.134(3) 0.501(6) 0.428(2) 0.142(15) 
F2 0.2614(16) 0.624(3) 0.1640(12) 0.130(7) 
O2 0.535(2) 0.275(3) 0.4399(13) 0.112(7) 
C3 0.0884(16) 0.306(5) 0.4077(15) 0.079(7) 
C4 0.092(3) 0.119(4) 0.3353(16) 0.121(13) 
C5 0.143(2) 0.158(5) 0.2682(19) 0.106(10) 
C6 0.207(2) 0.363(4) 0.2871(13) 0.083(8) 
C7 0.290(2) 0.423(4) 0.2189(13) 0.074(7) 
C8 0.339(2) 0.226(4) 0.1642(16) 0.095(8) 
C9 0.3873(16) 0.355(3) 0.2660(16) 0.075(7) 
C10 0.4462(16) 0.208(4) 0.3678(16) 0.071(7) 
 
 
Table 12. Bond lengths (Å) for 3b. 
C1-C6 1.38(3) C1-C2 1.53(5) 
C1-H1A 0.94 F1-C3 1.52(3) 
O1-C10 1.25(3) O1-H1O 1.07(9) 
C2-C3 1.22(4) C2-H2A 0.94 
F2-C7 1.33(2) O2-C10 1.26(2) 
C3-C4 1.45(4) C4-C5 1.30(4) 
C4-H4A 0.94 C5-C6 1.37(4) 
C5-H5A 0.94 C6-C7 1.64(3) 
C7-C9 1.22(3) C7-C8 1.57(4) 
C8-C9 1.50(3) C8-H8A 0.98 
C8-H8B 0.98 C9-C10 1.57(3) 
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C9-H9A 0.99 
  
 
 
Table 13. Bond angles (°) for 3b. 
C6-C1-C2 118.(2) C6-C1-H1A 121.0 
C2-C1-H1A 120.8 C10-O1-H1O 100.(6) 
C3-C2-C1 108.(2) C3-C2-H2A 125.9 
C1-C2-H2A 126.0 C2-C3-C4 133.(3) 
C2-C3-F1 112.(2) C4-C3-F1 115.(2) 
C5-C4-C3 119.(2) C5-C4-H4A 120.2 
C3-C4-H4A 120.4 C4-C5-C6 113.(2) 
C4-C5-H5A 123.3 C6-C5-H5A 123.3 
C5-C6-C1 127.(3) C5-C6-C7 120.(2) 
C1-C6-C7 114.(2) C9-C7-F2 126.(2) 
C9-C7-C6 110.0(16) F2-C7-C6 113.(2) 
C9-C7-C8 63.5(18) F2-C7-C8 113.7(17) 
C6-C7-C8 123.2(19) C9-C8-C7 46.9(12) 
C9-C8-H8A 118.9 C7-C8-H8A 119.0 
C9-C8-H8B 118.9 C7-C8-H8B 118.9 
H8A-C8-H8B 116.4 C7-C9-C8 69.6(16) 
C7-C9-C10 135.(2) C8-C9-C10 119.0(17) 
C7-C9-H9A 108.6 C8-C9-H9A 108.7 
C10-C9-H9A 108.7 O2-C10-O1 119.(2) 
O2-C10-C9 123.8(19) O1-C10-C9 116.7(15) 
 
 
Table 14. Anisotropic atomic displacement parameters (Å2) for 3b. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
C1 0.25(3) 0.063(14) 0.049(11) -0.020(9) 0.045(15) -0.077(18) 
F1 0.198(17) 0.107(12) 0.143(12) -0.013(9) 0.130(11) -0.011(11) 
O1 0.173(18) 0.057(10) 0.132(14) 0.008(9) 0.069(13) 0.011(12) 
C2 0.18(3) 0.12(2) 0.12(2) -0.086(18) 0.04(2) -0.08(2) 
F2 0.213(16) 0.086(11) 0.139(12) 0.052(8) 0.119(10) 0.051(10) 
O2 0.190(19) 0.067(11) 0.109(12) 0.015(8) 0.090(13) 0.037(12) 
C3 0.048(11) 0.14(2) 0.059(11) 0.013(12) 0.031(9) 0.012(13) 
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U11 U22 U33 U23 U13 U12 
C4 0.26(4) 0.065(15) 0.054(12) -0.015(9) 0.069(17) -0.045(18) 
C5 0.16(3) 0.085(19) 0.074(15) -0.033(12) 0.034(16) -0.037(18) 
C6 0.128(19) 0.066(13) 0.041(9) -0.008(7) 0.013(11) -0.033(12) 
C7 0.107(18) 0.076(14) 0.039(10) -0.003(8) 0.023(10) -0.009(12) 
C8 0.16(2) 0.060(14) 0.080(13) -0.016(10) 0.060(14) -0.029(14) 
C9 0.069(12) 0.047(11) 0.087(14) -0.023(9) -0.001(11) -0.038(9) 
C10 0.050(10) 0.075(14) 0.070(12) -0.036(10) -0.002(9) -0.016(9) 
 
 
Table 15. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 3b. 
 x/a y/b z/c U(eq) 
H1A 0.2622 0.6629 0.3735 0.147 
H2A 0.1240 0.6124 0.4755 0.171 
H4A 0.0567 -0.0285 0.3368 0.145 
H5A 0.1376 0.0554 0.2121 0.128 
H8A 0.3134 0.0609 0.1644 0.114 
H8B 0.3646 0.2715 0.1061 0.114 
H9A 0.4416 0.4778 0.2592 0.089 
H1O 0.459(8) -0.057(17) 0.443(7) 0.00(2) 
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Figure 59. X-ray structural information for rac-6a. 
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Table 16. Crystal data for 6a. 
Chemical formula C22H21ClF4N2O 
Formula weight 440.86 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 7.5803(4) Å α = 77.301(3)° 
 
b = 8.3837(4) Å β = 86.162(3)° 
 
c = 17.4921(8) Å γ = 73.979(3)° 
Volume 1042.30(9) Å3 
 
Z 2 
Density (calculated) 1.405 g/cm3 
Absorption coefficient 2.086 mm-1 
F(000) 456 
 
 
 
Table 17. Data collection and structure refinement for 6a. 
Diffractometer Bruker Apex II CCD 
Radiation source Bruker X8 Prospector Ultra, IMuS Cu K/a 
Theta range for data collection 2.59 to 68.34° 
Index ranges -9<=h<=9, -10<=k<=10, -21<=l<=20 
Reflections collected 15778 
Independent reflections 3736 [R(int) = 0.1862] 
Absorption correction multi-scan 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3736 / 0 / 271 
Goodness-of-fit on F2 3.374 
Δ/σmax 0.006 
Final R indices 2740 data; I>2σ(I) R1 = 0.1853, wR2 = 0.4655 
 
all data R1 = 0.2076, wR2 = 0.4848 
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Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 3.223 and -0.725 eÅ-3 
R.M.S. deviation from mean 0.176 eÅ-3 
 
 
 
Table 18. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 6a. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 
x/a y/b z/c U(eq) 
C1 0.4716(10) 0.5561(9) 0.8607(5) 0.0434(18) 
C2 0.5876(10) 0.3899(10) 0.8748(5) 0.051(2) 
C3 0.5185(10) 0.2667(9) 0.9198(5) 0.0420(18) 
C4 0.3499(12) 0.2910(10) 0.9495(5) 0.053(2) 
C5 0.2371(12) 0.4582(11) 0.9370(6) 0.060(3) 
C6 0.2966(9) 0.5906(9) 0.8899(4) 0.0378(16) 
C7 0.1651(9) 0.7660(9) 0.8741(4) 0.0369(16) 
C8 0.0853(10) 0.8472(9) 0.9418(5) 0.0433(18) 
C9 0.2242(9) 0.9135(9) 0.8900(4) 0.0385(17) 
C10 0.0423(12) 0.7919(11) 0.8063(6) 0.061(2) 
C11 0.1592(10) 0.0962(9) 0.8426(4) 0.0394(17) 
C12 0.2220(14) 0.3223(11) 0.7389(5) 0.071(3) 
C13 0.2467(13) 0.3241(12) 0.6548(6) 0.065(3) 
C14 0.4539(15) 0.0418(12) 0.7623(7) 0.081(4) 
C15 0.4721(15) 0.0562(11) 0.6803(6) 0.075(3) 
C16 0.4751(13) 0.2509(11) 0.5547(5) 0.055(2) 
C17 0.3405(13) 0.3078(11) 0.4968(5) 0.060(2) 
C18 0.3879(15) 0.3287(13) 0.4181(6) 0.072(3) 
C19 0.5678(15) 0.2996(13) 0.3960(6) 0.070(3) 
C20 0.7037(16) 0.2477(12) 0.4517(6) 0.068(3) 
C21 0.6597(12) 0.2290(13) 0.5343(6) 0.063(3) 
C22 0.8160(17) 0.1725(18) 0.5937(7) 0.092(4) 
Cl1 0.2140(5) 0.3842(5) 0.34800(19) 0.1125(14) 
F1 0.6287(6) 0.1010(5) 0.9314(3) 0.0591(14) 
F2 0.9397(8) 0.6803(8) 0.8182(4) 0.090(2) 
F3 0.9231(8) 0.9460(7) 0.7900(4) 0.0835(19) 
F4 0.1328(9) 0.7732(8) 0.7412(3) 0.0819(18) 
N1 0.2695(10) 0.1435(8) 0.7832(4) 0.0548(19) 
 186 
 
x/a y/b z/c U(eq) 
N2 0.4346(9) 0.2365(9) 0.6383(4) 0.058(2) 
O1 0.0194(7) 0.1923(7) 0.8599(3) 0.0509(15) 
 
 
Table 19. Bond lengths (Å) for 6a. 
C1-C6 1.366(10) C1-C2 1.406(10) 
C1-H1A 0.94 C2-C3 1.359(11) 
C2-H2A 0.94 C3-C4 1.326(12) 
C3-F1 1.388(8) C4-C5 1.405(11) 
C4-H4A 0.94 C5-C6 1.392(11) 
C5-H5A 0.94 C6-C7 1.510(9) 
C7-C10 1.497(11) C7-C8 1.504(10) 
C7-C9 1.510(10) C8-C9 1.487(10) 
C8-H8A 0.98 C8-H8B 0.98 
C9-C11 1.535(9) C9-H9A 0.99 
C10-F4 1.307(12) C10-F2 1.348(11) 
C10-F3 1.340(9) C11-O1 1.207(9) 
C11-N1 1.349(9) C12-C13 1.468(14) 
C12-N1 1.486(10) C12-H12A 0.98 
C12-H12B 0.98 C13-N2 1.453(11) 
C13-H13A 0.98 C13-H13B 0.98 
C14-C15 1.414(16) C14-N1 1.491(11) 
C14-H14A 0.98 C14-H14B 0.98 
C15-N2 1.486(11) C15-H15A 0.98 
C15-H15B 0.98 C16-C17 1.396(13) 
C16-C21 1.393(12) C16-N2 1.460(11) 
C17-C18 1.386(13) C17-H17A 0.94 
C18-C19 1.362(15) C18-Cl1 1.756(11) 
C19-C20 1.378(16) C19-H19A 0.94 
C20-C21 1.446(14) C20-H20A 0.94 
C21-C22 1.531(15) C22-H22A 0.97 
C22-H22B 0.97 C22-H22C 0.97 
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Table 20. Bond angles (°) for 6a. 
C6-C1-C2 121.2(7) C6-C1-H1A 119.4 
C2-C1-H1A 119.4 C3-C2-C1 116.9(7) 
C3-C2-H2A 121.6 C1-C2-H2A 121.6 
C2-C3-C4 125.0(7) C2-C3-F1 117.5(7) 
C4-C3-F1 117.4(6) C3-C4-C5 117.6(7) 
C3-C4-H4A 121.2 C5-C4-H4A 121.2 
C4-C5-C6 120.6(7) C4-C5-H5A 119.7 
C6-C5-H5A 119.7 C1-C6-C5 118.5(7) 
C1-C6-C7 123.1(6) C5-C6-C7 118.4(6) 
C10-C7-C6 111.7(6) C10-C7-C8 117.8(7) 
C6-C7-C8 119.5(6) C10-C7-C9 120.0(6) 
C6-C7-C9 119.5(6) C8-C7-C9 59.1(5) 
C9-C8-C7 60.6(5) C9-C8-H8A 117.7 
C7-C8-H8A 117.7 C9-C8-H8B 117.7 
C7-C8-H8B 117.7 H8A-C8-H8B 114.8 
C8-C9-C7 60.3(5) C8-C9-C11 116.5(6) 
C7-C9-C11 124.1(6) C8-C9-H9A 114.9 
C7-C9-H9A 114.9 C11-C9-H9A 114.9 
F4-C10-F2 105.6(8) F4-C10-F3 105.6(8) 
F2-C10-F3 105.8(7) F4-C10-C7 112.9(7) 
F2-C10-C7 112.4(7) F3-C10-C7 113.9(8) 
O1-C11-N1 122.7(7) O1-C11-C9 120.9(6) 
N1-C11-C9 116.4(6) C13-C12-N1 109.0(8) 
C13-C12-H12A 109.9 N1-C12-H12A 109.9 
C13-C12-H12B 109.9 N1-C12-H12B 109.9 
H12A-C12-H12B 108.3 C12-C13-N2 110.4(8) 
C12-C13-H13A 109.6 N2-C13-H13A 109.6 
C12-C13-H13B 109.6 N2-C13-H13B 109.6 
H13A-C13-H13B 108.1 C15-C14-N1 110.9(9) 
C15-C14-H14A 109.5 N1-C14-H14A 109.5 
C15-C14-H14B 109.5 N1-C14-H14B 109.5 
H14A-C14-H14B 108.1 C14-C15-N2 111.5(9) 
C14-C15-H15A 109.3 N2-C15-H15A 109.3 
C14-C15-H15B 109.3 N2-C15-H15B 109.3 
H15A-C15-H15B 108.0 C17-C16-C21 120.5(9) 
C17-C16-N2 123.7(8) C21-C16-N2 115.1(8) 
C18-C17-C16 120.9(9) C18-C17-H17A 119.5 
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C16-C17-H17A 119.5 C19-C18-C17 120.1(10) 
C19-C18-Cl1 120.8(8) C17-C18-Cl1 119.1(8) 
C18-C19-C20 120.3(10) C18-C19-H19A 119.9 
C20-C19-H19A 119.9 C19-C20-C21 121.3(10) 
C19-C20-H20A 119.3 C21-C20-H20A 119.3 
C16-C21-C20 116.5(9) C16-C21-C22 124.1(9) 
C20-C21-C22 119.2(9) C21-C22-H22A 109.5 
C21-C22-H22B 109.5 H22A-C22-H22B 109.5 
C21-C22-H22C 109.5 H22A-C22-H22C 109.5 
H22B-C22-H22C 109.5 C11-N1-C12 119.1(7) 
C11-N1-C14 127.0(6) C12-N1-C14 113.2(7) 
C16-N2-C13 113.3(7) C16-N2-C15 111.5(7) 
C13-N2-C15 108.7(6) 
  
 
 
 
Table 21. Anisotropic atomic displacement parameters (Å2) for 6a. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
C1 0.034(4) 0.037(4) 0.050(4) -0.001(3) 0.009(3) -0.001(3) 
C2 0.032(3) 0.044(4) 0.059(5) 0.004(4) -0.004(3) 0.007(3) 
C3 0.039(4) 0.026(3) 0.052(4) 0.001(3) -0.015(3) 0.003(3) 
C4 0.053(5) 0.035(4) 0.063(5) -0.001(4) 0.009(4) -0.007(4) 
C5 0.047(4) 0.043(5) 0.074(6) 0.001(4) 0.030(4) -0.005(4) 
C6 0.032(3) 0.033(3) 0.042(4) -0.010(3) -0.004(3) 0.005(3) 
C7 0.030(3) 0.038(4) 0.038(4) -0.008(3) -0.007(3) 0.001(3) 
C8 0.033(3) 0.043(4) 0.051(5) -0.015(3) 0.006(3) -0.004(3) 
C9 0.033(3) 0.039(4) 0.037(4) -0.010(3) 0.002(3) 0.003(3) 
C10 0.048(5) 0.050(5) 0.075(6) -0.015(5) -0.028(4) 0.013(4) 
C11 0.038(4) 0.041(4) 0.033(4) -0.007(3) 0.006(3) -0.002(3) 
C12 0.074(6) 0.041(5) 0.063(6) 0.014(4) 0.032(5) 0.015(4) 
C13 0.054(5) 0.052(5) 0.075(6) -0.009(4) 0.002(4) 0.007(4) 
C14 0.076(7) 0.047(5) 0.084(7) 0.007(5) 0.038(6) 0.018(5) 
C15 0.071(6) 0.043(5) 0.084(7) 0.000(5) 0.039(5) 0.010(4) 
C16 0.059(5) 0.047(4) 0.060(5) -0.017(4) 0.000(4) -0.010(4) 
C17 0.056(5) 0.060(5) 0.063(6) -0.017(4) 0.001(4) -0.007(4) 
C18 0.079(7) 0.062(6) 0.066(6) -0.017(5) -0.011(5) -0.001(5) 
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U11 U22 U33 U23 U13 U12 
C19 0.077(7) 0.070(6) 0.064(6) -0.018(5) 0.016(5) -0.025(6) 
C20 0.074(6) 0.054(5) 0.075(7) -0.017(5) 0.011(5) -0.014(5) 
C21 0.042(4) 0.067(6) 0.060(6) 0.007(4) 0.008(4) 0.000(4) 
C22 0.078(8) 0.122(11) 0.085(8) -0.018(7) 0.000(6) -0.045(8) 
Cl1 0.107(3) 0.135(3) 0.075(2) -0.031(2) -0.0352(17) 0.016(2) 
F1 0.045(2) 0.037(2) 0.077(3) 0.000(2) -0.012(2) 0.0113(19) 
F2 0.066(4) 0.074(4) 0.132(6) -0.018(4) -0.050(4) -0.014(3) 
F3 0.061(3) 0.058(3) 0.118(5) -0.029(3) -0.055(3) 0.028(3) 
F4 0.084(4) 0.100(4) 0.048(3) -0.026(3) -0.025(3) 0.013(3) 
N1 0.054(4) 0.030(3) 0.061(4) -0.002(3) 0.014(3) 0.012(3) 
N2 0.042(4) 0.050(4) 0.056(4) 0.013(3) 0.018(3) 0.007(3) 
O1 0.032(3) 0.046(3) 0.062(4) -0.011(3) 0.010(2) 0.008(2) 
 
 
 
Table 22. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 6a. 
 
x/a y/b z/c U(eq) 
H1A 0.5154 -0.3549 0.8307 0.052 
H2A 0.7073 -0.6349 0.8540 0.061 
H4A 0.3075 -0.8003 0.9780 0.064 
H5A 0.1203 -0.5190 0.9606 0.072 
H8A -0.0422 -0.0831 0.9377 0.052 
H8B 0.1233 -0.2168 0.9947 0.052 
H9A 0.3478 -0.1170 0.9131 0.046 
H12A 0.0943 0.3791 0.7498 0.085 
H12B 0.3013 0.3832 0.7552 0.085 
H13A 0.2179 0.4418 0.6252 0.078 
H13B 0.1623 0.2686 0.6382 0.078 
H14A 0.5493 0.0818 0.7813 0.097 
H14B 0.4708 -0.0776 0.7880 0.097 
H15A 0.3864 0.0037 0.6624 0.09 
H15B 0.5969 -0.0051 0.6678 0.09 
H17A 0.2159 0.3323 0.5115 0.072 
H19A 0.5995 0.3151 0.3425 0.084 
H20A 0.8273 0.2240 0.4356 0.082 
H22A 0.9322 0.1660 0.5661 0.138 
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x/a y/b z/c U(eq) 
H22B 0.7979 0.2539 0.6272 0.138 
H22C 0.8169 0.0618 0.6255 0.138 
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Figure 60. X-ray structural information for rac-11a. 
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Table 23. Crystal data for 11a. 
Chemical formula C22H21ClF4N2O 
Formula weight 440.86 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.180 x 0.150 x 0.110 mm 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 10.0445(3) Å α = 90° 
 
b = 19.2372(6) Å β = 96.4030(16)° 
 
c = 10.7617(3) Å γ = 90° 
Volume 2066.49(11) Å3 
 
Z 4 
Density (calculated) 1.417 g/cm3 
Absorption coefficient 2.105 mm-1 
F(000) 912 
 
 
 
Table 24. Data collection and structure refinement for 11a. 
Diffractometer Bruker Apex II CCD 
Radiation source Bruker X8 Prospector Ultra, IMuS Cu K/a 
Theta range for data collection 4.43 to 68.61° 
Index ranges -12<=h<=12, -23<=k<=23, -12<=l<=12 
Reflections collected 21368 
Independent reflections 3771 [R(int) = 0.0335] 
Absorption correction multi-scan 
Max. and min. transmission 0.9800 and 0.9500 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3771 / 0 / 344 
Goodness-of-fit on F2 1.508 
Final R indices 3360 data; I>2σ(I) R1 = 0.0387, wR2 = 0.1264 
 
all data R1 = 0.0429, wR2 = 0.1301 
Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
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Largest diff. peak and hole 0.246 and -0.411 eÅ-3 
R.M.S. deviation from mean 0.046 eÅ-3 
 
 
 
Table 25. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 11a. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
x/a y/b z/c U(eq) 
Cl 0.59290(7) 0.04930(3) 0.41410(5) 0.0813(2) 
O 0.13357(13) 0.24498(6) 0.74991(13) 0.0568(3) 
F1 0.23430(13) 0.03012(7) 0.27604(10) 0.0709(4) 
N1 0.32362(13) 0.18220(6) 0.78810(12) 0.0393(3) 
C1 0.19640(16) 0.04025(9) 0.15272(14) 0.0455(4) 
N2 0.54194(12) 0.16345(6) 0.97698(11) 0.0343(3) 
F2 0.08444(15) 0.05829(7) 0.50384(11) 0.0769(4) 
C2 0.20732(15) 0.98568(8) 0.07215(15) 0.0417(3) 
C3 0.16829(14) 0.99612(7) 0.94620(14) 0.0349(3) 
F3 0.09894(15) 0.16797(7) 0.47993(11) 0.0772(4) 
F4 0.27416(11) 0.10957(7) 0.53875(9) 0.0627(3) 
C4 0.11827(13) 0.05969(7) 0.90068(13) 0.0338(3) 
C5 0.10833(16) 0.11353(8) 0.98583(16) 0.0412(3) 
C6 0.14727(17) 0.10404(9) 0.11240(16) 0.0477(4) 
C7 0.07645(14) 0.06591(8) 0.76383(14) 0.0385(3) 
C8 0.97496(16) 0.11847(10) 0.71051(18) 0.0487(4) 
C9 0.11840(14) 0.12724(8) 0.68569(14) 0.0388(3) 
C10 0.14520(17) 0.11483(9) 0.55352(15) 0.0482(4) 
C11 0.19309(15) 0.18974(7) 0.74538(14) 0.0385(3) 
C12 0.40100(19) 0.24225(8) 0.84021(16) 0.0477(4) 
C13 0.46027(17) 0.22701(7) 0.97327(15) 0.0422(4) 
C14 0.40050(15) 0.11749(8) 0.79609(14) 0.0373(3) 
C15 0.45854(14) 0.10458(7) 0.93071(14) 0.0350(3) 
C16 0.61897(14) 0.15284(7) 0.09561(13) 0.0326(3) 
C17 0.57355(15) 0.11064(8) 0.18657(14) 0.0388(3) 
C18 0.65342(18) 0.10030(8) 0.29894(14) 0.0451(4) 
C19 0.77781(18) 0.13015(9) 0.32166(15) 0.0472(4) 
C20 0.82138(16) 0.17269(8) 0.23206(15) 0.0439(4) 
C21 0.74435(14) 0.18528(7) 0.11842(14) 0.0380(3) 
 194 
 
x/a y/b z/c U(eq) 
C22 0.79683(18) 0.23146(10) 0.02258(18) 0.0557(4) 
 
 
 
Table 26. Bond lengths (Å) for 11a. 
Cl-C18 1.7425(16) O-C11 1.2231(19) 
F1-C1 1.353(2) N1-C11 1.348(2) 
N1-C14 1.4625(19) N1-C12 1.4682(19) 
C1-C2 1.374(2) C1-C6 1.375(3) 
N2-C16 1.4318(18) N2-C15 1.4627(18) 
N2-C13 1.4704(19) F2-C10 1.330(2) 
C2-C3 1.383(2) C2-H2 0.96(2) 
C3-C4 1.390(2) C3-H3 0.94(2) 
F3-C10 1.344(2) F4-C10 1.326(2) 
C4-C5 1.394(2) C4-C7 1.491(2) 
C5-C6 1.387(3) C5-H5 0.92(2) 
C6-H6 0.94(2) C7-C8 1.503(2) 
C7-C9 1.535(2) C7-H7 1.000(18) 
C8-C9 1.504(2) C8-H8A 1.01(2) 
C8-H8B 0.91(2) C9-C10 1.496(2) 
C9-C11 1.521(2) C12-C13 1.517(2) 
C12-H12A 0.95(2) C12-H12B 0.99(2) 
C13-H13A 1.01(2) C13-H13B 0.98(2) 
C14-C15 1.520(2) C14-H14A 0.976(19) 
C14-H14B 0.97(2) C15-H15A 0.990(19) 
C15-H15B 0.95(2) C16-C17 1.387(2) 
C16-C21 1.402(2) C17-C18 1.389(2) 
C17-H17 0.92(2) C18-C19 1.372(3) 
C19-C20 1.373(3) C19-H19 0.91(3) 
C20-C21 1.394(2) C20-H20 0.92(2) 
C21-C22 1.501(2) C22-H22A 0.97 
C22-H22B 0.97 C22-H22C 0.97 
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Table 27. Bond angles (°) for 11a. 
C11-N1-C14 126.78(12) C11-N1-C12 119.94(13) 
C14-N1-C12 113.18(12) F1-C1-C2 118.39(16) 
F1-C1-C6 119.32(15) C2-C1-C6 122.28(15) 
C16-N2-C15 115.16(11) C16-N2-C13 112.78(11) 
C15-N2-C13 109.76(11) C1-C2-C3 118.29(15) 
C1-C2-H2 120.5(12) C3-C2-H2 121.2(12) 
C2-C3-C4 121.65(14) C2-C3-H3 119.8(11) 
C4-C3-H3 118.5(12) C3-C4-C5 118.13(14) 
C3-C4-C7 118.02(13) C5-C4-C7 123.84(14) 
C6-C5-C4 120.99(15) C6-C5-H5 119.4(13) 
C4-C5-H5 119.6(13) C1-C6-C5 118.65(15) 
C1-C6-H6 117.8(13) C5-C6-H6 123.5(13) 
C4-C7-C8 122.38(14) C4-C7-C9 122.59(12) 
C8-C7-C9 59.32(10) C4-C7-H7 114.5(10) 
C8-C7-H7 114.5(10) C9-C7-H7 112.5(10) 
C7-C8-C9 61.38(10) C7-C8-H8A 115.4(13) 
C9-C8-H8A 116.2(14) C7-C8-H8B 117.2(14) 
C9-C8-H8B 113.4(14) H8A-C8-H8B 120.(2) 
C10-C9-C8 115.37(14) C10-C9-C11 113.28(13) 
C8-C9-C11 116.80(14) C10-C9-C7 119.18(14) 
C8-C9-C7 59.30(10) C11-C9-C7 121.93(12) 
F4-C10-F2 107.45(16) F4-C10-F3 105.39(14) 
F2-C10-F3 105.80(14) F4-C10-C9 114.07(13) 
F2-C10-C9 112.94(14) F3-C10-C9 110.59(15) 
O-C11-N1 122.75(14) O-C11-C9 118.91(13) 
N1-C11-C9 118.31(12) N1-C12-C13 110.12(12) 
N1-C12-H12A 108.9(13) C13-C12-H12A 109.8(13) 
N1-C12-H12B 105.8(12) C13-C12-H12B 112.2(12) 
H12A-C12-H12B 109.8(17) N2-C13-C12 110.20(13) 
N2-C13-H13A 112.9(11) C12-C13-H13A 108.9(12) 
N2-C13-H13B 109.8(12) C12-C13-H13B 109.5(12) 
H13A-C13-H13B 105.4(17) N1-C14-C15 109.81(12) 
N1-C14-H14A 111.1(10) C15-C14-H14A 111.0(10) 
N1-C14-H14B 110.4(11) C15-C14-H14B 108.9(11) 
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H14A-C14-H14B 105.6(15) N2-C15-C14 110.00(11) 
N2-C15-H15A 113.7(10) C14-C15-H15A 105.3(10) 
N2-C15-H15B 109.5(12) C14-C15-H15B 106.8(11) 
H15A-C15-H15B 111.2(15) C17-C16-C21 119.76(13) 
C17-C16-N2 121.67(12) C21-C16-N2 118.55(12) 
C16-C17-C18 119.64(14) C16-C17-H17 121.3(12) 
C18-C17-H17 118.9(12) C19-C18-C17 121.42(15) 
C19-C18-Cl 119.47(13) C17-C18-Cl 119.10(14) 
C18-C19-C20 118.65(15) C18-C19-H19 119.6(17) 
C20-C19-H19 121.8(17) C19-C20-C21 122.05(15) 
C19-C20-H20 120.7(14) C21-C20-H20 117.2(14) 
C20-C21-C16 118.43(14) C20-C21-C22 120.19(14) 
C16-C21-C22 121.37(14) C21-C22-H22A 109.5 
C21-C22-H22B 109.5 H22A-C22-H22B 109.5 
C21-C22-H22C 109.5 H22A-C22-H22C 109.5 
H22B-C22-H22C 109.5 
  
 
 
 
Table 28. Anisotropic atomic displacement parameters (Å2) for 11a. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
Cl 0.0992(4) 0.0921(4) 0.0536(3) 0.0316(3) 0.0128(3) -0.0040(3) 
O 0.0527(7) 0.0372(6) 0.0775(9) 0.0061(5) -0.0065(6) 0.0108(5) 
F1 0.0807(8) 0.0980(9) 0.0336(5) 0.0024(5) 0.0045(5) -0.0134(7) 
N1 0.0399(6) 0.0314(6) 0.0439(7) 0.0047(5) -0.0071(5) -0.0008(5) 
C1 0.0419(8) 0.0624(10) 0.0330(7) -0.0006(6) 0.0081(6) -0.0125(7) 
N2 0.0326(6) 0.0318(6) 0.0371(6) 0.0022(4) -0.0028(5) -0.0029(5) 
F2 0.0931(9) 0.0898(8) 0.0462(6) -0.0154(6) 0.0005(6) -0.0374(7) 
C2 0.0388(7) 0.0444(8) 0.0424(8) 0.0093(6) 0.0066(6) -0.0038(7) 
C3 0.0343(7) 0.0329(7) 0.0383(7) -0.0014(6) 0.0069(5) -0.0034(6) 
F3 0.0861(8) 0.0938(9) 0.0494(6) 0.0305(6) -0.0032(5) 0.0141(7) 
F4 0.0507(6) 0.0957(9) 0.0412(5) -0.0031(5) 0.0027(4) 0.0013(5) 
C4 0.0284(6) 0.0337(7) 0.0393(7) 0.0007(5) 0.0040(5) -0.0038(6) 
C5 0.0380(7) 0.0349(7) 0.0516(9) -0.0043(6) 0.0089(6) 0.0000(6) 
C6 0.0458(8) 0.0515(9) 0.0478(9) -0.0158(7) 0.0143(7) -0.0109(7) 
C7 0.0350(7) 0.0391(8) 0.0403(8) 0.0014(6) -0.0006(6) -0.0051(6) 
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U11 U22 U33 U23 U13 U12 
C8 0.0339(8) 0.0566(10) 0.0533(10) 0.0089(8) -0.0053(7) 0.0006(7) 
C9 0.0344(7) 0.0394(7) 0.0405(8) 0.0061(6) -0.0051(6) 0.0001(6) 
C10 0.0441(8) 0.0579(10) 0.0398(8) 0.0080(7) -0.0077(6) -0.0057(7) 
C11 0.0404(8) 0.0339(7) 0.0398(7) 0.0092(6) -0.0011(6) 0.0024(6) 
C12 0.0540(9) 0.0310(7) 0.0540(9) 0.0086(6) -0.0121(8) -0.0063(7) 
C13 0.0475(8) 0.0291(7) 0.0473(8) 0.0004(6) -0.0072(7) -0.0005(6) 
C14 0.0335(7) 0.0359(7) 0.0415(8) -0.0016(6) -0.0003(6) 0.0008(6) 
C15 0.0304(7) 0.0301(7) 0.0429(8) 0.0006(5) -0.0027(6) 0.0014(6) 
C16 0.0325(6) 0.0289(6) 0.0357(7) -0.0019(5) 0.0005(5) 0.0023(5) 
C17 0.0360(7) 0.0392(7) 0.0411(8) 0.0026(6) 0.0037(6) -0.0004(6) 
C18 0.0560(9) 0.0429(8) 0.0365(8) 0.0032(6) 0.0050(7) 0.0072(7) 
C19 0.0548(9) 0.0464(8) 0.0372(8) -0.0077(7) -0.0090(7) 0.0099(8) 
C20 0.0374(8) 0.0430(8) 0.0488(9) -0.0117(7) -0.0068(6) -0.0014(7) 
C21 0.0356(7) 0.0337(7) 0.0440(8) -0.0046(6) 0.0003(6) -0.0030(6) 
C22 0.0476(9) 0.0544(10) 0.0642(11) 0.0070(8) 0.0029(8) -0.0181(8) 
 
 
 
Table 29. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 11a. 
 x/a y/b z/c U(eq) 
H2 0.240(2) -0.0586(11) 0.1031(19) 0.049(5) 
H3 0.1745(18) -0.0407(10) -0.1109(18) 0.043(5) 
H5 0.076(2) 0.1564(11) -0.0425(19) 0.052(5) 
H6 0.139(2) 0.1382(11) 0.173(2) 0.056(5) 
H7 0.0742(18) 0.0209(9) -0.2829(18) 0.042(4) 
H8A -0.090(3) 0.1017(12) -0.362(2) 0.068(6) 
H8B -0.052(2) 0.1507(11) -0.236(2) 0.053(5) 
H12A 0.343(2) 0.2814(11) -0.161(2) 0.055(5) 
H12B 0.471(2) 0.2505(10) -0.216(2) 0.054(5) 
H13A 0.385(2) 0.2242(10) 0.0284(19) 0.051(5) 
H13B 0.516(2) 0.2662(11) 0.0055(19) 0.056(5) 
H14A 0.3453(18) 0.0784(9) -0.2364(16) 0.038(4) 
H14B 0.474(2) 0.1201(9) -0.2560(18) 0.043(5) 
H15A 0.3801(19) 0.0968(9) -0.0229(16) 0.038(4) 
H15B 0.512(2) 0.0638(10) -0.0696(17) 0.045(5) 
H17 0.489(2) 0.0916(10) 0.1764(17) 0.045(5) 
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 x/a y/b z/c U(eq) 
H19 0.829(3) 0.1219(12) 0.396(3) 0.075(7) 
H20 0.905(2) 0.1926(11) 0.244(2) 0.062(6) 
H22A 0.7795 0.2102 -0.0593 0.067 
H22B 0.8926 0.2378 0.0431 0.067 
H22C 0.7524 0.2762 0.0220 0.067 
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Figure 61. X-ray structural information for rac-15. 
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Table 30. Crystal data for 15. 
Chemical formula C24H18F12N2O 
Formula weight 578.40 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.050 x 0.090 x 0.190 mm 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 5.9316(2) Å α = 79.476(2)° 
 
b = 9.3304(3) Å β = 83.146(2)° 
 
c = 23.4340(8) Å γ = 78.234(3)° 
Volume 1243.78(7) Å3 
 
Z 2 
Density (calculated) 1.544 g/cm3 
Absorption coefficient 1.414 mm-1 
F(000) 584 
 
 
Table 31. Data collection and structure refinement for 15. 
Diffractometer Bruker Apex II CCD 
Radiation source Bruker X8 Prospector Ultra, IMuS Cu K/a 
Theta range for data collection 1.92 to 68.24° 
Index ranges -7<=h<=7, -11<=k<=11, -28<=l<=28 
Reflections collected 19374 
Independent reflections 4443 [R(int) = 0.0329] 
Absorption correction multi-scan 
Max. and min. transmission 0.9300 and 0.7800 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4443 / 0 / 424 
Goodness-of-fit on F2 2.234 
Final R indices 3652 data; I>2σ(I) R1 = 0.0689, wR2 = 0.2059 
 
all data R1 = 0.0799, wR2 = 0.2143 
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Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.907 and -0.558 eÅ-3 
R.M.S. deviation from mean 0.062 eÅ-3 
 
 
 
Table 32. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 15. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
x/a y/b z/c U(eq) 
C1 0.1387(6) 0.0949(4) 0.68813(14) 0.0593(8) 
F1 0.1790(7) 0.1909(5) 0.71821(12) 0.1347(14) 
N1 0.4022(4) 0.3430(3) 0.28993(10) 0.0450(5) 
O1 0.1494(4) 0.2140(3) 0.34568(10) 0.0612(6) 
C2 0.2077(5) 0.1298(3) 0.62488(12) 0.0440(6) 
F2 0.9125(4) 0.0979(3) 0.70028(10) 0.0865(7) 
N2 0.4347(4) 0.5411(3) 0.18436(10) 0.0509(6) 
C3 0.4069(5) 0.1864(3) 0.60637(14) 0.0488(7) 
F3 0.2312(6) 0.9583(4) 0.71066(11) 0.1278(14) 
C4 0.4775(5) 0.2125(3) 0.54724(13) 0.0434(6) 
F4 0.2722(4) 0.49915(18) 0.46309(8) 0.0595(5) 
C5 0.3495(4) 0.1846(2) 0.50639(11) 0.0360(5) 
F5 0.9961(3) 0.4641(2) 0.42056(11) 0.0704(6) 
C6 0.1466(4) 0.1309(3) 0.52569(12) 0.0403(6) 
F6 0.2436(3) 0.58778(17) 0.37316(8) 0.0601(5) 
C7 0.0774(5) 0.1021(3) 0.58414(12) 0.0428(6) 
F7 0.8490(4) 0.5045(4) 0.10095(12) 0.1072(10) 
C8 0.4318(4) 0.1965(3) 0.44338(12) 0.0395(6) 
F8 0.5839(5) 0.3950(3) 0.08522(11) 0.0926(8) 
C9 0.6089(5) 0.2854(3) 0.41434(13) 0.0455(6) 
F9 0.7417(5) 0.5293(4) 0.01498(11) 0.1069(10) 
C10 0.3637(4) 0.3295(3) 0.39644(11) 0.0360(5) 
F10 0.8120(12) 0.0407(9) 0.1129(5) 0.291(5) 
C11 0.2201(5) 0.4676(3) 0.41380(12) 0.0412(6) 
F11 0.0081(13) 0.0817(5) 0.16276(19) 0.218(3) 
C12 0.2963(4) 0.2910(3) 0.34117(12) 0.0399(6) 
F12 0.0278(15) 0.1585(5) 0.0731(2) 0.244(4) 
C13 0.5732(5) 0.4390(3) 0.27959(13) 0.0469(6) 
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x/a y/b z/c U(eq) 
C14 0.4865(6) 0.5795(3) 0.23806(13) 0.0496(7) 
C15 0.3407(7) 0.3071(4) 0.23611(14) 0.0552(7) 
C16 0.2560(6) 0.4499(4) 0.19546(15) 0.0563(8) 
C17 0.3826(6) 0.6660(4) 0.13831(13) 0.0554(7) 
C18 0.4880(6) 0.6564(4) 0.08244(14) 0.0595(8) 
C19 0.4337(8) 0.7732(5) 0.03745(16) 0.0761(11) 
C20 0.2823(9) 0.8992(5) 0.04746(18) 0.0835(13) 
C21 0.1852(9) 0.9122(4) 0.10287(17) 0.0866(13) 
C22 0.2351(8) 0.7950(5) 0.14818(16) 0.0766(12) 
C23 0.6650(7) 0.5192(6) 0.07090(16) 0.0760(11) 
C24 0.0372(18) 0.0559(8) 0.1153(3) 0.167(4) 
 
 
Table 33. Bond lengths (Å) for 15. 
C1-F1 1.310(4) C1-F3 1.319(4) 
C1-F2 1.334(4) C1-C2 1.485(4) 
N1-C12 1.343(4) N1-C13 1.457(4) 
N1-C15 1.466(4) O1-C12 1.222(3) 
C2-C3 1.382(4) C2-C7 1.387(4) 
N2-C17 1.446(4) N2-C14 1.452(4) 
N2-C16 1.462(4) C3-C4 1.391(4) 
C3-H3 0.99(4) C4-C5 1.380(4) 
C4-H4 0.95(4) F4-C11 1.328(3) 
C5-C6 1.392(4) C5-C8 1.490(4) 
F5-C11 1.325(3) C6-C7 1.376(4) 
C6-H6 0.92(3) F6-C11 1.351(3) 
C7-H7 0.91(4) F7-C23 1.339(5) 
C8-C9 1.494(4) C8-C10 1.522(3) 
C8-H8 0.96(4) F8-C23 1.317(6) 
C9-C10 1.516(4) C9-H9A 0.90(3) 
C9-H9B 1.01(4) F9-C23 1.328(4) 
C10-C11 1.488(4) C10-C12 1.523(4) 
F10-C24 1.381(13) F11-C24 1.166(7) 
F12-C24 1.243(7) C13-C14 1.519(4) 
C13-H13A 1.01(4) C13-H13B 1.00(4) 
C14-H14A 1.00(4) C14-H14B 0.97(3) 
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C15-C16 1.521(4) C15-H15A 0.99(5) 
C15-H15B 0.99(5) C16-H16A 1.03(4) 
C16-H16B 1.00(4) C17-C22 1.375(5) 
C17-C18 1.392(5) C18-C19 1.386(5) 
C18-C23 1.525(5) C19-C20 1.365(6) 
C19-H19 1.05(5) C20-C21 1.372(6) 
C20-H20 0.83(5) C21-C22 1.389(5) 
C21-C24 1.501(7) C22-H22 0.93(5) 
 
 
Table 34. Bond angles (°) for 15. 
F1-C1-F3 110.9(3) F1-C1-F2 103.0(3) 
F3-C1-F2 103.1(3) F1-C1-C2 113.4(3) 
F3-C1-C2 112.2(3) F2-C1-C2 113.4(3) 
C12-N1-C13 127.7(2) C12-N1-C15 119.3(2) 
C13-N1-C15 113.0(2) C3-C2-C7 119.6(3) 
C3-C2-C1 119.9(3) C7-C2-C1 120.5(3) 
C17-N2-C14 114.6(2) C17-N2-C16 112.1(2) 
C14-N2-C16 111.1(2) C2-C3-C4 119.9(3) 
C2-C3-H3 121.(2) C4-C3-H3 119.(2) 
C5-C4-C3 120.9(3) C5-C4-H4 117.(2) 
C3-C4-H4 122.(2) C4-C5-C6 118.4(2) 
C4-C5-C8 122.3(2) C6-C5-C8 119.0(2) 
C7-C6-C5 121.1(3) C7-C6-H6 122.(2) 
C5-C6-H6 117.(2) C6-C7-C2 120.0(3) 
C6-C7-H7 120.(2) C2-C7-H7 120.(2) 
C5-C8-C9 124.3(2) C5-C8-C10 125.9(2) 
C9-C8-C10 60.36(17) C5-C8-H8 111.(2) 
C9-C8-H8 115.(2) C10-C8-H8 111.(2) 
C8-C9-C10 60.72(16) C8-C9-H9A 118.(2) 
C10-C9-H9A 118.2(19) C8-C9-H9B 115.(2) 
C10-C9-H9B 118.(2) H9A-C9-H9B 116.(3) 
C11-C10-C9 117.7(2) C11-C10-C8 119.1(2) 
C9-C10-C8 58.92(17) C11-C10-C12 113.7(2) 
C9-C10-C12 122.0(2) C8-C10-C12 114.6(2) 
F5-C11-F4 106.3(2) F5-C11-F6 105.8(2) 
F4-C11-F6 105.5(2) F5-C11-C10 112.8(2) 
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F4-C11-C10 114.1(2) F6-C11-C10 111.7(2) 
O1-C12-N1 123.3(3) O1-C12-C10 118.4(2) 
N1-C12-C10 118.3(2) N1-C13-C14 109.7(2) 
N1-C13-H13A 109.8(19) C14-C13-H13A 110.(2) 
N1-C13-H13B 109.(2) C14-C13-H13B 109.(2) 
H13A-C13-H13B 110.(3) N2-C14-C13 109.7(3) 
N2-C14-H14A 112.(2) C13-C14-H14A 107.(2) 
N2-C14-H14B 113.1(18) C13-C14-H14B 104.2(18) 
H14A-C14-H14B 110.(3) N1-C15-C16 109.4(3) 
N1-C15-H15A 109.(2) C16-C15-H15A 111.(2) 
N1-C15-H15B 107.(2) C16-C15-H15B 111.(2) 
H15A-C15-H15B 109.(3) N2-C16-C15 109.3(3) 
N2-C16-H16A 112.(2) C15-C16-H16A 109.(2) 
N2-C16-H16B 113.(2) C15-C16-H16B 106.(2) 
H16A-C16-H16B 108.(3) C22-C17-C18 118.9(3) 
C22-C17-N2 122.1(3) C18-C17-N2 119.0(3) 
C19-C18-C17 119.7(3) C19-C18-C23 120.1(3) 
C17-C18-C23 120.2(3) C20-C19-C18 120.8(4) 
C20-C19-H19 117.(3) C18-C19-H19 122.(3) 
C19-C20-C21 119.9(4) C19-C20-H20 122.(4) 
C21-C20-H20 118.(4) C20-C21-C22 119.8(4) 
C20-C21-C24 120.2(4) C22-C21-C24 119.9(4) 
C17-C22-C21 120.8(4) C17-C22-H22 118.(3) 
C21-C22-H22 121.(3) F8-C23-F9 106.9(4) 
F8-C23-F7 107.4(3) F9-C23-F7 107.0(3) 
F8-C23-C18 113.5(3) F9-C23-C18 111.3(3) 
F7-C23-C18 110.4(4) F11-C24-F12 120.4(8) 
F11-C24-F10 94.8(8) F12-C24-F10 93.0(7) 
F11-C24-C21 119.8(4) F12-C24-C21 114.3(5) 
F10-C24-C21 105.8(8) 
  
 
 
 
 
 
Table 35. Anisotropic atomic displacement parameters (Å2) for 15. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
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U11 U22 U33 U23 U13 U12 
C1 0.0647(19) 0.0578(18) 0.0530(17) -0.0120(14) -0.0047(14) -0.0034(16) 
F1 0.193(3) 0.187(3) 0.0657(15) -0.0610(19) 0.0213(17) -0.112(3) 
N1 0.0476(12) 0.0413(12) 0.0470(12) -0.0070(10) -0.0020(9) -0.0120(10) 
O1 0.0632(13) 0.0715(14) 0.0616(13) -0.0192(11) 0.0041(10) -0.0396(12) 
C2 0.0465(14) 0.0343(12) 0.0491(15) -0.0095(11) -0.0041(11) -0.0001(11) 
F2 0.0824(15) 0.1058(18) 0.0630(13) -0.0102(12) 0.0180(10) -0.0155(14) 
N2 0.0558(14) 0.0452(13) 0.0461(13) -0.0028(10) -0.0030(10) -0.0010(11) 
C3 0.0518(16) 0.0433(14) 0.0557(16) -0.0140(12) -0.0139(12) -0.0085(13) 
F3 0.152(3) 0.111(2) 0.0654(15) 0.0239(15) 0.0115(15) 0.057(2) 
C4 0.0400(14) 0.0344(12) 0.0581(16) -0.0085(11) -0.0061(11) -0.0106(11) 
F4 0.0840(13) 0.0377(8) 0.0586(10) -0.0159(7) -0.0088(9) -0.0071(8) 
C5 0.0339(12) 0.0234(10) 0.0495(14) -0.0038(9) -0.0038(10) -0.0041(9) 
F5 0.0360(9) 0.0584(11) 0.1188(17) -0.0353(11) 0.0101(9) -0.0045(8) 
C6 0.0376(13) 0.0364(12) 0.0491(15) -0.0077(11) -0.0068(11) -0.0098(11) 
F6 0.0768(12) 0.0303(8) 0.0647(11) -0.0007(7) 0.0013(9) -0.0007(8) 
C7 0.0369(13) 0.0393(13) 0.0521(15) -0.0072(11) 0.0005(11) -0.0092(11) 
F7 0.0691(14) 0.146(3) 0.0902(17) -0.0214(17) -0.0139(12) 0.0236(16) 
C8 0.0366(13) 0.0280(12) 0.0514(15) -0.0061(10) 0.0001(10) -0.0031(10) 
F8 0.118(2) 0.0663(14) 0.0815(16) -0.0256(12) -0.0061(13) 0.0218(14) 
C9 0.0320(13) 0.0484(15) 0.0528(16) -0.0024(13) 0.0014(11) -0.0082(12) 
F9 0.0976(17) 0.137(2) 0.0613(13) -0.0218(14) 0.0102(11) 0.0314(17) 
C10 0.0321(12) 0.0291(11) 0.0463(13) -0.0036(10) 0.0007(9) -0.0094(10) 
F10 0.176(6) 0.212(7) 0.469(16) -0.170(9) -0.013(7) 0.095(5) 
C11 0.0406(13) 0.0305(12) 0.0528(15) -0.0062(11) 0.0000(10) -0.0103(11) 
F11 0.366(8) 0.128(3) 0.099(3) -0.044(2) -0.031(4) 0.126(4) 
C12 0.0355(12) 0.0337(12) 0.0498(14) -0.0095(10) 0.0009(10) -0.0056(11) 
F12 0.384(9) 0.094(3) 0.151(4) 0.021(3) 0.055(5) 0.106(4) 
C13 0.0404(14) 0.0493(15) 0.0489(15) -0.0013(12) -0.0012(11) -0.0111(13) 
C14 0.0534(16) 0.0453(15) 0.0492(15) -0.0026(12) -0.0032(12) -0.0122(14) 
C15 0.069(2) 0.0493(16) 0.0505(16) -0.0102(13) -0.0066(14) -0.0154(16) 
C16 0.0594(18) 0.0562(18) 0.0533(17) -0.0101(14) -0.0116(14) -0.0058(15) 
C17 0.0637(18) 0.0510(16) 0.0452(16) -0.0032(13) -0.0051(13) 0.0004(15) 
C18 0.0644(19) 0.0595(18) 0.0494(17) -0.0069(14) -0.0071(14) -0.0001(16) 
C19 0.092(3) 0.080(3) 0.0461(18) -0.0025(17) -0.0027(16) -0.001(2) 
C20 0.123(4) 0.062(2) 0.053(2) 0.0052(17) -0.014(2) 0.002(2) 
C21 0.128(4) 0.057(2) 0.059(2) -0.0059(17) -0.012(2) 0.020(2) 
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U11 U22 U33 U23 U13 U12 
C22 0.101(3) 0.064(2) 0.0462(18) -0.0047(16) -0.0010(17) 0.020(2) 
C23 0.068(2) 0.097(3) 0.0510(19) -0.0131(19) -0.0072(15) 0.014(2) 
C24 0.235(9) 0.126(5) 0.066(3) 0.009(3) -0.002(4) 0.113(6) 
 
 
Table 36. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 15. 
 x/a y/b z/c U(eq) 
H3 0.496(7) 0.216(5) 0.6342(18) 0.073(11) 
H4 0.615(7) 0.249(5) 0.5330(18) 0.073(11) 
H6 0.060(6) 0.118(4) 0.4977(15) 0.050(8) 
H7 -0.056(6) 0.067(4) 0.5957(15) 0.052(9) 
H8 0.438(6) 0.104(4) 0.4297(15) 0.053(9) 
H9A 0.720(6) 0.244(4) 0.3894(14) 0.041(7) 
H9B 0.660(7) 0.348(5) 0.4396(19) 0.076(12) 
H13A 0.602(6) 0.465(4) 0.3176(15) 0.053(9) 
H13B 0.719(6) 0.386(4) 0.2614(15) 0.058(9) 
H14A 0.609(7) 0.642(5) 0.2315(18) 0.074(11) 
H14B 0.352(5) 0.628(4) 0.2594(13) 0.041(7) 
H15A 0.477(7) 0.248(5) 0.2176(18) 0.071(11) 
H15B 0.217(7) 0.247(5) 0.2472(18) 0.076(12) 
H16A 0.215(6) 0.424(4) 0.1574(16) 0.058(9) 
H16B 0.110(6) 0.498(4) 0.2157(16) 0.059(9) 
H19 0.493(8) 0.765(5) -0.006(2) 0.095(14) 
H20 0.238(8) 0.967(6) 0.020(2) 0.089(14) 
H22 0.160(9) 0.798(6) 0.185(2) 0.095(15) 
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Figure 62. X-ray structural information for (-)-6b. 
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Table 37. Crystal data for (-)-6b. 
Chemical formula C22H21ClF4N2O 
Formula weight 440.86 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.040 x 0.090 x 0.180 mm 
Crystal system orthorhombic 
Space group P 21 21 21 
Unit cell dimensions a = 6.8983(15) Å α = 90° 
 
b = 15.715(4) Å β = 90° 
 
c = 19.766(5) Å γ = 90° 
Volume 2142.8(8) Å3 
 
Z 4 
Density (calculated) 1.367 g/cm3 
Absorption coefficient 2.030 mm-1 
F(000) 912 
 
 
Table 38. Data collection and structure refinement for (-)-6b. 
Diffractometer Bruker Apex II CCD 
Radiation source Bruker X8 Prospector Ultra, Cu Kα 
Theta range for data collection 4.47 to 50.54° 
Index ranges -6<=h<=6, -13<=k<=15, -19<=l<=14 
Reflections collected 3721 
Independent reflections 2051 [R(int) = 0.0606] 
Absorption correction multi-scan 
Max. and min. transmission 0.9230 and 0.7110 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 2051 / 0 / 273 
Goodness-of-fit on F2 1.182 
Final R indices 1683 data; I>2σ(I) R1 = 0.0614, wR2 = 0.1569 
 
all data R1 = 0.0724, wR2 = 0.1644 
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Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.00(7) 
Extinction coefficient 0.0050(10) 
Largest diff. peak and hole 0.251 and -0.263 eÅ-3 
R.M.S. deviation from mean 0.061 eÅ-3 
 
 
Table 39. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for (-)-6b. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
x/a y/b z/c U(eq) 
C1 0.9793(15) 0.5959(6) 0.4443(4) 0.048(3) 
C2 0.8428(15) 0.6608(6) 0.4445(5) 0.054(3) 
C3 0.7900(14) 0.7020(6) 0.5012(5) 0.057(3) 
C4 0.8724(16) 0.6795(6) 0.5628(5) 0.056(3) 
C5 0.0102(15) 0.6149(6) 0.5656(5) 0.052(3) 
C6 0.0665(12) 0.5735(5) 0.5068(4) 0.038(2) 
C7 0.0282(17) 0.5478(7) 0.3812(5) 0.073(3) 
C8 0.2014(14) 0.4538(5) 0.5685(4) 0.040(2) 
C9 0.3138(14) 0.3731(5) 0.5555(4) 0.044(2) 
C10 0.5292(14) 0.4559(6) 0.4796(5) 0.048(3) 
C11 0.4031(13) 0.5327(6) 0.4948(5) 0.047(2) 
C12 0.6598(16) 0.3375(6) 0.5443(4) 0.045(2) 
C13 0.6304(15) 0.2662(5) 0.5926(4) 0.047(3) 
C14 0.7970(15) 0.2181(6) 0.6192(4) 0.053(3) 
C15 0.6882(14) 0.2766(5) 0.6648(4) 0.043(2) 
C16 0.5605(18) 0.2351(7) 0.7177(6) 0.064(3) 
C17 0.7815(14) 0.3565(6) 0.6902(4) 0.044(3) 
C18 0.9623(18) 0.3544(7) 0.7197(5) 0.065(3) 
C19 0.0461(19) 0.4270(10) 0.7461(6) 0.086(4) 
C20 0.946(2) 0.5012(9) 0.7440(5) 0.075(4) 
C21 0.7658(18) 0.5079(7) 0.7157(5) 0.067(3) 
C22 0.6833(17) 0.4334(6) 0.6896(5) 0.056(3) 
Cl1 0.8111(6) 0.73345(19) 0.63604(15) 0.0989(13) 
F1 0.4828(11) 0.1637(4) 0.6959(4) 0.100(3) 
F2 0.4145(9) 0.2852(4) 0.7339(3) 0.083(2) 
F3 0.6530(11) 0.2171(4) 0.7745(3) 0.090(2) 
F4 0.0308(13) 0.5730(6) 0.7688(4) 0.134(4) 
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x/a y/b z/c U(eq) 
N1 0.2033(10) 0.5059(4) 0.5086(3) 0.0388(18) 
N2 0.5097(11) 0.3912(4) 0.5302(3) 0.0413(19) 
O1 0.8198(10) 0.3492(4) 0.5166(3) 0.0577(18) 
 
 
Table 40. Bond lengths (Å) for (-)-6b. 
C1-C2 1.388(13) C1-C6 1.418(12) 
C1-C7 1.498(13) C2-C3 1.346(13) 
C2-H2A 0.94 C3-C4 1.388(13) 
C3-H3A 0.94 C4-C5 1.392(13) 
C4-Cl1 1.731(10) C5-C6 1.387(12) 
C5-H5A 0.94 C6-N1 1.422(10) 
C7-H7A 0.97 C7-H7B 0.97 
C7-H7C 0.97 C8-N1 1.441(10) 
C8-C9 1.507(12) C8-H8A 0.98 
C8-H8B 0.98 C9-N2 1.469(11) 
C9-H9A 0.98 C9-H9B 0.98 
C10-N2 1.432(11) C10-C11 1.519(12) 
C10-H10A 0.98 C10-H10B 0.98 
C11-N1 1.467(10) C11-H11A 0.98 
C11-H11B 0.98 C12-O1 1.246(11) 
C12-N2 1.365(12) C12-C13 1.486(12) 
C13-C14 1.473(13) C13-C15 1.492(12) 
C13-H13A 0.99 C14-C15 1.492(12) 
C14-H14A 0.98 C14-H14B 0.98 
C15-C17 1.497(12) C15-C16 1.515(13) 
C16-F1 1.317(12) C16-F2 1.317(12) 
C16-F3 1.321(12) C17-C18 1.378(13) 
C17-C22 1.384(13) C18-C19 1.381(16) 
C18-H18A 0.94 C19-C20 1.354(17) 
C19-H19A 0.94 C20-F4 1.361(13) 
C20-C21 1.370(16) C21-C22 1.400(14) 
C21-H21A 0.94 C22-H22A 0.94 
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Table 41. Bond angles (°) for (-)-6b. 
C2-C1-C6 117.9(8) C2-C1-C7 121.7(9) 
C6-C1-C7 120.4(9) C3-C2-C1 122.6(9) 
C3-C2-H2A 118.7 C1-C2-H2A 118.7 
C2-C3-C4 119.8(9) C2-C3-H3A 120.1 
C4-C3-H3A 120.1 C3-C4-C5 120.1(9) 
C3-C4-Cl1 120.5(8) C5-C4-Cl1 119.4(8) 
C6-C5-C4 119.9(9) C6-C5-H5A 120.0 
C4-C5-H5A 120.0 C5-C6-C1 119.7(9) 
C5-C6-N1 121.1(8) C1-C6-N1 119.2(8) 
C1-C7-H7A 109.5 C1-C7-H7B 109.5 
H7A-C7-H7B 109.5 C1-C7-H7C 109.5 
H7A-C7-H7C 109.5 H7B-C7-H7C 109.5 
N1-C8-C9 109.4(7) N1-C8-H8A 109.8 
C9-C8-H8A 109.8 N1-C8-H8B 109.8 
C9-C8-H8B 109.8 H8A-C8-H8B 108.2 
N2-C9-C8 111.7(7) N2-C9-H9A 109.3 
C8-C9-H9A 109.3 N2-C9-H9B 109.3 
C8-C9-H9B 109.3 H9A-C9-H9B 108.0 
N2-C10-C11 111.9(7) N2-C10-H10A 109.2 
C11-C10-H10A 109.2 N2-C10-H10B 109.2 
C11-C10-H10B 109.2 H10A-C10-H10B 107.9 
N1-C11-C10 110.2(7) N1-C11-H11A 109.6 
C10-C11-H11A 109.6 N1-C11-H11B 109.6 
C10-C11-H11B 109.6 H11A-C11-H11B 108.1 
O1-C12-N2 119.4(8) O1-C12-C13 121.0(9) 
N2-C12-C13 119.6(9) C14-C13-C12 120.6(9) 
C14-C13-C15 60.4(6) C12-C13-C15 119.7(8) 
C14-C13-H13A 115.1 C12-C13-H13A 115.1 
C15-C13-H13A 115.1 C13-C14-C15 60.4(6) 
C13-C14-H14A 117.7 C15-C14-H14A 117.7 
C13-C14-H14B 117.7 C15-C14-H14B 117.7 
H14A-C14-H14B 114.8 C14-C15-C13 59.2(6) 
C14-C15-C17 120.3(8) C13-C15-C17 121.9(7) 
C14-C15-C16 116.4(8) C13-C15-C16 117.2(9) 
C17-C15-C16 112.3(7) F1-C16-F2 106.1(10) 
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F1-C16-F3 107.0(9) F2-C16-F3 106.9(9) 
F1-C16-C15 112.2(9) F2-C16-C15 110.8(9) 
F3-C16-C15 113.4(10) C18-C17-C22 117.9(9) 
C18-C17-C15 120.7(9) C22-C17-C15 121.3(9) 
C17-C18-C19 121.2(11) C17-C18-H18A 119.4 
C19-C18-H18A 119.4 C20-C19-C18 119.2(11) 
C20-C19-H19A 120.4 C18-C19-H19A 120.4 
C19-C20-F4 119.1(13) C19-C20-C21 122.7(11) 
F4-C20-C21 118.2(13) C20-C21-C22 117.1(11) 
C20-C21-H21A 121.5 C22-C21-H21A 121.5 
C17-C22-C21 121.9(10) C17-C22-H22A 119.1 
C21-C22-H22A 119.1 C6-N1-C8 116.0(7) 
C6-N1-C11 113.8(6) C8-N1-C11 109.0(7) 
C12-N2-C10 120.7(8) C12-N2-C9 120.6(7) 
C10-N2-C9 117.5(7) 
  
 
 
Table 42. Anisotropic atomic displacement parameters (Å2) for (-)-6b. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
C1 0.053(7) 0.045(6) 0.047(6) 0.009(5) -0.007(5) -0.012(5) 
C2 0.050(7) 0.055(6) 0.055(7) 0.019(5) -0.014(6) 0.002(6) 
C3 0.046(7) 0.049(6) 0.075(8) 0.021(6) 0.010(6) 0.008(5) 
C4 0.059(8) 0.044(6) 0.066(7) 0.010(5) 0.011(6) 0.012(5) 
C5 0.049(7) 0.056(6) 0.052(6) 0.012(5) -0.004(5) 0.002(6) 
C6 0.037(6) 0.035(5) 0.042(5) 0.003(4) 0.010(5) -0.008(4) 
C7 0.088(10) 0.079(8) 0.052(6) -0.002(6) -0.014(7) 0.003(7) 
C8 0.029(6) 0.047(5) 0.043(5) 0.007(4) 0.001(5) -0.002(4) 
C9 0.040(7) 0.042(5) 0.051(5) 0.006(4) -0.001(5) -0.003(5) 
C10 0.034(6) 0.058(6) 0.051(5) 0.008(5) 0.009(5) -0.010(5) 
C11 0.041(7) 0.043(6) 0.057(6) 0.003(5) 0.006(5) -0.008(5) 
C12 0.046(7) 0.046(6) 0.043(6) -0.009(4) 0.002(6) -0.008(6) 
C13 0.040(7) 0.043(6) 0.059(6) 0.006(5) 0.007(5) 0.005(5) 
C14 0.052(7) 0.048(6) 0.060(6) 0.000(5) 0.005(5) 0.016(5) 
C15 0.053(7) 0.038(5) 0.039(5) 0.006(4) 0.006(5) 0.006(5) 
C16 0.074(9) 0.045(7) 0.073(8) 0.003(6) 0.013(7) 0.004(6) 
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U11 U22 U33 U23 U13 U12 
C17 0.037(7) 0.057(6) 0.037(5) 0.005(4) -0.001(5) 0.001(5) 
C18 0.069(9) 0.072(8) 0.054(6) 0.006(6) -0.020(6) 0.010(7) 
C19 0.057(10) 0.117(12) 0.084(9) 0.002(8) -0.032(7) -0.019(9) 
C20 0.086(11) 0.082(10) 0.056(7) -0.004(6) -0.017(7) -0.034(8) 
C21 0.087(10) 0.056(7) 0.059(7) -0.017(5) -0.003(6) 0.000(6) 
C22 0.051(7) 0.055(6) 0.063(6) -0.011(5) -0.012(6) 0.007(6) 
Cl1 0.127(3) 0.085(2) 0.084(2) -0.0091(16) 0.024(2) 0.051(2) 
F1 0.115(6) 0.071(5) 0.115(6) 0.010(4) 0.027(5) -0.031(5) 
F2 0.070(5) 0.071(4) 0.107(5) 0.024(4) 0.040(4) 0.008(4) 
F3 0.095(5) 0.111(5) 0.064(4) 0.036(4) -0.001(4) 0.009(5) 
F4 0.140(9) 0.129(7) 0.134(7) -0.050(6) -0.023(6) -0.063(6) 
N1 0.033(5) 0.038(4) 0.045(4) 0.007(3) 0.003(4) -0.005(4) 
N2 0.030(5) 0.041(5) 0.053(5) 0.005(4) 0.012(4) -0.001(4) 
O1 0.042(5) 0.062(4) 0.070(4) 0.004(3) 0.004(4) 0.005(4) 
 
 
Table 43. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for (-)-6b. 
 
x/a y/b z/c U(eq) 
H2A -0.2150 0.6766 0.4033 0.064 
H3A -0.3024 0.7459 0.4992 0.068 
H5A 0.0650 0.5993 0.6074 0.063 
H7A 0.1260 0.5053 0.3912 0.11 
H7B -0.0873 0.5200 0.3640 0.11 
H7C 0.0777 0.5869 0.3474 0.11 
H8A 0.0675 0.4398 0.5807 0.048 
H8B 0.2599 0.4850 0.6063 0.048 
H9A 0.3232 0.3404 0.5976 0.053 
H9B 0.2441 0.3384 0.5223 0.053 
H10A 0.4928 0.4323 0.4355 0.057 
H10B 0.6651 0.4738 0.4771 0.057 
H11A 0.4548 0.5631 0.5341 0.056 
H11B 0.4047 0.5717 0.4561 0.056 
H13A 0.5114 0.2322 0.5851 0.057 
H14A 0.9269 0.2355 0.6046 0.064 
H14B 0.7808 0.1567 0.6261 0.064 
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x/a y/b z/c U(eq) 
H18A 1.0300 0.3025 0.7220 0.078 
H19A 1.1707 0.4250 0.7652 0.103 
H21A 0.7000 0.5602 0.7139 0.081 
H22A 0.5578 0.4356 0.6713 0.067 
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Figure 63. X-ray structural information for (-)-11a. 
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Table 44. Crystal data for (-)-11a. 
Chemical formula C22H21ClF4N2O 
Formula weight 440.86 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.130 x 0.150 x 0.220 mm 
Crystal system orthorhombic 
Space group P 21 21 21 
Unit cell dimensions a = 10.0283(6) Å α = 90° 
 
b = 13.7511(8) Å β = 90° 
 
c = 15.1078(8) Å γ = 90° 
Volume 2083.4(2) Å3 
 
Z 4 
Density (calculated) 1.406 g/cm3 
Absorption coefficient 2.088 mm-1 
F(000) 912 
 
 
Table 45. Data collection and structure refinement for (-)-11a. 
Diffractometer Bruker Aoex II CCD 
Theta range for data collection 4.35 to 68.55° 
Index ranges -12<=h<=11, -16<=k<=16, -18<=l<=18 
Reflections collected 17703 
Independent reflections 3828 [R(int) = 0.0491] 
Absorption correction multi-scan 
Max. and min. transmission 0.7700 and 0.6600 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3828 / 0 / 357 
Goodness-of-fit on F2 0.914 
Final R indices 3484 data; I>2σ(I) R1 = 0.0293, wR2 = 0.0865 
 
all data R1 = 0.0329, wR2 = 0.0899 
Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
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Absolute structure parameter 0.02(2) 
Extinction coefficient 0.0055(6) 
Largest diff. peak and hole 0.165 and -0.154 eÅ-3 
R.M.S. deviation from mean 0.026 eÅ-3 
 
 
Table 46. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for (-)-11a. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
x/a y/b z/c U(eq) 
C1 0.7000(3) 0.66744(18) 0.02808(17) 0.0481(6) 
Cl1 0.92547(9) 0.63048(8) 0.77098(5) 0.0865(3) 
F1 0.2877(2) 0.5075(2) 0.25638(15) 0.0984(8) 
N1 0.8377(2) 0.54237(13) 0.09626(12) 0.0399(4) 
O1 0.1065(2) 0.32358(13) 0.27177(13) 0.0572(5) 
C2 0.6698(3) 0.7229(2) 0.9541(2) 0.0598(7) 
F2 0.1736(2) 0.62440(14) 0.30840(15) 0.0823(6) 
N2 0.9640(2) 0.44444(14) 0.23766(12) 0.0431(5) 
C3 0.7367(3) 0.7130(2) 0.87433(19) 0.0632(8) 
F3 0.31977(19) 0.55688(16) 0.38888(14) 0.0817(6) 
C4 0.8368(3) 0.6451(2) 0.86905(16) 0.0565(7) 
F4 0.0751(2) 0.83459(14) 0.63672(12) 0.0809(6) 
C5 0.8715(3) 0.5880(2) 0.94092(16) 0.0479(6) 
C6 0.8047(2) 0.59981(17) 0.02126(15) 0.0406(5) 
C7 0.6177(3) 0.6766(3) 0.1110(2) 0.0662(8) 
C8 0.9092(3) 0.45211(17) 0.07964(15) 0.0439(5) 
C9 0.9081(3) 0.38989(18) 0.16295(16) 0.0480(6) 
C10 0.8994(3) 0.53848(17) 0.25265(14) 0.0421(5) 
C11 0.9023(3) 0.59703(17) 0.16777(15) 0.0416(5) 
C12 0.0632(2) 0.40545(17) 0.28563(14) 0.0414(5) 
C13 0.1240(2) 0.46550(17) 0.36023(16) 0.0425(5) 
C14 0.1517(3) 0.4100(2) 0.44391(18) 0.0569(7) 
C15 0.0451(3) 0.48547(18) 0.44470(15) 0.0440(5) 
C16 0.2259(3) 0.5374(2) 0.32882(18) 0.0548(7) 
C17 0.0552(2) 0.57782(18) 0.49689(14) 0.0433(5) 
C18 0.1551(3) 0.5944(2) 0.55924(17) 0.0537(6) 
C19 0.1623(3) 0.6803(2) 0.60632(17) 0.0577(7) 
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x/a y/b z/c U(eq) 
C20 0.0672(3) 0.7496(2) 0.59128(15) 0.0559(6) 
C21 0.9645(3) 0.7358(2) 0.53322(18) 0.0592(7) 
C22 0.9591(3) 0.6494(2) 0.48593(16) 0.0516(6) 
 
 
Table 47. Bond lengths (Å) for (-)-11a. 
C1-C2 1.386(4) C1-C6 1.406(4) 
C1-C7 1.505(4) Cl1-C4 1.740(3) 
F1-C16 1.323(3) N1-C6 1.420(3) 
N1-C8 1.455(3) N1-C11 1.467(3) 
O1-C12 1.225(3) C2-C3 1.387(5) 
C2-H2 0.96(4) F2-C16 1.342(4) 
N2-C12 1.343(3) N2-C10 1.464(3) 
N2-C9 1.466(3) C3-C4 1.373(5) 
C3-H3 1.00(4) F3-C16 1.334(4) 
C4-C5 1.385(4) F4-C20 1.358(3) 
C5-C6 1.396(4) C5-H5 0.90(3) 
C7-H7A 0.99(4) C7-H7B 1.01(4) 
C7-H7C 0.99(4) C8-C9 1.522(3) 
C8-H8A 1.03(3) C8-H8B 0.99(3) 
C9-H9A 1.00(3) C9-H9B 0.90(3) 
C10-C11 1.514(3) C10-H10A 1.00(3) 
C10-H10B 0.99(3) C11-H11A 0.97(3) 
C11-H11B 1.02(3) C12-C13 1.525(3) 
C13-C16 1.499(4) C13-C14 1.503(3) 
C13-C15 1.526(3) C14-C15 1.490(4) 
C14-H14A 1.01(4) C14-H14B 1.01(4) 
C15-C17 1.498(4) C15-H15 0.98(3) 
C17-C22 1.388(4) C17-C18 1.394(4) 
C18-C19 1.380(4) C18-H18 0.91(3) 
C19-C20 1.367(4) C19-H19 0.96(4) 
C20-C21 1.366(4) C21-C22 1.387(4) 
C21-H21 0.89(4) C22-H22 0.99(4) 
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Table 48. Bond angles (°) for (-)-11a. 
C2-C1-C6 117.9(3) C2-C1-C7 120.3(3) 
C6-C1-C7 121.7(2) C6-N1-C8 116.83(19) 
C6-N1-C11 113.92(18) C8-N1-C11 110.26(19) 
C1-C2-C3 122.7(3) C1-C2-H2 117.(2) 
C3-C2-H2 120.(2) C12-N2-C10 126.7(2) 
C12-N2-C9 119.6(2) C10-N2-C9 113.7(2) 
C4-C3-C2 118.1(2) C4-C3-H3 120.(2) 
C2-C3-H3 122.(2) C3-C4-C5 121.6(3) 
C3-C4-Cl1 120.1(2) C5-C4-Cl1 118.3(2) 
C4-C5-C6 119.7(3) C4-C5-H5 120.(2) 
C6-C5-H5 120.(2) C5-C6-C1 119.9(2) 
C5-C6-N1 121.1(2) C1-C6-N1 118.9(2) 
C1-C7-H7A 108.7(19) C1-C7-H7B 110.(2) 
H7A-C7-H7B 105.(3) C1-C7-H7C 111.(2) 
H7A-C7-H7C 112.(3) H7B-C7-H7C 110.(3) 
N1-C8-C9 109.47(19) N1-C8-H8A 113.4(16) 
C9-C8-H8A 107.4(16) N1-C8-H8B 107.3(17) 
C9-C8-H8B 111.8(16) H8A-C8-H8B 108.(2) 
N2-C9-C8 110.3(2) N2-C9-H9A 107.7(18) 
C8-C9-H9A 111.8(17) N2-C9-H9B 110.(2) 
C8-C9-H9B 105.(2) H9A-C9-H9B 112.(3) 
N2-C10-C11 109.29(19) N2-C10-H10A 110.1(17) 
C11-C10-H10A 108.2(18) N2-C10-H10B 108.6(15) 
C11-C10-H10B 109.6(15) H10A-C10-H10B 111.(2) 
N1-C11-C10 110.05(19) N1-C11-H11A 110.(2) 
C10-C11-H11A 110.(2) N1-C11-H11B 108.3(15) 
C10-C11-H11B 109.7(15) H11A-C11-H11B 109.(3) 
O1-C12-N2 122.5(2) O1-C12-C13 118.8(2) 
N2-C12-C13 118.6(2) C16-C13-C14 118.4(2) 
C16-C13-C12 113.3(2) C14-C13-C12 114.9(2) 
C16-C13-C15 120.0(2) C14-C13-C15 58.93(17) 
C12-C13-C15 120.5(2) C15-C14-C13 61.33(16) 
C15-C14-H14A 116.(2) C13-C14-H14A 114.(2) 
C15-C14-H14B 121.(2) C13-C14-H14B 117.(2) 
H14A-C14-H14B 116.(3) C14-C15-C17 123.1(2) 
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C14-C15-C13 59.74(16) C17-C15-C13 123.9(2) 
C14-C15-H15 113.1(18) C17-C15-H15 115.3(18) 
C13-C15-H15 110.2(18) F1-C16-F3 107.2(2) 
F1-C16-F2 105.7(3) F3-C16-F2 104.7(2) 
F1-C16-C13 112.1(2) F3-C16-C13 113.4(2) 
F2-C16-C13 113.2(2) C22-C17-C18 117.6(2) 
C22-C17-C15 119.4(2) C18-C17-C15 122.9(2) 
C19-C18-C17 121.7(3) C19-C18-H18 115.(2) 
C17-C18-H18 123.(2) C20-C19-C18 118.3(3) 
C20-C19-H19 121.(2) C18-C19-H19 121.(2) 
F4-C20-C21 119.2(3) F4-C20-C19 118.4(3) 
C21-C20-C19 122.4(3) C20-C21-C22 118.6(3) 
C20-C21-H21 121.(3) C22-C21-H21 120.(3) 
C21-C22-C17 121.2(3) C21-C22-H22 117.1(19) 
C17-C22-H22 121.6(19) 
  
 
 
Table 49. Anisotropic atomic displacement parameters (Å2) for (-)-11a. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
C1 0.0517(13) 0.0375(13) 0.0551(13) -0.0070(10) -0.0151(11) 0.0007(11) 
Cl1 0.0816(6) 0.1331(8) 0.0447(3) 0.0170(4) -0.0013(3) -0.0318(5) 
F1 0.0873(14) 0.1165(18) 0.0915(14) -0.0407(13) 0.0496(12) -0.0383(13) 
N1 0.0467(10) 0.0329(10) 0.0401(9) -0.0022(7) -0.0028(8) 0.0029(8) 
O1 0.0668(12) 0.0363(10) 0.0685(10) -0.0005(8) -0.0035(9) 0.0143(8) 
C2 0.0705(19) 0.0390(15) 0.0700(17) 0.0011(12) -0.0321(15) -0.0003(13) 
F2 0.0828(12) 0.0603(11) 0.1038(14) 0.0294(10) 0.0145(11) -0.0173(10) 
N2 0.0571(12) 0.0310(10) 0.0411(9) 0.0002(7) -0.0013(8) 0.0072(8) 
C3 0.082(2) 0.0491(16) 0.0586(16) 0.0156(13) -0.0305(15) -0.0167(15) 
F3 0.0547(10) 0.1015(16) 0.0889(13) -0.0164(11) -0.0043(9) -0.0198(10) 
C4 0.0592(16) 0.0672(19) 0.0430(12) 0.0087(11) -0.0114(12) -0.0229(14) 
F4 0.1158(17) 0.0623(11) 0.0645(9) -0.0160(8) -0.0108(10) 0.0042(11) 
C5 0.0461(14) 0.0527(16) 0.0448(12) 0.0030(10) -0.0063(10) -0.0070(12) 
C6 0.0452(12) 0.0342(12) 0.0426(11) -0.0007(9) -0.0088(9) -0.0044(9) 
C7 0.0613(19) 0.071(2) 0.0659(17) -0.0158(15) -0.0100(14) 0.0229(15) 
C8 0.0531(14) 0.0380(12) 0.0407(11) -0.0044(9) -0.0017(10) 0.0066(10) 
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U11 U22 U33 U23 U13 U12 
C9 0.0637(16) 0.0333(13) 0.0470(12) -0.0028(9) -0.0024(12) 0.0021(12) 
C10 0.0527(14) 0.0331(12) 0.0405(11) -0.0019(8) 0.0000(10) 0.0074(10) 
C11 0.0503(13) 0.0326(12) 0.0419(10) 0.0004(9) -0.0068(10) 0.0021(10) 
C12 0.0473(12) 0.0322(12) 0.0446(11) 0.0060(8) 0.0062(9) 0.0020(9) 
C13 0.0434(12) 0.0367(12) 0.0473(12) 0.0049(9) 0.0003(9) 0.0058(9) 
C14 0.0713(18) 0.0438(16) 0.0558(14) 0.0078(11) -0.0103(13) 0.0136(14) 
C15 0.0503(14) 0.0390(13) 0.0428(11) 0.0116(9) 0.0023(10) 0.0008(10) 
C16 0.0485(15) 0.0602(17) 0.0557(14) -0.0064(12) 0.0100(12) -0.0054(12) 
C17 0.0503(13) 0.0438(13) 0.0357(9) 0.0097(9) 0.0059(9) 0.0010(10) 
C18 0.0541(15) 0.0602(18) 0.0469(12) 0.0053(11) -0.0050(11) 0.0082(13) 
C19 0.0598(16) 0.0701(19) 0.0433(12) -0.0021(12) -0.0053(12) -0.0007(14) 
C20 0.0783(18) 0.0493(15) 0.0401(11) 0.0000(10) 0.0055(12) -0.0003(14) 
C21 0.0724(19) 0.0546(18) 0.0507(13) 0.0017(11) -0.0038(13) 0.0180(14) 
C22 0.0535(14) 0.0552(16) 0.0461(12) 0.0036(10) -0.0037(11) 0.0080(11) 
 
 
Table 50. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for (-)-11a. 
 x/a y/b z/c U(eq) 
H2 0.598(4) 0.769(3) -0.040(2) 0.076(11) 
H3 0.716(3) 0.755(2) -0.178(2) 0.068(9) 
H5 0.933(3) 0.541(2) -0.065(2) 0.053(8) 
H7A 0.525(4) 0.693(2) 0.094(2) 0.063(9) 
H7B 0.612(4) 0.611(3) 0.142(3) 0.083(11) 
H7C 0.657(4) 0.725(3) 0.152(3) 0.085(12) 
H8A 1.007(3) 0.463(2) 0.0620(19) 0.048(7) 
H8B 0.864(3) 0.419(2) 0.0298(19) 0.047(7) 
H9A 0.962(3) 0.329(2) 0.1555(19) 0.058(8) 
H9B 0.821(3) 0.376(2) 0.173(2) 0.058(9) 
H10A 0.804(3) 0.529(2) 0.270(2) 0.054(8) 
H10B 0.949(3) 0.5737(19) 0.2997(18) 0.041(7) 
H11A 0.857(3) 0.659(2) 0.176(2) 0.068(10) 
H11B 0.999(3) 0.610(2) 0.1498(17) 0.048(7) 
H14A 1.239(4) 0.428(3) 0.474(2) 0.070(10) 
H14B 1.128(4) 0.339(3) 0.444(2) 0.072(10) 
H15 0.955(3) 0.458(2) 0.440(2) 0.051(8) 
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 x/a y/b z/c U(eq) 
H18 1.215(4) 0.548(2) 0.575(2) 0.062(9) 
H19 1.233(4) 0.692(3) 0.648(2) 0.074(10) 
H21 0.900(4) 0.780(3) 0.527(3) 0.082(11) 
H22 0.882(3) 0.641(2) 0.445(2) 0.062(9) 
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Figure 64. X-ray structural information for (-)-34. 
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Table 51. Crystal data for (-)-34. 
Identification code st769031 
Chemical formula C23H20F8N2O 
Formula weight 492.41 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.020 x 0.120 x 0.200 mm 
Crystal system monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 10.9909(9) Å α = 90° 
 
b = 10.5085(10) Å β = 99.376(7)° 
 
c = 20.090(2) Å γ = 90° 
Volume 2289.4(4) Å3 
 
Z 4 
Density (calculated) 1.429 g/cm3 
Absorption coefficient 1.173 mm-1 
F(000) 1008 
 
 
Table 52. Data collection and structure refinement for (-)-34. 
Diffractometer Bruker Apex II CCD 
Radiation source Bruker X8 Prospector Ultra, IMuS Cu K/a 
Theta range for data collection 2.23 to 68.39° 
Index ranges -13<=h<=12, -12<=k<=11, -24<=l<=24 
Reflections collected 32756 
Independent reflections 8340 [R(int) = 0.1472] 
Absorption correction multi-scan 
Max. and min. transmission 0.9770 and 0.7990 
Structure solution technique direct methods 
Structure solution program SHELXT 2014/4 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2016/6 (Sheldrick, 2016) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 8340 / 1 / 616 
Goodness-of-fit on F2 1.231 
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Δ/σmax 0.001 
Final R indices 3994 data; I>2σ(I) R1 = 0.1068, wR2 = 0.2497 
 
all data R1 = 0.1921, wR2 = 0.2934 
Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2]; where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.1(5) 
Largest diff. peak and hole 0.584 and -0.347 eÅ-3 
R.M.S. deviation from mean 0.096 eÅ-3 
 
 
Table 53. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for (-)-34. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
x/a y/b z/c U(eq) 
C1 0.9924(12) 0.3615(12) 0.3377(6) 0.058(3) 
C2 0.0956(13) 0.4129(12) 0.3155(7) 0.061(4) 
C3 0.0860(17) 0.5264(14) 0.2815(7) 0.081(5) 
C4 0.9739(16) 0.5835(13) 0.2674(8) 0.076(4) 
C5 0.8663(15) 0.5334(12) 0.2857(6) 0.066(4) 
C6 0.8793(13) 0.4189(11) 0.3226(6) 0.059(3) 
C7 0.2092(16) 0.3451(15) 0.3345(9) 0.080(4) 
C8 0.7431(15) 0.5970(14) 0.2655(7) 0.082(5) 
C9 0.7698(13) 0.2305(10) 0.3574(7) 0.062(3) 
C10 0.6428(13) 0.1860(12) 0.3613(7) 0.063(4) 
C011 0.5365(12) 0.5951(10) 0.8257(6) 0.052(3) 
C11 0.7286(13) 0.4352(11) 0.4006(6) 0.057(3) 
C12 0.6000(13) 0.3955(11) 0.4080(7) 0.064(4) 
C13 0.5532(12) 0.1938(12) 0.4656(7) 0.061(3) 
C14 0.5112(13) 0.2716(12) 0.5202(7) 0.062(3) 
C15 0.5325(12) 0.2293(12) 0.5886(8) 0.067(4) 
C16 0.6076(12) 0.3390(10) 0.5758(6) 0.056(3) 
C17 0.7398(12) 0.3361(10) 0.5768(6) 0.054(3) 
C18 0.8048(12) 0.2245(10) 0.5642(6) 0.059(3) 
C19 0.9302(11) 0.2296(11) 0.5608(7) 0.056(3) 
C20 0.9946(13) 0.3464(11) 0.5699(6) 0.061(3) 
C21 0.9305(14) 0.4527(12) 0.5843(7) 0.071(4) 
C22 0.8048(14) 0.4486(11) 0.5864(7) 0.069(4) 
C23 0.1272(16) 0.3522(15) 0.5669(9) 0.085(5) 
C24 0.4322(12) 0.6502(11) 0.8452(6) 0.057(3) 
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x/a y/b z/c U(eq) 
C25 0.3173(13) 0.5958(11) 0.8234(6) 0.059(3) 
C26 0.3079(14) 0.4858(11) 0.7846(6) 0.064(4) 
C27 0.4131(14) 0.4335(12) 0.7656(7) 0.066(4) 
C28 0.5278(13) 0.4875(11) 0.7845(6) 0.056(3) 
C29 0.2093(15) 0.6538(13) 0.8428(9) 0.071(4) 
C30 0.6371(14) 0.4330(13) 0.7592(7) 0.072(4) 
C31 0.6613(12) 0.7835(10) 0.8661(7) 0.061(3) 
C32 0.7962(12) 0.8300(12) 0.8731(7) 0.066(4) 
C33 0.7331(11) 0.5733(11) 0.9012(6) 0.055(3) 
C34 0.8685(13) 0.6172(11) 0.9105(6) 0.061(3) 
C35 0.9383(12) 0.8094(11) 0.9790(7) 0.057(3) 
C36 0.0103(12) 0.7189(12) 0.0293(6) 0.059(3) 
C37 0.0312(13) 0.7503(11) 0.1002(7) 0.060(3) 
C38 0.9448(11) 0.6473(10) 0.0821(6) 0.050(3) 
C39 0.8090(11) 0.6576(10) 0.0800(5) 0.046(3) 
C40 0.7434(12) 0.7717(10) 0.0748(6) 0.055(3) 
C41 0.6171(14) 0.7720(12) 0.0729(8) 0.069(4) 
C42 0.5551(12) 0.6584(12) 0.0748(7) 0.060(3) 
C43 0.6201(14) 0.5440(12) 0.0783(7) 0.069(4) 
C44 0.7446(15) 0.5464(12) 0.0814(7) 0.071(4) 
C45 0.4175(16) 0.6583(17) 0.0736(10) 0.089(5) 
F1 0.2082(10) 0.2228(11) 0.3167(7) 0.139(4) 
F2 0.3040(9) 0.3860(10) 0.3019(5) 0.114(3) 
F3 0.2619(12) 0.3495(18) 0.3968(6) 0.181(7) 
F4 0.4416(7) 0.2475(8) 0.6278(4) 0.085(2) 
F5 0.5870(7) 0.1189(6) 0.6101(4) 0.078(2) 
F6 0.1712(9) 0.2497(10) 0.5443(7) 0.124(4) 
F7 0.1540(10) 0.4491(11) 0.5272(6) 0.126(4) 
F8 0.1947(10) 0.3803(13) 0.6264(6) 0.139(4) 
F9 0.1873(13) 0.6264(18) 0.8990(6) 0.188(8) 
F10 0.1035(10) 0.6201(13) 0.8052(7) 0.148(5) 
F11 0.2045(11) 0.7757(10) 0.8354(9) 0.160(6) 
F12 0.9980(7) 0.8614(7) 0.1271(4) 0.075(2) 
F13 0.1443(7) 0.7174(8) 0.1393(4) 0.082(2) 
F14 0.3640(10) 0.7617(11) 0.0543(9) 0.164(6) 
F15 0.3608(10) 0.5672(12) 0.0368(7) 0.141(5) 
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x/a y/b z/c U(eq) 
F16 0.3902(12) 0.6337(17) 0.1348(8) 0.179(6) 
N1 0.7698(10) 0.3683(9) 0.3427(5) 0.055(3) 
N2 0.5977(10) 0.2558(9) 0.4167(5) 0.059(3) 
N3 0.6582(10) 0.6479(8) 0.8461(5) 0.054(3) 
N4 0.8739(10) 0.7547(9) 0.9237(6) 0.061(3) 
O1 0.5486(10) 0.0755(8) 0.4683(5) 0.082(3) 
O2 0.9430(10) 0.9245(8) 0.9875(5) 0.080(3) 
 
 
Table 54. Bond lengths (Å) for (-)-34. 
C1-C6 1.371(18) C1-C2 1.393(18) 
C1-H1A 0.94 C2-C3 1.370(19) 
C2-C7 1.43(2) C3-C4 1.36(2) 
C3-H3A 0.94 C4-C5 1.40(2) 
C4-H4A 0.94 C5-C6 1.408(17) 
C5-C8 1.51(2) C6-N1 1.433(16) 
C7-F3 1.293(18) C7-F1 1.334(18) 
C7-F2 1.385(17) C8-H8A 0.97 
C8-H8B 0.97 C8-H8C 0.97 
C9-N1 1.478(14) C9-C10 1.486(19) 
C9-H9A 0.98 C9-H9B 0.98 
C10-N2 1.483(15) C10-H10A 0.98 
C10-H10B 0.98 C011-C28 1.395(16) 
C011-C24 1.396(17) C011-N3 1.444(15) 
C11-N1 1.491(15) C11-C12 1.504(18) 
C11-H11A 0.98 C11-H11B 0.98 
C12-N2 1.479(15) C12-H12A 0.98 
C12-H12B 0.98 C13-O1 1.246(14) 
C13-N2 1.336(16) C13-C14 1.501(18) 
C14-C15 1.425(19) C14-C16 1.577(18) 
C14-H14A 0.99 C15-F5 1.345(14) 
C15-F4 1.383(16) C15-C16 1.465(17) 
C16-C17 1.450(18) C16-H16A 0.99 
C17-C22 1.378(16) C17-C18 1.418(16) 
C18-C19 1.392(17) C18-H18A 0.94 
C19-C20 1.413(16) C19-H19A 0.94 
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C20-C21 1.377(19) C20-C23 1.47(2) 
C21-C22 1.39(2) C21-H21A 0.94 
C22-H22A 0.94 C23-F6 1.293(18) 
C23-F8 1.333(18) C23-F7 1.354(18) 
C24-C25 1.391(17) C24-H24A 0.94 
C25-C26 1.389(18) C25-C29 1.442(19) 
C26-C27 1.388(19) C26-H26A 0.94 
C27-C28 1.379(19) C27-H27A 0.94 
C28-C30 1.494(19) C29-F9 1.229(17) 
C29-F11 1.289(17) C29-F10 1.327(18) 
C30-H30A 0.97 C30-H30B 0.97 
C30-H30C 0.97 C31-N3 1.479(14) 
C31-C32 1.545(18) C31-H31A 0.98 
C31-H31B 0.98 C32-N4 1.452(16) 
C32-H32A 0.98 C32-H32B 0.98 
C33-N3 1.490(14) C33-C34 1.540(18) 
C33-H33A 0.98 C33-H33B 0.98 
C34-N4 1.469(15) C34-H34A 0.98 
C34-H34B 0.98 C35-O2 1.222(14) 
C35-N4 1.345(16) C35-C36 1.514(17) 
C36-C37 1.443(17) C36-C38 1.567(17) 
C36-H36A 0.99 C37-F12 1.361(13) 
C37-F13 1.401(15) C37-C38 1.447(17) 
C38-C39 1.490(17) C38-H38A 0.99 
C39-C44 1.369(17) C39-C40 1.395(16) 
C40-C41 1.383(19) C40-H40A 0.94 
C41-C42 1.377(18) C41-H41A 0.94 
C42-C43 1.394(19) C42-C45 1.51(2) 
C43-C44 1.36(2) C43-H43A 0.94 
C44-H44A 0.94 C45-F14 1.267(19) 
C45-F15 1.30(2) C45-F16 1.34(2) 
 
 
Table 55. Bond angles (°) for (-)-34. 
C6-C1-C2 120.9(12) C6-C1-H1A 119.5 
C2-C1-H1A 119.5 C3-C2-C1 119.8(15) 
C3-C2-C7 123.9(14) C1-C2-C7 116.2(12) 
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C4-C3-C2 118.8(16) C4-C3-H3A 120.6 
C2-C3-H3A 120.6 C3-C4-C5 123.8(14) 
C3-C4-H4A 118.1 C5-C4-H4A 118.1 
C4-C5-C6 116.3(13) C4-C5-C8 121.6(12) 
C6-C5-C8 122.1(14) C1-C6-C5 120.2(13) 
C1-C6-N1 123.2(11) C5-C6-N1 116.6(13) 
F3-C7-F1 106.1(14) F3-C7-F2 101.2(14) 
F1-C7-F2 98.4(14) F3-C7-C2 118.2(15) 
F1-C7-C2 116.0(14) F2-C7-C2 114.2(13) 
C5-C8-H8A 109.5 C5-C8-H8B 109.5 
H8A-C8-H8B 109.5 C5-C8-H8C 109.5 
H8A-C8-H8C 109.5 H8B-C8-H8C 109.5 
N1-C9-C10 110.4(10) N1-C9-H9A 109.6 
C10-C9-H9A 109.6 N1-C9-H9B 109.6 
C10-C9-H9B 109.6 H9A-C9-H9B 108.1 
N2-C10-C9 108.4(10) N2-C10-H10A 110.0 
C9-C10-H10A 110.0 N2-C10-H10B 110.0 
C9-C10-H10B 110.0 H10A-C10-H10B 108.4 
C28-C011-C24 121.5(12) C28-C011-N3 116.8(12) 
C24-C011-N3 121.7(11) N1-C11-C12 110.9(10) 
N1-C11-H11A 109.5 C12-C11-H11A 109.5 
N1-C11-H11B 109.5 C12-C11-H11B 109.5 
H11A-C11-H11B 108.1 N2-C12-C11 108.7(10) 
N2-C12-H12A 109.9 C11-C12-H12A 109.9 
N2-C12-H12B 109.9 C11-C12-H12B 109.9 
H12A-C12-H12B 108.3 O1-C13-N2 122.7(12) 
O1-C13-C14 119.5(12) N2-C13-C14 117.8(11) 
C15-C14-C13 120.9(12) C15-C14-C16 58.2(8) 
C13-C14-C16 120.7(11) C15-C14-H14A 115.1 
C13-C14-H14A 115.1 C16-C14-H14A 115.1 
F5-C15-F4 105.2(11) F5-C15-C14 124.9(13) 
F4-C15-C14 119.1(12) F5-C15-C16 120.0(11) 
F4-C15-C16 118.1(11) C14-C15-C16 66.1(9) 
C17-C16-C15 125.0(10) C17-C16-C14 123.8(11) 
C15-C16-C14 55.7(9) C17-C16-H16A 113.5 
C15-C16-H16A 113.5 C14-C16-H16A 113.5 
C22-C17-C18 118.1(13) C22-C17-C16 118.6(11) 
C18-C17-C16 123.2(11) C19-C18-C17 120.5(11) 
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C19-C18-H18A 119.7 C17-C18-H18A 119.7 
C18-C19-C20 120.4(12) C18-C19-H19A 119.8 
C20-C19-H19A 119.8 C21-C20-C19 118.0(13) 
C21-C20-C23 121.3(12) C19-C20-C23 120.7(12) 
C20-C21-C22 121.8(12) C20-C21-H21A 119.1 
C22-C21-H21A 119.1 C17-C22-C21 121.1(12) 
C17-C22-H22A 119.4 C21-C22-H22A 119.4 
F6-C23-F8 108.3(15) F6-C23-F7 107.0(15) 
F8-C23-F7 102.7(13) F6-C23-C20 114.2(13) 
F8-C23-C20 112.5(15) F7-C23-C20 111.5(13) 
C25-C24-C011 119.1(12) C25-C24-H24A 120.4 
C011-C24-H24A 120.4 C26-C25-C24 119.9(13) 
C26-C25-C29 120.9(13) C24-C25-C29 119.1(12) 
C27-C26-C25 119.7(14) C27-C26-H26A 120.1 
C25-C26-H26A 120.1 C28-C27-C26 121.7(13) 
C28-C27-H27A 119.1 C26-C27-H27A 119.1 
C27-C28-C011 118.0(12) C27-C28-C30 119.9(12) 
C011-C28-C30 122.1(13) F9-C29-F11 109.1(15) 
F9-C29-F10 100.1(15) F11-C29-F10 100.6(15) 
F9-C29-C25 116.3(14) F11-C29-C25 114.2(13) 
F10-C29-C25 114.7(13) C28-C30-H30A 109.5 
C28-C30-H30B 109.5 H30A-C30-H30B 109.5 
C28-C30-H30C 109.5 H30A-C30-H30C 109.5 
H30B-C30-H30C 109.5 N3-C31-C32 108.0(10) 
N3-C31-H31A 110.1 C32-C31-H31A 110.1 
N3-C31-H31B 110.1 C32-C31-H31B 110.1 
H31A-C31-H31B 108.4 N4-C32-C31 109.7(10) 
N4-C32-H32A 109.7 C31-C32-H32A 109.7 
N4-C32-H32B 109.7 C31-C32-H32B 109.7 
H32A-C32-H32B 108.2 N3-C33-C34 109.8(9) 
N3-C33-H33A 109.7 C34-C33-H33A 109.7 
N3-C33-H33B 109.7 C34-C33-H33B 109.7 
H33A-C33-H33B 108.2 N4-C34-C33 109.0(10) 
N4-C34-H34A 109.9 C33-C34-H34A 109.9 
N4-C34-H34B 109.9 C33-C34-H34B 109.9 
H34A-C34-H34B 108.3 O2-C35-N4 122.8(12) 
O2-C35-C36 121.6(12) N4-C35-C36 115.5(11) 
C37-C36-C35 119.8(11) C37-C36-C38 57.3(8) 
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C35-C36-C38 120.4(11) C37-C36-H36A 115.6 
C35-C36-H36A 115.6 C38-C36-H36A 115.6 
F12-C37-F13 105.1(10) F12-C37-C36 125.3(11) 
F13-C37-C36 118.7(11) F12-C37-C38 122.3(11) 
F13-C37-C38 116.2(10) C36-C37-C38 65.7(9) 
C37-C38-C39 124.5(10) C37-C38-C36 57.0(8) 
C39-C38-C36 121.0(10) C37-C38-H38A 114.2 
C39-C38-H38A 114.2 C36-C38-H38A 114.2 
C44-C39-C40 118.2(12) C44-C39-C38 117.2(11) 
C40-C39-C38 124.6(10) C41-C40-C39 120.6(11) 
C41-C40-H40A 119.7 C39-C40-H40A 119.7 
C42-C41-C40 119.8(11) C42-C41-H41A 120.1 
C40-C41-H41A 120.1 C41-C42-C43 119.8(12) 
C41-C42-C45 120.0(13) C43-C42-C45 120.3(13) 
C44-C43-C42 119.3(12) C44-C43-H43A 120.3 
C42-C43-H43A 120.3 C43-C44-C39 122.4(13) 
C43-C44-H44A 118.8 C39-C44-H44A 118.8 
F14-C45-F15 107.5(17) F14-C45-F16 106.5(18) 
F15-C45-F16 102.8(15) F14-C45-C42 114.7(14) 
F15-C45-C42 113.3(15) F16-C45-C42 111.1(15) 
C6-N1-C9 116.6(10) C6-N1-C11 114.9(9) 
C9-N1-C11 107.3(9) C13-N2-C12 125.8(10) 
C13-N2-C10 121.2(10) C12-N2-C10 112.9(10) 
C011-N3-C31 115.3(10) C011-N3-C33 112.5(9) 
C31-N3-C33 108.6(9) C35-N4-C32 121.1(10) 
C35-N4-C34 124.7(11) C32-N4-C34 114.0(11) 
 
 
Table 56. Anisotropic atomic displacement parameters (Å2) for (-)-34. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
C1 0.063(9) 0.046(7) 0.062(8) 0.003(6) 0.002(7) 0.008(6) 
C2 0.068(10) 0.060(8) 0.054(8) 0.009(6) 0.007(7) -0.017(7) 
C3 0.118(15) 0.066(10) 0.062(10) -0.012(7) 0.022(10) 0.006(9) 
C4 0.094(13) 0.053(8) 0.086(11) 0.011(7) 0.029(9) 0.005(8) 
C5 0.095(12) 0.056(8) 0.049(8) 0.001(6) 0.014(8) 0.022(7) 
C6 0.073(10) 0.048(7) 0.058(9) -0.002(5) 0.016(7) -0.008(6) 
C7 0.089(13) 0.072(11) 0.077(11) 0.018(8) 0.011(10) -0.012(9) 
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U11 U22 U33 U23 U13 U12 
C8 0.094(13) 0.080(10) 0.075(11) 0.016(7) 0.024(9) 0.022(8) 
C9 0.077(10) 0.038(7) 0.071(9) -0.003(5) 0.013(7) 0.010(6) 
C10 0.072(10) 0.056(8) 0.062(9) -0.018(6) 0.014(7) -0.007(6) 
C011 0.057(9) 0.043(6) 0.051(8) 0.005(5) -0.003(6) -0.005(5) 
C11 0.077(10) 0.037(6) 0.057(8) 0.000(5) 0.005(7) 0.001(6) 
C12 0.076(10) 0.046(7) 0.069(9) -0.004(6) 0.009(7) 0.022(6) 
C13 0.055(9) 0.049(8) 0.075(10) -0.007(6) -0.003(7) -0.005(6) 
C14 0.052(8) 0.067(8) 0.065(10) -0.002(7) 0.002(7) -0.011(6) 
C15 0.039(8) 0.054(8) 0.102(12) 0.005(7) -0.003(8) -0.005(6) 
C16 0.066(10) 0.033(6) 0.068(9) -0.004(5) 0.007(7) 0.005(5) 
C17 0.068(9) 0.035(6) 0.057(8) 0.005(5) 0.003(6) 0.000(5) 
C18 0.061(9) 0.030(6) 0.083(9) -0.003(5) 0.006(7) 0.002(5) 
C19 0.043(8) 0.042(6) 0.081(9) -0.005(5) -0.001(6) -0.005(5) 
C20 0.070(10) 0.043(7) 0.065(8) -0.006(5) -0.002(7) -0.010(6) 
C21 0.083(12) 0.042(8) 0.087(11) -0.020(6) 0.010(9) -0.016(7) 
C22 0.070(11) 0.037(7) 0.102(12) -0.013(6) 0.024(9) -0.012(6) 
C23 0.075(12) 0.065(10) 0.108(13) -0.003(9) -0.009(10) -0.014(8) 
C24 0.060(9) 0.050(7) 0.058(8) 0.004(6) -0.001(7) 0.003(6) 
C25 0.069(10) 0.050(8) 0.058(8) 0.011(6) 0.013(7) -0.010(6) 
C26 0.078(11) 0.047(7) 0.061(9) 0.008(6) -0.005(8) -0.003(6) 
C27 0.069(11) 0.055(8) 0.071(10) -0.006(6) 0.004(8) -0.002(7) 
C28 0.079(10) 0.046(7) 0.042(8) 0.002(5) 0.005(7) 0.005(6) 
C29 0.067(11) 0.055(9) 0.094(13) -0.009(7) 0.016(9) -0.001(7) 
C30 0.087(11) 0.070(9) 0.061(9) -0.008(6) 0.013(8) 0.003(7) 
C31 0.055(9) 0.036(6) 0.087(10) 0.005(5) 0.002(7) 0.005(5) 
C32 0.069(10) 0.053(8) 0.068(9) 0.014(6) -0.015(7) -0.008(6) 
C33 0.061(9) 0.040(6) 0.060(8) 0.004(5) -0.004(7) -0.005(5) 
C34 0.082(10) 0.042(7) 0.057(8) -0.002(5) 0.004(7) -0.004(6) 
C35 0.061(9) 0.049(8) 0.060(9) 0.000(6) 0.007(7) -0.008(6) 
C36 0.056(8) 0.054(7) 0.065(9) -0.004(6) 0.005(7) -0.007(6) 
C37 0.058(9) 0.048(8) 0.070(10) -0.008(6) 0.002(7) 0.009(6) 
C38 0.051(8) 0.041(6) 0.059(8) 0.001(5) 0.012(6) 0.005(5) 
C39 0.060(9) 0.037(6) 0.042(7) 0.002(4) 0.005(6) -0.001(5) 
C40 0.064(9) 0.035(6) 0.065(9) -0.009(5) 0.008(7) -0.007(6) 
C41 0.072(11) 0.042(7) 0.099(11) -0.008(6) 0.024(9) 0.015(6) 
C42 0.047(9) 0.060(8) 0.073(9) -0.006(6) 0.010(7) -0.003(6) 
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U11 U22 U33 U23 U13 U12 
C43 0.070(11) 0.049(8) 0.092(11) -0.002(6) 0.028(9) -0.014(7) 
C44 0.083(12) 0.039(7) 0.089(11) 0.006(6) 0.010(9) -0.011(7) 
C45 0.075(13) 0.071(11) 0.124(15) 0.021(10) 0.025(11) -0.004(9) 
F1 0.081(7) 0.091(8) 0.245(14) 0.007(8) 0.026(8) 0.019(5) 
F2 0.091(8) 0.130(9) 0.123(8) 0.015(6) 0.020(6) -0.020(6) 
F3 0.120(10) 0.35(2) 0.068(8) -0.001(10) -0.006(7) 0.098(13) 
F4 0.057(5) 0.098(6) 0.102(6) -0.011(5) 0.026(5) -0.011(4) 
F5 0.079(6) 0.052(4) 0.099(6) 0.017(4) 0.004(5) -0.005(4) 
F6 0.069(7) 0.097(8) 0.208(12) -0.040(7) 0.027(7) -0.001(5) 
F7 0.079(7) 0.109(8) 0.196(12) 0.023(7) 0.040(7) -0.013(5) 
F8 0.079(8) 0.197(13) 0.128(9) -0.040(8) -0.023(7) -0.005(7) 
F9 0.147(12) 0.33(2) 0.100(9) 0.068(11) 0.062(9) 0.139(13) 
F10 0.067(7) 0.167(12) 0.215(14) -0.058(10) 0.038(8) -0.009(7) 
F11 0.108(9) 0.078(7) 0.318(18) -0.011(9) 0.109(11) 0.007(6) 
F12 0.090(6) 0.056(4) 0.081(5) -0.014(4) 0.017(4) -0.013(4) 
F13 0.057(5) 0.104(6) 0.080(6) 0.003(4) -0.003(4) -0.004(4) 
F14 0.071(8) 0.089(8) 0.33(2) 0.044(10) 0.028(9) 0.004(6) 
F15 0.076(8) 0.121(9) 0.222(14) -0.005(9) 0.010(8) -0.028(6) 
F16 0.090(9) 0.271(19) 0.192(14) 0.032(13) 0.066(9) 0.015(10) 
N1 0.060(7) 0.046(6) 0.059(6) -0.001(4) 0.009(5) 0.004(5) 
N2 0.061(7) 0.043(6) 0.069(7) -0.006(5) 0.003(6) -0.004(5) 
N3 0.063(7) 0.039(5) 0.055(6) 0.001(4) -0.009(5) -0.009(5) 
N4 0.061(7) 0.047(6) 0.073(7) -0.005(5) 0.009(6) -0.011(5) 
O1 0.105(8) 0.047(6) 0.099(8) -0.015(5) 0.031(6) -0.015(5) 
O2 0.107(9) 0.043(5) 0.086(7) -0.001(4) 0.006(6) -0.022(5) 
 
 
Table 57. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for (-)-34. 
 x/a y/b z/c U(eq) 
H1A 1.0006 0.2863 0.3635 0.069 
H3A 1.1557 0.5641 0.2682 0.097 
H4A 0.9684 0.6613 0.2440 0.091 
H8A 0.6801 0.5328 0.2532 0.123 
H8B 0.7463 0.6524 0.2272 0.123 
H8C 0.7237 0.6469 0.3030 0.123 
H9A 0.8237 0.2134 0.4003 0.074 
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 x/a y/b z/c U(eq) 
H9B 0.8021 0.1837 0.3219 0.074 
H10A 0.5884 0.2022 0.3184 0.075 
H10B 0.6432 0.0943 0.3702 0.075 
H11A 0.7306 0.5274 0.3934 0.069 
H11B 0.7852 0.4154 0.4422 0.069 
H12A 0.5754 0.4376 0.4473 0.077 
H12B 0.5419 0.4204 0.3678 0.077 
H14A 0.4332 0.3188 0.5065 0.075 
H16A 0.5777 0.4206 0.5918 0.067 
H18A 0.7629 0.1463 0.5581 0.07 
H19A 0.9724 0.1550 0.5524 0.068 
H21A 0.9729 0.5302 0.5929 0.086 
H22A 0.7633 0.5239 0.5945 0.082 
H24A 0.4396 0.7231 0.8727 0.069 
H26A 0.2308 0.4470 0.7712 0.077 
H27A 0.4059 0.3593 0.7391 0.079 
H30A 0.6114 0.3976 0.7145 0.109 
H30B 0.6733 0.3664 0.7895 0.109 
H30C 0.6975 0.4995 0.7570 0.109 
H31A 0.6312 0.7933 0.9091 0.073 
H31B 0.6084 0.8338 0.8318 0.073 
H32A 0.8252 0.8219 0.8296 0.08 
H32B 0.8009 0.9199 0.8862 0.08 
H33A 0.7280 0.4825 0.8900 0.066 
H33B 0.7005 0.5856 0.9434 0.066 
H34A 0.9169 0.5716 0.9484 0.073 
H34B 0.9034 0.5983 0.8697 0.073 
H36A 1.0777 0.6716 1.0131 0.071 
H38A 0.9789 0.5618 1.0946 0.06 
H40A 0.7854 0.8491 1.0727 0.066 
H41A 0.5736 0.8493 1.0703 0.083 
H43A 0.5783 0.4660 1.0785 0.082 
H44A 0.7879 0.4690 1.0847 0.085 
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